
1	60	BCDKTRS	T4	T6	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
1	60	BCDKTRS	T4	T6	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
1	60	BCDKTRS	T4	T6	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
1	60	BCDKTRS	T5	T6	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
0	45	BCDKS	T5	T4	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
0	37	CDKLN1X	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag T2 increases in cellular volume RNA synthesis and T3 protein levels and enhanced binding of 7-aminoactinomycin D
1	27	CDKLN2TR	T1	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag T2 increases in cellular volume RNA synthesis and T3 protein levels and enhanced binding of 7-aminoactinomycin D
1	27	CDKLN1TR	T1	T3	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag T2 increases in cellular volume RNA synthesis and T3 protein levels and enhanced binding of 7-aminoactinomycin D
0	47	CDKLN2TRS	T11	T14	In the present investigation the differential binding of previously characterized endothelial cell EC  and smooth muscle cell T11 derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	47	CDKLN2TRS	T12	T14	In the present investigation the differential binding of previously characterized endothelial cell EC- and smooth muscle cell T11-derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	17	CDKLN2T	T13	T14	In the present investigation the differential binding of previously characterized endothelial cell EC- and smooth muscle cell T11-derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	58	CDKN2XRS	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta 1-28 produced strong immunoreactivity with A beta antibodies at tissue sites enriched in T15 which was partially removed by pretreatment with heparitinase but not by chondroitin T16 lyase
0	78	BCDKN2XRS	T18	T17	[35S]-Sulfate labeled proteoglycans T17 derived from cultured ECs and SMCs bound to affinity columns containing A beta 1-28 or 1-40 with virtually no binding to A beta 40-1 reverse peptide beta-amyloid precursor protein 410-429 or bovine T18
0	72	CDKLN1TURS	T9	T10	Overall the results indicate that specific vascular cell-derived T9 differentially interact with A beta and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of T10
0	37	CDKLN2X	T12	T11	In the present investigation the differential binding of previously characterized endothelial cell EC  and smooth muscle cell T11 derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	67	CDKLN2XRS	T13	T11	In the present investigation the differential binding of previously characterized endothelial cell EC  and smooth muscle cell T11 derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	67	CDKLN2XRS	T13	T12	In the present investigation the differential binding of previously characterized endothelial cell EC- and smooth muscle cell T11-derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	38	CDKN2XR	T21	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	CDKN2	T20	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	38	CDKN1XR	T23	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	38	CDKN1XR	T22	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN2R	T25	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T24	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	7	CDLN	T6	T8	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
0	7	CDLN	T7	T8	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
1	7	CDLN	T5	T8	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
1	7	CDLN	T7	T6	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
0	7	CDLN	T5	T6	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
1	7	CDLN	T5	T7	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
0	5	CDK1	T2	T4	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK	T3	T4	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK1	T1	T4	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK1	T3	T2	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK2	T1	T2	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK1	T1	T3	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
1	18	CDKN2TR	T20	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	CDKN1	T23	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	CDKN1	T22	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN2R	T25	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T24	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	38	CDKN1XR	T23	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	38	CDKN1XR	T22	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN2R	T25	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T24	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	CDKN	T22	T23	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T25	T23	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKNR	T24	T23	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T25	T22	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKNR	T24	T22	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	18	CDKNQ1	T24	T25	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	34	BCDLT	T3	T4	We show here that T3 phosphatase associates with T4 in somatic mammalian cells and in meiotic frog oocytes
1	35	CDEFK2	T1	T2	T1 interaction with T2 phosphatase ties mitogenic signal transduction to cell cycle activation
0	45	CD1XS	T3	T2	The tyrosine kinase T1 is physically associated with the Type I interferon T2 receptor complex and is rapidly activated during T3 stimulation
1	35	CD2TRS	T1	T2	The tyrosine kinase T1 is physically associated with the Type I interferon T2 receptor complex and is rapidly activated during T3 stimulation
1	35	CD1TRS	T1	T3	The tyrosine kinase T1 is physically associated with the Type I interferon T2 receptor complex and is rapidly activated during T3 stimulation
0	40	CDK1TRS	T2	T4	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
1	5	CDK	T3	T4	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	65	CDEFK1RS	T1	T4	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	60	CDK1XRS	T3	T2	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	45	CDEFK2R	T1	T2	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
1	65	CDEFK1RS	T1	T3	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	25	CDTS	T6	T8	The association of T6 with T7 was mediated by the NH2-terminal Src homology 2 SH2 domain of T8
1	25	CDTS	T7	T8	The association of T6 with T7 was mediated by the NH2-terminal Src homology 2 SH2 domain of T8
1	0	CD1	T10	T9	Complexes of either T9/T10/Syk/PLC-gamma1 could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate respectively
1	0	CD	T7	T6	The association of T6 with T7 was mediated by the NH2-terminal Src homology 2 SH2 domain of T8
1	34	CDLX	T5	T4	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for T4 regulates tyrosyl phosphorylation of T5
1	14	CDLT	T3	T4	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for T4 regulates tyrosyl phosphorylation of T5
0	14	CDLT	T3	T5	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for T4 regulates tyrosyl phosphorylation of T5
1	10	CDE2	T1	T2	T1 associates with T2 Syk and phospholipase C-gamma1 upon B cell activation
0	45	CD2XS	T15	T14	By contrast T14 was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type T15
0	14	CDKL2	T12	T11	Transient expression of T11 and a null mutant of T12 PTP-1CM in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
0	59	CDKL2XS	T13	T11	Transient expression of T11 and a null mutant of T12 PTP-1CM in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
1	59	CDKL2XS	T13	T12	Transient expression of T11 and a null mutant of T12 PTP-1CM in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
0	29	BCDL	T3	T4	We used cDNA probes for the T3 T4 and Etfa genes to determine localization of these mouse genes to chromosomes 3 7 and 13
0	0	CD2	T1	T2	Assignment of T1 T2 and Etfa to chromosomes 3 7 and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human
0	35	CDXR	T5	T4	The fact that the T3 mRNA editing protein also exists as a T4 has important implications for the mechanism of T5 mRNA editing in humans
0	25	CDTS	T3	T4	The fact that the T3 mRNA editing protein also exists as a T4 has important implications for the mechanism of T5 mRNA editing in humans
0	35	CDTRS	T3	T5	The fact that the T3 mRNA editing protein also exists as a T4 has important implications for the mechanism of T5 mRNA editing in humans
0	44	CDL2TRS	T1	T2	The human T1 mRNA editing protein is a T2 showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases
1	44	BCDLOR	T5	T4	This suggests that transmembrane T4 by providing docking sites for the Src homology 3 domain of T5 activates PI 3-kinase by mediating its recruitment to the membrane
1	30	CDK1X	T3	T2	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of T2 activates T3 in C2C12 cells
1	5	CDK2	T1	T2	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of T2 activates T3 in C2C12 cells
1	10	CDK1T	T1	T3	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of T2 activates T3 in C2C12 cells
1	94	BCDEFKLRS	T7	T8	T7 expressed in COS cells supported increased binding to immobilized T8
1	7	CDLN1	T10	T9	Finally T9 bound different glycoforms of T10 expressed in Chinese hamster ovary cells including unbranched core 1 and branched core 2 O:-linked glycans that are normally found on T11 in resting and activated T cells respectively
0	62	CDLN1XRS	T11	T9	Finally T9 bound different glycoforms of T10 expressed in Chinese hamster ovary cells including unbranched core 1 and branched core 2 O:-linked glycans that are normally found on T11 in resting and activated T cells respectively
0	5	CDK	T4	T6	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and T5 T6 respectively
0	5	CDK	T5	T6	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and T5 T6 respectively
0	5	CDK	T5	T4	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and T5 T6 respectively
0	0	CD1	T3	T2	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 T3
1	0	CD2	T1	T2	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 T3
1	0	CD1	T1	T3	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 T3
0	49	CDKL2TRS	T12	T14	These results identify T12 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
0	49	CDKL2TRS	T13	T14	These results identify T12 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
0	62	CDLN2XRS	T11	T10	Finally T9 bound different glycoforms of T10 expressed in Chinese hamster ovary cells including unbranched core 1 and branched core 2 O:-linked glycans that are normally found on T11 in resting and activated T cells respectively
1	14	CDKL2	T13	T12	These results identify T12 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
1	24	CDLTR	T7	T8	This work suggests that T7 is a regulated adapter between T8 and cytoplasmic dynein at sites involved in cargo-MT loading and/or in the control of MT dynamics
0	44	CDKLRS	T4	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	14	CDKL	T5	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	44	CDKLRS	T3	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	44	CDKLRS	T5	T4	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
1	14	CDKL	T3	T4	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	44	CDKLRS	T3	T5	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
1	14	CDKL2	T1	T2	Here we demonstrate colocalization and direct interaction between T1 and T2
0	-2	CDN	T9	T8	Specific glutamines or lysines of T7 were used to cross-link the different proteins such as glutamines 495 and 496 to T8 glutamine 288 to keratins and lysines 468 485 and 508 and glutamines 465 and 489 for interchain T9 cross-links
0	33	CDNTRS	T7	T8	Specific glutamines or lysines of T7 were used to cross-link the different proteins such as glutamines 495 and 496 to T8 glutamine 288 to keratins and lysines 468 485 and 508 and glutamines 465 and 489 for interchain T9 cross-links
0	33	CDNTRS	T7	T9	Specific glutamines or lysines of T7 were used to cross-link the different proteins such as glutamines 495 and 496 to T8 glutamine 288 to keratins and lysines 468 485 and 508 and glutamines 465 and 489 for interchain T9 cross-links
0	33	BCDNTR	T4	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDNTR	T5	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDN1TR	T2	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDNTR	T3	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	53	BCDN1TRS	T1	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	53	BCDNXR	T5	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	18	BCDN1	T2	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	18	BCDN	T3	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	48	BCDN1RS	T1	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDN1TR	T2	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDNTR	T3	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	53	BCDN1TRS	T1	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	18	BCDN1	T3	T2	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	48	BCDN2RS	T1	T2	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	48	BCDN1RS	T1	T3	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	25	CDX	T9	T8	In addition T8 was immunoprecipitated from human neutrophil lysates by anti-human T9 mAb
0	49	BCDLS	T7	T6	T5 detected by anti-CD18 mAb was coprecipitated with T6 from human neutrophil lysates by a mAb to T7
1	69	BCDELRS	T5	T6	T5 detected by anti-CD18 mAb was coprecipitated with T6 from human neutrophil lysates by a mAb to T7
0	69	BCDELRS	T5	T7	T5 detected by anti-CD18 mAb was coprecipitated with T6 from human neutrophil lysates by a mAb to T7
1	50	BCDKTS	T3	T4	To clarify the mechanisms by which T3 functions on leukocytes we explored the possibility of its physical association with T4 which is important for leukocyte adherence locomotion and extravasation
1	0	CD2	T1	T2	Physical association of T1 with T2 a novel glycosylphosphatidylinositol-anchored protein with potential for regulating adhesion and migration
1	54	CDL2XS	T11	T10	These results clearly show that T10 is physically associated with T11 in human neutrophils
1	10	CDE	T3	T4	T3 and T4 are two structurally different endocytic receptors that interact to serve such functions
0	10	CDE2	T1	T2	T1 and T2: multifunctional endocytic receptors
0	30	CDE2S	T1	T2	T1 type II isozyme contains a T2 homology domain at the N terminus and a sterile alpha motif domain at the C terminus
1	9	CDL2	T12	T14	Yet whether T12 and/or T13 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
1	9	CDL2	T13	T14	Yet whether T12 and/or T13 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
0	9	CDL2	T16	T15	In this work we show that T15 and T16 specifically interact with the T17/CyclinB1 complex but not with other Cdk/Cyclin complexes in vitro and in vivo
1	9	CDL2	T17	T15	In this work we show that T15 and T16 specifically interact with the T17/CyclinB1 complex but not with other Cdk/Cyclin complexes in vitro and in vivo
1	9	CDL2	T17	T16	In this work we show that T15 and T16 specifically interact with the T17/CyclinB1 complex but not with other Cdk/Cyclin complexes in vitro and in vivo
1	9	CDL2	T11	T10	Recent evidence has implicated T10 in inhibition of T11/cyclinB1 kinase and in G2/M cell cycle arrest
0	9	CDL2	T13	T12	Yet whether T12 and/or T13 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
0	5	CDK2	T19	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	5	CDK2	T21	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	5	CDK2	T20	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	15	CDK1R	T22	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	5	CDK2	T21	T19	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	5	CDK2	T20	T19	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	15	CDK1R	T22	T19	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	9	CDL	T9	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T6	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T7	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T4	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T5	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T6	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T7	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T4	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T5	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T7	T6	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T4	T6	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T5	T6	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T4	T7	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T5	T7	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T5	T4	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
1	15	CDK1R	T3	T2	T1 and T2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
0	35	CDEFK2	T1	T2	T1 and T2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
1	45	CDEFK1R	T1	T3	T1 and T2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
1	5	CDK2	T20	T21	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	15	CDK1R	T22	T21	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	15	CDK1R	T22	T20	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	14	CDKL1	T25	T23	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
1	14	CDKL	T24	T23	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	14	CDKL	T26	T23	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	14	CDKL1	T24	T25	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	39	CDKL1X	T26	T25	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	39	CDKLX	T26	T24	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	59	CDKLXS	T5	T4	Subcellular fractionation and antibody-uptake experiments indicate that T4 is indeed a type-I membrane protein but unlike other T5 isoforms lacks an N-terminal extracellular domain
0	25	CD1X	T3	T2	Here we cloned and characterized a mouse orthologue of human T1 protein as an atypical T2 named T3
0	30	CD2RS	T1	T2	Here we cloned and characterized a mouse orthologue of human T1 protein as an atypical T2 named T3
0	35	CD1TRS	T1	T3	Here we cloned and characterized a mouse orthologue of human T1 protein as an atypical T2 named T3
0	8	CDKN2T	T1	T2	By constructing deletion mutants we identified that amino acid residues 229-309 of Akt were involved in the binding to T1 and amino acid residues 327-340 of T2 were involved in the binding to Akt
1	47	CDKLNXR	T5	T4	In this report we demonstrate the stable association of T3 with T4 in a clathrin-coated vesicle complex which not only binds to the carboxyl-terminal SH2 domain of T5 but also inhibits its enzymatic activity in a dose-dependent manner
1	12	CDKLN	T3	T4	In this report we demonstrate the stable association of T3 with T4 in a clathrin-coated vesicle complex which not only binds to the carboxyl-terminal SH2 domain of T5 but also inhibits its enzymatic activity in a dose-dependent manner
0	27	CDKLNTR	T3	T5	In this report we demonstrate the stable association of T3 with T4 in a clathrin-coated vesicle complex which not only binds to the carboxyl-terminal SH2 domain of T5 but also inhibits its enzymatic activity in a dose-dependent manner
1	35	CDEFK2	T1	T2	T1 binds to the C-terminal SH2 domain of T2 and inhibits its enzymatic activity
1	20	BCD	T9	T8	To identify the regions of T8 that contact its receptor T9 we substituted all surface-exposed residues with alanine
1	59	BCDKLX	T7	T6	It was previously shown that the N-terminus of T6 is critical for binding T7
0	5	CDK	T5	T4	The receptor binding site of T3 also is significantly different from the binding sites of T4 and T5 providing insight into the issue of receptor specificity
0	10	CDKT	T3	T4	The receptor binding site of T3 also is significantly different from the binding sites of T4 and T5 providing insight into the issue of receptor specificity
0	10	CDKT	T3	T5	The receptor binding site of T3 also is significantly different from the binding sites of T4 and T5 providing insight into the issue of receptor specificity
1	0	CD2	T1	T2	Identification of residues in the T1 that contact the MCP-1 receptor T2
0	5	CDK1	T3	T2	Cloning and characterization of two evolutionarily conserved subunits T1 and T2 of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	5	CDK2	T1	T2	Cloning and characterization of two evolutionarily conserved subunits T1 and T2 of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	5	CDK1	T1	T3	Cloning and characterization of two evolutionarily conserved subunits T1 and T2 of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	20	BCD	T7	T6	T5 promotes coprecipitation of p85 with T6 the signal-transducing component of the T7
1	30	BCDE	T5	T6	T5 promotes coprecipitation of p85 with T6 the signal-transducing component of the T7
0	30	BCDE	T5	T7	T5 promotes coprecipitation of p85 with T6 the signal-transducing component of the T7
0	0	CD	T3	T4	RESULTS: Tyrosine phosphorylation of p85 is upregulated by T3 in both LNCaP and T4
1	30	BCDE2	T1	T2	T1 activates T2 which inhibits apoptosis in human prostate cancer cell lines
0	9	CDL	T9	T8	Previously we showed that the T8 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains T10 and F beta alpha respectively
0	64	CDL1XRS	T10	T8	Previously we showed that the T8 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains T10 and F beta alpha respectively
0	64	CDL1XRS	T10	T9	Previously we showed that the T8 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains T10 and F beta alpha respectively
0	28	BCDNR	T7	T6	This is relevant for the case of LH and FSH because both are synthesized in the same cell i.e. pituitary gonadotrophs and several of the alpha subunit sequences required for association with either the T6 or T7 subunits are different
0	3	CDKN	T5	T4	The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/T4 subunit since CG single chain interacts with the monomeric T5 subunit and exhibits FSH activity
0	20	BCD1	T3	T2	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the T2 and T3 monomer
0	20	BCD2	T1	T2	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the T2 and T3 monomer
0	20	BCD1	T1	T3	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the T2 and T3 monomer
1	14	CDKL	T7	T8	Secondly T7 induces expression of an extracellular activation epitope of T8 and the exchange factor function is not essential for this activity
1	60	CDK1XRS	T10	T9	In contrast LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a T9 mutant which fails to catalyze T10 GDP-GTP exchange in vitro
1	5	CDK	T5	T6	Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of T5 depends on its interaction with T6 unless the integrin is activated by exogenous divalent cations
1	24	CDKLR	T3	T4	Here we provide evidence of how T3 an integrin-binding protein and guanine-nucleotide exchange factor GEF for T4 GTPases regulates cell adhesion
1	55	BCDEFK2	T1	T2	T1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with T2
1	50	CDK2XS	T12	T11	Thus T11 is involved in the activation of T12 most probably through direct interaction with the integrin and induces cell spreading by its ARF-GEF activity
0	0	CD	T4	T6	Immobilized T3 also bound T4 besides T5 and T6
0	0	CD	T5	T6	Immobilized T3 also bound T4 besides T5 and T6
1	50	CDTUS	T3	T6	Immobilized T3 also bound T4 besides T5 and T6
0	0	CD	T5	T4	Immobilized T3 also bound T4 besides T5 and T6
1	50	CDTUS	T3	T4	Immobilized T3 also bound T4 besides T5 and T6
1	50	CDTUS	T3	T5	Immobilized T3 also bound T4 besides T5 and T6
0	0	CD2	T1	T2	In solution FGFR4ed formed complexes with T1 and T2 both in the presence and absence of heparin
0	37	CDLNRS	T6	T8	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	7	CDLN	T7	T8	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	37	CDLNRS	T5	T8	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	50	CDK1XS	T10	T9	Finally a direct interaction between PPARgamma and T9 was confirmed by T10 pull-down assay
0	37	CDLNRS	T7	T6	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	22	CDLNQ	T5	T6	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	37	CDLNRS	T5	T7	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	22	CDLNQ	T3	T4	Deletion analysis showed that the element responsible for the PPARgamma effect is located in a region containing the nuclear factor E2 T3/T4 site -98/-88 which was indicated to be the major promoter of the TXS gene
1	5	CDK2	T1	T2	Suppression of rat thromboxane synthase gene transcription by T1 in macrophages via an interaction with T2
0	0	CD	T9	T8	Preincubation with genistein a tyrosine kinase inhibitor blocked the GH-stimulated adhesion and T8 T9 p125FAK and T10 phosphorylation
0	0	CD1	T10	T8	Preincubation with genistein a tyrosine kinase inhibitor blocked the GH-stimulated adhesion and T8 T9 p125FAK and T10 phosphorylation
0	0	CD1	T10	T9	Preincubation with genistein a tyrosine kinase inhibitor blocked the GH-stimulated adhesion and T8 T9 p125FAK and T10 phosphorylation
0	0	CD	T7	T6	Pituitary GH triggered the tyrosine phosphorylation of T5 T6 and T7 in neutrophils
0	0	CD	T5	T6	Pituitary GH triggered the tyrosine phosphorylation of T5 T6 and T7 in neutrophils
0	0	CD	T5	T7	Pituitary GH triggered the tyrosine phosphorylation of T5 T6 and T7 in neutrophils
0	9	CDL	T3	T4	These results suggest that pituitary GH modulates neutrophil adhesion through tyrosine phosphorylation of T3 p125FAK and T4 and actin polymerization
0	0	CD2	T1	T2	Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of T1 p125FAK and T2
1	0	CD2	T12	T11	Immunoprecipitation experiments revealed a physical association of T11 with p125FAK via T12 in vivo
0	42	CDLNTRS	T6	T8	In contrast phosphorylation of T6 by ATR is independent of T7 and replication protein A suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
0	27	CDLNS	T7	T8	In contrast phosphorylation of T6 by ATR is independent of T7 and replication protein A suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
0	18	CDN1S	T10	T9	In addition both T9 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG and phosphorylation of T11 is required for cellular survival
0	43	CDN1XS	T11	T9	In addition both T9 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG and phosphorylation of T11 is required for cellular survival
0	62	CDLNXRS	T7	T6	In contrast phosphorylation of T6 by ATR is independent of T7 and replication protein A suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
1	54	BCDLX	T5	T4	We found that phosphorylation of T4 by ATR also requires checkpoint proteins T5 and replication protein A
0	18	BCDN1	T3	T2	We report that T1 MutS homolog 2 protein interacts with the ATR ATM- and Rad3-related kinase to form a signaling module and regulate the phosphorylation of T2 and T3 structure maintenance of chromosome 1
1	48	BCDN2TU	T1	T2	We report that T1 MutS homolog 2 protein interacts with the ATR ATM- and Rad3-related kinase to form a signaling module and regulate the phosphorylation of T2 and T3 structure maintenance of chromosome 1
1	48	BCDN1TU	T1	T3	We report that T1 MutS homolog 2 protein interacts with the ATR ATM- and Rad3-related kinase to form a signaling module and regulate the phosphorylation of T2 and T3 structure maintenance of chromosome 1
0	23	CDN2X	T11	T10	In addition both T9 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG and phosphorylation of T11 is required for cellular survival
1	75	BCDEFKS	T9	T8	T8 is modified by T9 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
0	75	BCDEFK1S	T10	T8	T8 is modified by T9 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
0	25	BCDK1	T10	T9	T8 is modified by T9 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
1	67	CDKLNXRS	T7	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	12	CDKLN	T4	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	12	CDKLN	T5	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	22	CDKLNR	T3	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	47	CDKLNTRS	T4	T7	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	47	CDKLNTRS	T5	T7	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	47	CDKLNTRS	T3	T7	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	12	CDKLN	T5	T4	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	22	CDKLNR	T3	T4	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	22	CDKLNR	T3	T5	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	5	CDK2	T1	T2	Modification of de novo DNA methyltransferase 3a T1 by T2 modulates its interaction with histone deacetylases HDACs and its capacity to repress transcription
1	5	CDK2	T12	T11	Functionally sumoylation of T11 disrupts its ability to interact with histone deacetylases T12/2 but not with another interaction partner T13
0	55	CDK2XY	T13	T11	Functionally sumoylation of T11 disrupts its ability to interact with histone deacetylases T12/2 but not with another interaction partner T13
0	5	CDK2	T13	T12	Functionally sumoylation of T11 disrupts its ability to interact with histone deacetylases T12/2 but not with another interaction partner T13
1	19	CDKLT	T3	T4	These results suggest that the relative abundance of the two splice variants of T3 in brain could be an important determinant for the expression of T4
1	39	CDKL2TS	T1	T2	Transient expression of the full-length T1 without RSRS in U1240MG glioblastoma cells resulted in repression of T2 promoter activity
1	78	BCDN2TURS	T1	T2	We report here that PLZF and a structurally similar transcriptional repressor T1 can interact with a variety of corepressor proteins in addition to SMRT including the mSin3A protein and for PLZF T2
0	10	CDKT	T4	T6	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	5	CDK	T5	T6	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
0	10	CDKT	T3	T6	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	30	CDKX	T5	T4	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
0	5	CDK	T3	T4	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	10	CDKT	T3	T5	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	5	CDK2	T1	T2	Specific interaction of T1 and c/EBPbeta leads to the transcriptional activation of the human T2 gene
0	5	CDK	T9	T8	The interaction between AR and T7 was assessed by T8 T9 pull-down assay and mammalian two-hybrid system assay
0	30	CDKTS	T7	T8	The interaction between AR and T7 was assessed by T8 T9 pull-down assay and mammalian two-hybrid system assay
0	30	CDKTS	T7	T9	The interaction between AR and T7 was assessed by T8 T9 pull-down assay and mammalian two-hybrid system assay
0	9	CDL	T4	T6	BACKGROUND: Both T4 AR and orphan receptor T5 T6 belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	9	CDL	T5	T6	BACKGROUND: Both T4 AR and orphan receptor T5 T6 belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	9	CDL	T5	T4	BACKGROUND: Both T4 AR and orphan receptor T5 T6 belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	20	BCD1	T3	T2	T1 orphan receptor functions as negative modulator for T2 in prostate cancer cells T3
1	30	BCDE2	T1	T2	T1 orphan receptor functions as negative modulator for T2 in prostate cancer cells T3
0	30	BCDE1	T1	T3	T1 orphan receptor functions as negative modulator for T2 in prostate cancer cells T3
1	24	CDL2TR	T13	T14	Blockade of T13 expression by small interfering RNA siRNA causes prolonged degradation kinetics of T14
0	25	CDK2S	T16	T15	Several distinct mutations in exon 2 of T15 disrupt binding of T16 to T17
1	25	CDK2S	T17	T15	Several distinct mutations in exon 2 of T15 disrupt binding of T16 to T17
1	5	CDK2	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of T16 to T17
1	34	CDL2X	T11	T10	Overexpression of T10 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of T12
0	44	CDL2XR	T12	T10	Overexpression of T10 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of T12
1	44	CDL2XR	T12	T11	Overexpression of T10 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of T12
1	35	CD2XR	T19	T18	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	55	CD2XRS	T21	T18	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	35	CD2XR	T20	T18	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	55	CD2XRS	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	0	CD2	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	0	CD	T9	T8	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
1	10	CDE	T6	T8	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
0	0	CD	T7	T8	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
1	10	CDE	T6	T9	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
0	0	CD	T7	T9	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
1	10	CDE	T7	T6	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
0	34	BCDKL	T5	T4	We establish that T3 binds to T4 T5 a component of the 19S regulatory complex of the proteasome
1	34	BCDKL	T3	T4	We establish that T3 binds to T4 T5 a component of the 19S regulatory complex of the proteasome
1	34	BCDKL	T3	T5	We establish that T3 binds to T4 T5 a component of the 19S regulatory complex of the proteasome
1	15	CD2TR	T1	T2	The protein T1 functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor T2 for proteasomal degradation during normoxia
0	35	CD2TRS	T20	T21	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
1	74	CDKLTURS	T22	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	59	CDKL1XS	T25	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	14	CDKL	T24	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	59	CDKLXS	T26	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	94	CDKL1XYRS	T25	T22	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
1	94	CDKLXYRS	T24	T22	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	94	CDKLXYRS	T26	T22	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	39	CDKL1TS	T24	T25	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
1	14	CDKL1	T26	T25	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	59	CDKLXS	T26	T24	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	0	CD	T5	T6	Three SR-rich proteins were identified that interact with the C-terminus of Pnn: T5 and T6 known components of spliceosome machinery and a novel 130-kDa nuclear protein SRrp130
1	0	CD1	T2	T4	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
0	0	CD	T3	T4	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
1	0	CD1	T1	T4	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
1	0	CD1	T3	T2	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
0	15	CDQ2	T1	T2	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
1	0	CD1	T1	T3	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
0	12	CDLNT	T6	T8	The results of complementation experiments show that in contrast to mouse T6 mouse T7 can partially alleviate the growth defect of the corresponding yeast null strain indicating that the role of T8 in pre-rRNA processing is evolutionarily conserved
0	12	CDLNT	T7	T8	The results of complementation experiments show that in contrast to mouse T6 mouse T7 can partially alleviate the growth defect of the corresponding yeast null strain indicating that the role of T8 in pre-rRNA processing is evolutionarily conserved
0	9	CDL1	T10	T9	The results of density gradient centrifugation experiments show that in contrast to hU3-55K the human T9 and T10 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
1	9	CDL1	T11	T9	The results of density gradient centrifugation experiments show that in contrast to hU3-55K the human T9 and T10 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
0	7	CDLN	T7	T6	The results of complementation experiments show that in contrast to mouse T6 mouse T7 can partially alleviate the growth defect of the corresponding yeast null strain indicating that the role of T8 in pre-rRNA processing is evolutionarily conserved
0	20	BCD	T5	T4	We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins T4 and T5
1	35	CD1XR	T3	T2	The human T1 and T2 proteins form a ternary complex with hMpp10 which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	20	CD2S	T1	T2	The human T1 and T2 proteins form a ternary complex with hMpp10 which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	35	CD1TRS	T1	T3	The human T1 and T2 proteins form a ternary complex with hMpp10 which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	9	CDL2	T11	T10	The results of density gradient centrifugation experiments show that in contrast to hU3-55K the human T9 and T10 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
0	30	CDRS	T7	T8	In addition electron microscopy experiments revealed that T7 and T8 are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers
0	34	CDLTS	T4	T6	In contrast to T4 the potency of direct activation of T5 was not affected by co-expression with T6
0	34	CDLTS	T5	T6	In contrast to T4 the potency of direct activation of T5 was not affected by co-expression with T6
0	9	CDL	T5	T4	In contrast to T4 the potency of direct activation of T5 was not affected by co-expression with T6
0	9	CDL1	T3	T2	In the present study we observed evidence of cross-talk between the cannabinoid receptor T1 and the T2 T3 using a heterologous system
1	9	CDL2	T1	T2	In the present study we observed evidence of cross-talk between the cannabinoid receptor T1 and the T2 T3 using a heterologous system
1	9	CDL1	T1	T3	In the present study we observed evidence of cross-talk between the cannabinoid receptor T1 and the T2 T3 using a heterologous system
0	114	BCDKL2XYRS	T15	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	BCDKL2TURS	T12	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	BCDKL2TURS	T13	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	BCDKL2TURS	T12	T15	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	BCDKL2TURS	T13	T15	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
0	0	CD2	T17	T16	This work led to identification of a novel T16 T17 for Rho family GTPases
1	45	CD2XS	T11	T10	In addition T10 contains several classic proline-rich motifs and it interacts with the first SH3 domain of Crk and full-length T11 in vitro
0	34	BCDKL2	T13	T12	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
0	39	CDKL2X	T19	T18	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA T19 and T20 in vitro
0	39	CDKL2X	T20	T18	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA T19 and T20 in vitro
0	14	CDKL2	T20	T19	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA T19 and T20 in vitro
0	0	CD	T9	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	15	CDTR	T6	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
0	0	CD	T7	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	20	CDER	T5	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	15	CDTR	T6	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
0	0	CD	T7	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	20	CDER	T5	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	35	CDXR	T7	T6	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
0	10	CDE	T5	T6	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	20	CDER	T5	T7	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	10	CD1R	T2	T4	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
0	0	CD	T3	T4	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	20	CDE1R	T1	T4	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	10	CD1R	T3	T2	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
0	10	CDE2	T1	T2	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	20	CDE1R	T1	T3	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	85	CDK1XYRS	T23	T21	The protein was named T21 for its ability to interact with T22 proteins and its activity toward Rac and T23
1	85	CDK1XYRS	T22	T21	The protein was named T21 for its ability to interact with T22 proteins and its activity toward Rac and T23
0	5	CDK	T22	T23	The protein was named T21 for its ability to interact with T22 proteins and its activity toward Rac and T23
1	25	CD1TS	T24	T25	Expression of T24 in 293T cells led to a reduction in active T25 and T26 levels but not RhoA
0	0	CD1	T26	T25	Expression of T24 in 293T cells led to a reduction in active T25 and T26 levels but not RhoA
1	45	CDXS	T26	T24	Expression of T24 in 293T cells led to a reduction in active T25 and T26 levels but not RhoA
0	47	CDKLNTRS	T6	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	37	CDKLNTS	T7	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	47	CDKLNTRS	T4	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	47	CDKLNTRS	T5	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	47	CDKLNTRS	T3	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	62	CDLN1XRS	T10	T9	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	62	CDLN1XRS	T11	T9	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	62	CDLN1XRS	T12	T9	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	47	CDKLNXR	T7	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	17	CDKLNT	T4	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	17	CDKLNT	T5	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	17	CDKLNT	T3	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	27	CDKLNTR	T4	T7	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	27	CDKLNTR	T5	T7	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	27	CDKLNTR	T3	T7	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	12	CDKLN	T5	T4	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	12	CDKLN	T3	T4	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	12	CDKLN	T3	T5	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	0	CD2	T1	T2	A role for T1 phosphorylation of T2 in cytokinesis
1	9	CDL2	T13	T14	These results suggest that T13 phosphorylation of T14 may influence cytokinesis
0	7	CDLN2	T11	T10	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	7	CDLN2	T12	T10	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	7	CDLN2	T12	T11	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
1	12	CDKLN	T9	T8	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	CDKLN1XS	T10	T8	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	CDKLN1XS	T11	T8	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	CDKLN1XS	T10	T9	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	CDKLN1XS	T11	T9	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	5	CDK	T7	T6	T5/T6 'T7'-binding protein CBP interacting with transcription factors is able to increase their activity on target gene promoters
0	20	CDKQ	T5	T6	T5/T6 'T7'-binding protein CBP interacting with transcription factors is able to increase their activity on target gene promoters
0	5	CDK	T5	T7	T5/T6 'T7'-binding protein CBP interacting with transcription factors is able to increase their activity on target gene promoters
1	5	CDK1	T2	T4	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
1	5	CDK	T3	T4	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
1	5	CDK1	T1	T4	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
0	5	CDK1	T3	T2	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
0	20	CDKQ2	T1	T2	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
0	5	CDK1	T1	T3	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
1	12	CDKLN2	T11	T10	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	40	BCDER	T5	T4	T4 is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing T5
1	0	CD1	T3	T2	A prominent isolate designated T1/T2 specifically interacts with the T3 not only in vivo but also in vitro
0	15	CDQ2	T1	T2	A prominent isolate designated T1/T2 specifically interacts with the T3 not only in vivo but also in vitro
1	0	CD1	T1	T3	A prominent isolate designated T1/T2 specifically interacts with the T3 not only in vivo but also in vitro
1	30	CDES	T7	T8	T7 also interacted with other members of the catenin gene family including T8 and gamma-catenin
0	69	CDKL1XRS	T10	T9	The interaction with T9 is likely to be direct as the interaction occurs in K562 cells lacking functional adherens junctions and T10 expression
0	44	CDLTRS	T4	T6	The T4 T5 also known as T6 is expressed predominantly in epithelial cells in a variety of tumor cell lines and in lymphocytes
0	44	CDLTRS	T5	T6	The T4 T5 also known as T6 is expressed predominantly in epithelial cells in a variety of tumor cell lines and in lymphocytes
0	9	CDL	T5	T4	The T4 T5 also known as T6 is expressed predominantly in epithelial cells in a variety of tumor cell lines and in lymphocytes
1	25	CD1X	T3	T2	The transmembrane T1 T2 interacts with T3
0	0	CD2	T1	T2	The transmembrane T1 T2 interacts with T3
1	5	CD1T	T1	T3	The transmembrane T1 T2 interacts with T3
0	12	CDKLN2	T12	T11	Catalytic domains of the tyrosine phosphatases T11 T12 and PTPbeta did not interact with proteins of the catenin family to detectable levels suggesting that the interaction of T13 with these proteins is specific
0	67	CDKLN2XRS	T13	T11	Catalytic domains of the tyrosine phosphatases T11 T12 and PTPbeta did not interact with proteins of the catenin family to detectable levels suggesting that the interaction of T13 with these proteins is specific
0	67	CDKLN2XRS	T13	T12	Catalytic domains of the tyrosine phosphatases T11 T12 and PTPbeta did not interact with proteins of the catenin family to detectable levels suggesting that the interaction of T13 with these proteins is specific
0	0	CD	T6	T8	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	0	CD	T7	T8	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	10	CDE	T5	T8	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	45	CD1XS	T10	T9	TBP and T9 however were not able to interact with T10
0	0	CD	T7	T6	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
1	10	CDE	T5	T6	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
1	10	CDE	T5	T7	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	0	CD	T3	T4	In contrast to T3 T4 did not interact with the AF2 domain of RXR
0	19	CDLO2T	T1	T2	Herein we show that a distinct IkappaB protein T1 also interacts with RXR as shown in the yeast two-hybrid tests and T2 pull-down assays
0	14	CDKL2	T13	T14	In addition coexpression of T13 but not T14 further stimulated the Bcl3-mediated enhancement of the 9-cis-RA-induced transactivations of RXR
0	40	CDK2XR	T12	T11	Accordingly T11 coactivated the 9-cis-RA-induced transactivations of RXR in contrast to the inhibitory actions of T12
1	60	BCDKTRS	T4	T6	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
1	60	BCDKTRS	T5	T6	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
0	45	BCDKS	T5	T4	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
0	37	CDKLN1X	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag T2 increases in cellular volume RNA synthesis and T3 protein levels and enhanced binding of 7-aminoactinomycin D
1	27	CDKLN2TR	T1	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag T2 increases in cellular volume RNA synthesis and T3 protein levels and enhanced binding of 7-aminoactinomycin D
1	27	CDKLN1TR	T1	T3	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag T2 increases in cellular volume RNA synthesis and T3 protein levels and enhanced binding of 7-aminoactinomycin D
0	47	CDKLN2TRS	T11	T14	In the present investigation the differential binding of previously characterized endothelial cell EC  and smooth muscle cell T11 derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	47	CDKLN2TRS	T12	T14	In the present investigation the differential binding of previously characterized endothelial cell EC- and smooth muscle cell T11-derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	17	CDKLN2T	T13	T14	In the present investigation the differential binding of previously characterized endothelial cell EC- and smooth muscle cell T11-derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	58	CDKN2XRS	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta 1-28 produced strong immunoreactivity with A beta antibodies at tissue sites enriched in T15 which was partially removed by pretreatment with heparitinase but not by chondroitin T16 lyase
0	78	BCDKN2XRS	T18	T17	[35S]-Sulfate labeled proteoglycans T17 derived from cultured ECs and SMCs bound to affinity columns containing A beta 1-28 or 1-40 with virtually no binding to A beta 40-1 reverse peptide beta-amyloid precursor protein 410-429 or bovine T18
0	72	CDKLN1TURS	T9	T10	Overall the results indicate that specific vascular cell-derived T9 differentially interact with A beta and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of T10
0	37	CDKLN2X	T12	T11	In the present investigation the differential binding of previously characterized endothelial cell EC  and smooth muscle cell T11 derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	67	CDKLN2XRS	T13	T11	In the present investigation the differential binding of previously characterized endothelial cell EC  and smooth muscle cell T11 derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	67	CDKLN2XRS	T13	T12	In the present investigation the differential binding of previously characterized endothelial cell EC- and smooth muscle cell T11-derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	38	CDKN2XR	T21	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	CDKN2	T20	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	38	CDKN1XR	T23	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	38	CDKN1XR	T22	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN2R	T25	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T24	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	7	CDLN	T6	T8	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
0	7	CDLN	T7	T8	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
1	7	CDLN	T5	T8	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
1	7	CDLN	T7	T6	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
0	7	CDLN	T5	T6	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
1	7	CDLN	T5	T7	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
0	5	CDK1	T2	T4	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK	T3	T4	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK1	T1	T4	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK1	T3	T2	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK2	T1	T2	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	CDK1	T1	T3	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
1	18	CDKN2TR	T20	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	CDKN1	T23	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	CDKN1	T22	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN2R	T25	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T24	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	38	CDKN1XR	T23	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	38	CDKN1XR	T22	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN2R	T25	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T24	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	CDKN	T22	T23	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T25	T23	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKNR	T24	T23	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKN1R	T25	T22	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	CDKNR	T24	T22	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	18	CDKNQ1	T24	T25	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	34	BCDLT	T3	T4	We show here that T3 phosphatase associates with T4 in somatic mammalian cells and in meiotic frog oocytes
1	35	CDEFK2	T1	T2	T1 interaction with T2 phosphatase ties mitogenic signal transduction to cell cycle activation
0	45	CD1XS	T3	T2	The tyrosine kinase T1 is physically associated with the Type I interferon T2 receptor complex and is rapidly activated during T3 stimulation
1	35	CD2TRS	T1	T2	The tyrosine kinase T1 is physically associated with the Type I interferon T2 receptor complex and is rapidly activated during T3 stimulation
1	35	CD1TRS	T1	T3	The tyrosine kinase T1 is physically associated with the Type I interferon T2 receptor complex and is rapidly activated during T3 stimulation
0	40	CDK1TRS	T2	T4	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
1	5	CDK	T3	T4	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	65	CDEFK1RS	T1	T4	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	60	CDK1XRS	T3	T2	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	45	CDEFK2R	T1	T2	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
1	65	CDEFK1RS	T1	T3	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	25	CDTS	T6	T8	The association of T6 with T7 was mediated by the NH2-terminal Src homology 2 SH2 domain of T8
1	25	CDTS	T7	T8	The association of T6 with T7 was mediated by the NH2-terminal Src homology 2 SH2 domain of T8
1	0	CD1	T10	T9	Complexes of either T9/T10/Syk/PLC-gamma1 could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate respectively
1	0	CD	T7	T6	The association of T6 with T7 was mediated by the NH2-terminal Src homology 2 SH2 domain of T8
1	34	CDLX	T5	T4	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for T4 regulates tyrosyl phosphorylation of T5
1	14	CDLT	T3	T4	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for T4 regulates tyrosyl phosphorylation of T5
0	14	CDLT	T3	T5	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for T4 regulates tyrosyl phosphorylation of T5
1	10	CDE2	T1	T2	T1 associates with T2 Syk and phospholipase C-gamma1 upon B cell activation
0	45	CD2XS	T15	T14	By contrast T14 was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type T15
0	14	CDKL2	T12	T11	Transient expression of T11 and a null mutant of T12 PTP-1CM in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
0	59	CDKL2XS	T13	T11	Transient expression of T11 and a null mutant of T12 PTP-1CM in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
1	59	CDKL2XS	T13	T12	Transient expression of T11 and a null mutant of T12 PTP-1CM in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
0	29	BCDL	T3	T4	We used cDNA probes for the T3 T4 and Etfa genes to determine localization of these mouse genes to chromosomes 3 7 and 13
0	0	CD2	T1	T2	Assignment of T1 T2 and Etfa to chromosomes 3 7 and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human
0	35	CDXR	T5	T4	The fact that the T3 mRNA editing protein also exists as a T4 has important implications for the mechanism of T5 mRNA editing in humans
0	25	CDTS	T3	T4	The fact that the T3 mRNA editing protein also exists as a T4 has important implications for the mechanism of T5 mRNA editing in humans
0	35	CDTRS	T3	T5	The fact that the T3 mRNA editing protein also exists as a T4 has important implications for the mechanism of T5 mRNA editing in humans
0	44	CDL2TRS	T1	T2	The human T1 mRNA editing protein is a T2 showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases
1	44	BCDLOR	T5	T4	This suggests that transmembrane T4 by providing docking sites for the Src homology 3 domain of T5 activates PI 3-kinase by mediating its recruitment to the membrane
1	30	CDK1X	T3	T2	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of T2 activates T3 in C2C12 cells
1	5	CDK2	T1	T2	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of T2 activates T3 in C2C12 cells
1	10	CDK1T	T1	T3	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of T2 activates T3 in C2C12 cells
1	94	BCDEFKLRS	T7	T8	T7 expressed in COS cells supported increased binding to immobilized T8
1	7	CDLN1	T10	T9	Finally T9 bound different glycoforms of T10 expressed in Chinese hamster ovary cells including unbranched core 1 and branched core 2 O:-linked glycans that are normally found on T11 in resting and activated T cells respectively
0	62	CDLN1XRS	T11	T9	Finally T9 bound different glycoforms of T10 expressed in Chinese hamster ovary cells including unbranched core 1 and branched core 2 O:-linked glycans that are normally found on T11 in resting and activated T cells respectively
0	5	CDK	T4	T6	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and T5 T6 respectively
0	5	CDK	T5	T6	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and T5 T6 respectively
0	5	CDK	T5	T4	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and T5 T6 respectively
0	0	CD1	T3	T2	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 T3
1	0	CD2	T1	T2	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 T3
1	0	CD1	T1	T3	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 T3
0	49	CDKL2TRS	T12	T14	These results identify T12 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
0	49	CDKL2TRS	T13	T14	These results identify T12 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
0	62	CDLN2XRS	T11	T10	Finally T9 bound different glycoforms of T10 expressed in Chinese hamster ovary cells including unbranched core 1 and branched core 2 O:-linked glycans that are normally found on T11 in resting and activated T cells respectively
1	14	CDKL2	T13	T12	These results identify T12 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
1	24	CDLTR	T7	T8	This work suggests that T7 is a regulated adapter between T8 and cytoplasmic dynein at sites involved in cargo-MT loading and/or in the control of MT dynamics
0	44	CDKLRS	T4	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	14	CDKL	T5	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	44	CDKLRS	T3	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	44	CDKLRS	T5	T4	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
1	14	CDKL	T3	T4	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	44	CDKLRS	T3	T5	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
1	14	CDKL2	T1	T2	Here we demonstrate colocalization and direct interaction between T1 and T2
0	-2	CDN	T9	T8	Specific glutamines or lysines of T7 were used to cross-link the different proteins such as glutamines 495 and 496 to T8 glutamine 288 to keratins and lysines 468 485 and 508 and glutamines 465 and 489 for interchain T9 cross-links
0	33	CDNTRS	T7	T8	Specific glutamines or lysines of T7 were used to cross-link the different proteins such as glutamines 495 and 496 to T8 glutamine 288 to keratins and lysines 468 485 and 508 and glutamines 465 and 489 for interchain T9 cross-links
0	33	CDNTRS	T7	T9	Specific glutamines or lysines of T7 were used to cross-link the different proteins such as glutamines 495 and 496 to T8 glutamine 288 to keratins and lysines 468 485 and 508 and glutamines 465 and 489 for interchain T9 cross-links
0	33	BCDNTR	T4	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDNTR	T5	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDN1TR	T2	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDNTR	T3	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	53	BCDN1TRS	T1	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	53	BCDNXR	T5	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	18	BCDN1	T2	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	18	BCDN	T3	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	48	BCDN1RS	T1	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDN1TR	T2	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	BCDNTR	T3	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	53	BCDN1TRS	T1	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	18	BCDN1	T3	T2	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	48	BCDN2RS	T1	T2	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	48	BCDN1RS	T1	T3	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	25	CDX	T9	T8	In addition T8 was immunoprecipitated from human neutrophil lysates by anti-human T9 mAb
0	49	BCDLS	T7	T6	T5 detected by anti-CD18 mAb was coprecipitated with T6 from human neutrophil lysates by a mAb to T7
1	69	BCDELRS	T5	T6	T5 detected by anti-CD18 mAb was coprecipitated with T6 from human neutrophil lysates by a mAb to T7
0	69	BCDELRS	T5	T7	T5 detected by anti-CD18 mAb was coprecipitated with T6 from human neutrophil lysates by a mAb to T7
1	50	BCDKTS	T3	T4	To clarify the mechanisms by which T3 functions on leukocytes we explored the possibility of its physical association with T4 which is important for leukocyte adherence locomotion and extravasation
1	0	CD2	T1	T2	Physical association of T1 with T2 a novel glycosylphosphatidylinositol-anchored protein with potential for regulating adhesion and migration
1	54	CDL2XS	T11	T10	These results clearly show that T10 is physically associated with T11 in human neutrophils
1	10	CDE	T3	T4	T3 and T4 are two structurally different endocytic receptors that interact to serve such functions
0	10	CDE2	T1	T2	T1 and T2: multifunctional endocytic receptors
0	30	CDE2S	T1	T2	T1 type II isozyme contains a T2 homology domain at the N terminus and a sterile alpha motif domain at the C terminus
1	9	CDL2	T12	T14	Yet whether T12 and/or T13 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
1	9	CDL2	T13	T14	Yet whether T12 and/or T13 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
0	9	CDL2	T16	T15	In this work we show that T15 and T16 specifically interact with the T17/CyclinB1 complex but not with other Cdk/Cyclin complexes in vitro and in vivo
1	9	CDL2	T17	T15	In this work we show that T15 and T16 specifically interact with the T17/CyclinB1 complex but not with other Cdk/Cyclin complexes in vitro and in vivo
1	9	CDL2	T17	T16	In this work we show that T15 and T16 specifically interact with the T17/CyclinB1 complex but not with other Cdk/Cyclin complexes in vitro and in vivo
1	9	CDL2	T11	T10	Recent evidence has implicated T10 in inhibition of T11/cyclinB1 kinase and in G2/M cell cycle arrest
0	9	CDL2	T13	T12	Yet whether T12 and/or T13 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
0	5	CDK2	T19	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	5	CDK2	T21	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	5	CDK2	T20	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	15	CDK1R	T22	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	5	CDK2	T21	T19	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	5	CDK2	T20	T19	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	15	CDK1R	T22	T19	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	9	CDL	T9	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T6	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T7	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T4	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T5	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T6	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T7	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T4	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T5	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T7	T6	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T4	T6	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T5	T6	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T4	T7	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	CDL	T5	T7	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	CDEL	T5	T4	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
1	15	CDK1R	T3	T2	T1 and T2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
0	35	CDEFK2	T1	T2	T1 and T2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
1	45	CDEFK1R	T1	T3	T1 and T2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
1	5	CDK2	T20	T21	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	15	CDK1R	T22	T21	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	15	CDK1R	T22	T20	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	14	CDKL1	T25	T23	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
1	14	CDKL	T24	T23	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	14	CDKL	T26	T23	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	14	CDKL1	T24	T25	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	39	CDKL1X	T26	T25	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	39	CDKLX	T26	T24	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	59	CDKLXS	T5	T4	Subcellular fractionation and antibody-uptake experiments indicate that T4 is indeed a type-I membrane protein but unlike other T5 isoforms lacks an N-terminal extracellular domain
0	25	CD1X	T3	T2	Here we cloned and characterized a mouse orthologue of human T1 protein as an atypical T2 named T3
0	30	CD2RS	T1	T2	Here we cloned and characterized a mouse orthologue of human T1 protein as an atypical T2 named T3
0	35	CD1TRS	T1	T3	Here we cloned and characterized a mouse orthologue of human T1 protein as an atypical T2 named T3
0	8	CDKN2T	T1	T2	By constructing deletion mutants we identified that amino acid residues 229-309 of Akt were involved in the binding to T1 and amino acid residues 327-340 of T2 were involved in the binding to Akt
1	47	CDKLNXR	T5	T4	In this report we demonstrate the stable association of T3 with T4 in a clathrin-coated vesicle complex which not only binds to the carboxyl-terminal SH2 domain of T5 but also inhibits its enzymatic activity in a dose-dependent manner
1	12	CDKLN	T3	T4	In this report we demonstrate the stable association of T3 with T4 in a clathrin-coated vesicle complex which not only binds to the carboxyl-terminal SH2 domain of T5 but also inhibits its enzymatic activity in a dose-dependent manner
0	27	CDKLNTR	T3	T5	In this report we demonstrate the stable association of T3 with T4 in a clathrin-coated vesicle complex which not only binds to the carboxyl-terminal SH2 domain of T5 but also inhibits its enzymatic activity in a dose-dependent manner
1	35	CDEFK2	T1	T2	T1 binds to the C-terminal SH2 domain of T2 and inhibits its enzymatic activity
1	20	BCD	T9	T8	To identify the regions of T8 that contact its receptor T9 we substituted all surface-exposed residues with alanine
1	59	BCDKLX	T7	T6	It was previously shown that the N-terminus of T6 is critical for binding T7
0	5	CDK	T5	T4	The receptor binding site of T3 also is significantly different from the binding sites of T4 and T5 providing insight into the issue of receptor specificity
0	10	CDKT	T3	T4	The receptor binding site of T3 also is significantly different from the binding sites of T4 and T5 providing insight into the issue of receptor specificity
0	10	CDKT	T3	T5	The receptor binding site of T3 also is significantly different from the binding sites of T4 and T5 providing insight into the issue of receptor specificity
1	0	CD2	T1	T2	Identification of residues in the T1 that contact the MCP-1 receptor T2
0	5	CDK1	T3	T2	Cloning and characterization of two evolutionarily conserved subunits T1 and T2 of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	5	CDK2	T1	T2	Cloning and characterization of two evolutionarily conserved subunits T1 and T2 of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	5	CDK1	T1	T3	Cloning and characterization of two evolutionarily conserved subunits T1 and T2 of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	20	BCD	T7	T6	T5 promotes coprecipitation of p85 with T6 the signal-transducing component of the T7
1	30	BCDE	T5	T6	T5 promotes coprecipitation of p85 with T6 the signal-transducing component of the T7
0	30	BCDE	T5	T7	T5 promotes coprecipitation of p85 with T6 the signal-transducing component of the T7
0	0	CD	T3	T4	RESULTS: Tyrosine phosphorylation of p85 is upregulated by T3 in both LNCaP and T4
1	30	BCDE2	T1	T2	T1 activates T2 which inhibits apoptosis in human prostate cancer cell lines
0	9	CDL	T9	T8	Previously we showed that the T8 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains T10 and F beta alpha respectively
0	64	CDL1XRS	T10	T8	Previously we showed that the T8 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains T10 and F beta alpha respectively
0	64	CDL1XRS	T10	T9	Previously we showed that the T8 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains T10 and F beta alpha respectively
0	28	BCDNR	T7	T6	This is relevant for the case of LH and FSH because both are synthesized in the same cell i.e. pituitary gonadotrophs and several of the alpha subunit sequences required for association with either the T6 or T7 subunits are different
0	3	CDKN	T5	T4	The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/T4 subunit since CG single chain interacts with the monomeric T5 subunit and exhibits FSH activity
0	20	BCD1	T3	T2	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the T2 and T3 monomer
0	20	BCD2	T1	T2	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the T2 and T3 monomer
0	20	BCD1	T1	T3	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the T2 and T3 monomer
1	14	CDKL	T7	T8	Secondly T7 induces expression of an extracellular activation epitope of T8 and the exchange factor function is not essential for this activity
1	60	CDK1XRS	T10	T9	In contrast LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a T9 mutant which fails to catalyze T10 GDP-GTP exchange in vitro
1	5	CDK	T5	T6	Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of T5 depends on its interaction with T6 unless the integrin is activated by exogenous divalent cations
1	24	CDKLR	T3	T4	Here we provide evidence of how T3 an integrin-binding protein and guanine-nucleotide exchange factor GEF for T4 GTPases regulates cell adhesion
1	55	BCDEFK2	T1	T2	T1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with T2
1	50	CDK2XS	T12	T11	Thus T11 is involved in the activation of T12 most probably through direct interaction with the integrin and induces cell spreading by its ARF-GEF activity
0	0	CD	T4	T6	Immobilized T3 also bound T4 besides T5 and T6
0	0	CD	T5	T6	Immobilized T3 also bound T4 besides T5 and T6
1	50	CDTUS	T3	T6	Immobilized T3 also bound T4 besides T5 and T6
0	0	CD	T5	T4	Immobilized T3 also bound T4 besides T5 and T6
1	50	CDTUS	T3	T4	Immobilized T3 also bound T4 besides T5 and T6
1	50	CDTUS	T3	T5	Immobilized T3 also bound T4 besides T5 and T6
0	0	CD2	T1	T2	In solution FGFR4ed formed complexes with T1 and T2 both in the presence and absence of heparin
0	37	CDLNRS	T6	T8	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	7	CDLN	T7	T8	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	37	CDLNRS	T5	T8	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	50	CDK1XS	T10	T9	Finally a direct interaction between PPARgamma and T9 was confirmed by T10 pull-down assay
0	37	CDLNRS	T7	T6	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	22	CDLNQ	T5	T6	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	37	CDLNRS	T5	T7	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	22	CDLNQ	T3	T4	Deletion analysis showed that the element responsible for the PPARgamma effect is located in a region containing the nuclear factor E2 T3/T4 site -98/-88 which was indicated to be the major promoter of the TXS gene
1	5	CDK2	T1	T2	Suppression of rat thromboxane synthase gene transcription by T1 in macrophages via an interaction with T2
0	0	CD	T9	T8	Preincubation with genistein a tyrosine kinase inhibitor blocked the GH-stimulated adhesion and T8 T9 p125FAK and T10 phosphorylation
0	0	CD1	T10	T8	Preincubation with genistein a tyrosine kinase inhibitor blocked the GH-stimulated adhesion and T8 T9 p125FAK and T10 phosphorylation
0	0	CD1	T10	T9	Preincubation with genistein a tyrosine kinase inhibitor blocked the GH-stimulated adhesion and T8 T9 p125FAK and T10 phosphorylation
0	0	CD	T7	T6	Pituitary GH triggered the tyrosine phosphorylation of T5 T6 and T7 in neutrophils
0	0	CD	T5	T6	Pituitary GH triggered the tyrosine phosphorylation of T5 T6 and T7 in neutrophils
0	0	CD	T5	T7	Pituitary GH triggered the tyrosine phosphorylation of T5 T6 and T7 in neutrophils
0	9	CDL	T3	T4	These results suggest that pituitary GH modulates neutrophil adhesion through tyrosine phosphorylation of T3 p125FAK and T4 and actin polymerization
0	0	CD2	T1	T2	Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of T1 p125FAK and T2
1	0	CD2	T12	T11	Immunoprecipitation experiments revealed a physical association of T11 with p125FAK via T12 in vivo
0	42	CDLNTRS	T6	T8	In contrast phosphorylation of T6 by ATR is independent of T7 and replication protein A suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
0	27	CDLNS	T7	T8	In contrast phosphorylation of T6 by ATR is independent of T7 and replication protein A suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
0	18	CDN1S	T10	T9	In addition both T9 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG and phosphorylation of T11 is required for cellular survival
0	43	CDN1XS	T11	T9	In addition both T9 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG and phosphorylation of T11 is required for cellular survival
0	62	CDLNXRS	T7	T6	In contrast phosphorylation of T6 by ATR is independent of T7 and replication protein A suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
1	54	BCDLX	T5	T4	We found that phosphorylation of T4 by ATR also requires checkpoint proteins T5 and replication protein A
0	18	BCDN1	T3	T2	We report that T1 MutS homolog 2 protein interacts with the ATR ATM- and Rad3-related kinase to form a signaling module and regulate the phosphorylation of T2 and T3 structure maintenance of chromosome 1
1	48	BCDN2TU	T1	T2	We report that T1 MutS homolog 2 protein interacts with the ATR ATM- and Rad3-related kinase to form a signaling module and regulate the phosphorylation of T2 and T3 structure maintenance of chromosome 1
1	48	BCDN1TU	T1	T3	We report that T1 MutS homolog 2 protein interacts with the ATR ATM- and Rad3-related kinase to form a signaling module and regulate the phosphorylation of T2 and T3 structure maintenance of chromosome 1
0	23	CDN2X	T11	T10	In addition both T9 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG and phosphorylation of T11 is required for cellular survival
1	75	BCDEFKS	T9	T8	T8 is modified by T9 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
0	75	BCDEFK1S	T10	T8	T8 is modified by T9 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
0	25	BCDK1	T10	T9	T8 is modified by T9 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
1	67	CDKLNXRS	T7	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	12	CDKLN	T4	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	12	CDKLN	T5	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	22	CDKLNR	T3	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	47	CDKLNTRS	T4	T7	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	47	CDKLNTRS	T5	T7	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	47	CDKLNTRS	T3	T7	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	12	CDKLN	T5	T4	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	22	CDKLNR	T3	T4	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	22	CDKLNR	T3	T5	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	5	CDK2	T1	T2	Modification of de novo DNA methyltransferase 3a T1 by T2 modulates its interaction with histone deacetylases HDACs and its capacity to repress transcription
1	5	CDK2	T12	T11	Functionally sumoylation of T11 disrupts its ability to interact with histone deacetylases T12/2 but not with another interaction partner T13
0	55	CDK2XY	T13	T11	Functionally sumoylation of T11 disrupts its ability to interact with histone deacetylases T12/2 but not with another interaction partner T13
0	5	CDK2	T13	T12	Functionally sumoylation of T11 disrupts its ability to interact with histone deacetylases T12/2 but not with another interaction partner T13
1	19	CDKLT	T3	T4	These results suggest that the relative abundance of the two splice variants of T3 in brain could be an important determinant for the expression of T4
1	39	CDKL2TS	T1	T2	Transient expression of the full-length T1 without RSRS in U1240MG glioblastoma cells resulted in repression of T2 promoter activity
1	78	BCDN2TURS	T1	T2	We report here that PLZF and a structurally similar transcriptional repressor T1 can interact with a variety of corepressor proteins in addition to SMRT including the mSin3A protein and for PLZF T2
0	10	CDKT	T4	T6	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	5	CDK	T5	T6	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
0	10	CDKT	T3	T6	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	30	CDKX	T5	T4	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
0	5	CDK	T3	T4	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	10	CDKT	T3	T5	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	5	CDK2	T1	T2	Specific interaction of T1 and c/EBPbeta leads to the transcriptional activation of the human T2 gene
0	5	CDK	T9	T8	The interaction between AR and T7 was assessed by T8 T9 pull-down assay and mammalian two-hybrid system assay
0	30	CDKTS	T7	T8	The interaction between AR and T7 was assessed by T8 T9 pull-down assay and mammalian two-hybrid system assay
0	30	CDKTS	T7	T9	The interaction between AR and T7 was assessed by T8 T9 pull-down assay and mammalian two-hybrid system assay
0	9	CDL	T4	T6	BACKGROUND: Both T4 AR and orphan receptor T5 T6 belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	9	CDL	T5	T6	BACKGROUND: Both T4 AR and orphan receptor T5 T6 belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	9	CDL	T5	T4	BACKGROUND: Both T4 AR and orphan receptor T5 T6 belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	20	BCD1	T3	T2	T1 orphan receptor functions as negative modulator for T2 in prostate cancer cells T3
1	30	BCDE2	T1	T2	T1 orphan receptor functions as negative modulator for T2 in prostate cancer cells T3
0	30	BCDE1	T1	T3	T1 orphan receptor functions as negative modulator for T2 in prostate cancer cells T3
1	24	CDL2TR	T13	T14	Blockade of T13 expression by small interfering RNA siRNA causes prolonged degradation kinetics of T14
0	25	CDK2S	T16	T15	Several distinct mutations in exon 2 of T15 disrupt binding of T16 to T17
1	25	CDK2S	T17	T15	Several distinct mutations in exon 2 of T15 disrupt binding of T16 to T17
1	5	CDK2	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of T16 to T17
1	34	CDL2X	T11	T10	Overexpression of T10 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of T12
0	44	CDL2XR	T12	T10	Overexpression of T10 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of T12
1	44	CDL2XR	T12	T11	Overexpression of T10 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of T12
1	35	CD2XR	T19	T18	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	55	CD2XRS	T21	T18	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	35	CD2XR	T20	T18	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	55	CD2XRS	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	0	CD2	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	0	CD	T9	T8	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
1	10	CDE	T6	T8	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
0	0	CD	T7	T8	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
1	10	CDE	T6	T9	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
0	0	CD	T7	T9	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
1	10	CDE	T7	T6	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
0	34	BCDKL	T5	T4	We establish that T3 binds to T4 T5 a component of the 19S regulatory complex of the proteasome
1	34	BCDKL	T3	T4	We establish that T3 binds to T4 T5 a component of the 19S regulatory complex of the proteasome
1	34	BCDKL	T3	T5	We establish that T3 binds to T4 T5 a component of the 19S regulatory complex of the proteasome
1	15	CD2TR	T1	T2	The protein T1 functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor T2 for proteasomal degradation during normoxia
0	35	CD2TRS	T20	T21	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
1	74	CDKLTURS	T22	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	59	CDKL1XS	T25	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	14	CDKL	T24	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	59	CDKLXS	T26	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	94	CDKL1XYRS	T25	T22	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
1	94	CDKLXYRS	T24	T22	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	94	CDKLXYRS	T26	T22	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	39	CDKL1TS	T24	T25	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
1	14	CDKL1	T26	T25	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	59	CDKLXS	T26	T24	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	0	CD	T5	T6	Three SR-rich proteins were identified that interact with the C-terminus of Pnn: T5 and T6 known components of spliceosome machinery and a novel 130-kDa nuclear protein SRrp130
1	0	CD1	T2	T4	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
0	0	CD	T3	T4	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
1	0	CD1	T1	T4	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
1	0	CD1	T3	T2	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
0	15	CDQ2	T1	T2	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
1	0	CD1	T1	T3	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
0	12	CDLNT	T6	T8	The results of complementation experiments show that in contrast to mouse T6 mouse T7 can partially alleviate the growth defect of the corresponding yeast null strain indicating that the role of T8 in pre-rRNA processing is evolutionarily conserved
0	12	CDLNT	T7	T8	The results of complementation experiments show that in contrast to mouse T6 mouse T7 can partially alleviate the growth defect of the corresponding yeast null strain indicating that the role of T8 in pre-rRNA processing is evolutionarily conserved
0	9	CDL1	T10	T9	The results of density gradient centrifugation experiments show that in contrast to hU3-55K the human T9 and T10 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
1	9	CDL1	T11	T9	The results of density gradient centrifugation experiments show that in contrast to hU3-55K the human T9 and T10 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
0	7	CDLN	T7	T6	The results of complementation experiments show that in contrast to mouse T6 mouse T7 can partially alleviate the growth defect of the corresponding yeast null strain indicating that the role of T8 in pre-rRNA processing is evolutionarily conserved
0	20	BCD	T5	T4	We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins T4 and T5
1	35	CD1XR	T3	T2	The human T1 and T2 proteins form a ternary complex with hMpp10 which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	20	CD2S	T1	T2	The human T1 and T2 proteins form a ternary complex with hMpp10 which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	35	CD1TRS	T1	T3	The human T1 and T2 proteins form a ternary complex with hMpp10 which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	9	CDL2	T11	T10	The results of density gradient centrifugation experiments show that in contrast to hU3-55K the human T9 and T10 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
0	30	CDRS	T7	T8	In addition electron microscopy experiments revealed that T7 and T8 are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers
0	34	CDLTS	T4	T6	In contrast to T4 the potency of direct activation of T5 was not affected by co-expression with T6
0	34	CDLTS	T5	T6	In contrast to T4 the potency of direct activation of T5 was not affected by co-expression with T6
0	9	CDL	T5	T4	In contrast to T4 the potency of direct activation of T5 was not affected by co-expression with T6
0	9	CDL1	T3	T2	In the present study we observed evidence of cross-talk between the cannabinoid receptor T1 and the T2 T3 using a heterologous system
1	9	CDL2	T1	T2	In the present study we observed evidence of cross-talk between the cannabinoid receptor T1 and the T2 T3 using a heterologous system
1	9	CDL1	T1	T3	In the present study we observed evidence of cross-talk between the cannabinoid receptor T1 and the T2 T3 using a heterologous system
0	114	BCDKL2XYRS	T15	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	BCDKL2TURS	T12	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	BCDKL2TURS	T13	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	BCDKL2TURS	T12	T15	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	BCDKL2TURS	T13	T15	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
0	0	CD2	T17	T16	This work led to identification of a novel T16 T17 for Rho family GTPases
1	45	CD2XS	T11	T10	In addition T10 contains several classic proline-rich motifs and it interacts with the first SH3 domain of Crk and full-length T11 in vitro
0	34	BCDKL2	T13	T12	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
0	39	CDKL2X	T19	T18	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA T19 and T20 in vitro
0	39	CDKL2X	T20	T18	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA T19 and T20 in vitro
0	14	CDKL2	T20	T19	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA T19 and T20 in vitro
0	0	CD	T9	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	15	CDTR	T6	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
0	0	CD	T7	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	20	CDER	T5	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	15	CDTR	T6	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
0	0	CD	T7	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	20	CDER	T5	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	35	CDXR	T7	T6	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
0	10	CDE	T5	T6	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	20	CDER	T5	T7	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	10	CD1R	T2	T4	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
0	0	CD	T3	T4	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	20	CDE1R	T1	T4	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	10	CD1R	T3	T2	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
0	10	CDE2	T1	T2	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	20	CDE1R	T1	T3	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	85	CDK1XYRS	T23	T21	The protein was named T21 for its ability to interact with T22 proteins and its activity toward Rac and T23
1	85	CDK1XYRS	T22	T21	The protein was named T21 for its ability to interact with T22 proteins and its activity toward Rac and T23
0	5	CDK	T22	T23	The protein was named T21 for its ability to interact with T22 proteins and its activity toward Rac and T23
1	25	CD1TS	T24	T25	Expression of T24 in 293T cells led to a reduction in active T25 and T26 levels but not RhoA
0	0	CD1	T26	T25	Expression of T24 in 293T cells led to a reduction in active T25 and T26 levels but not RhoA
1	45	CDXS	T26	T24	Expression of T24 in 293T cells led to a reduction in active T25 and T26 levels but not RhoA
0	47	CDKLNTRS	T6	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	37	CDKLNTS	T7	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	47	CDKLNTRS	T4	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	47	CDKLNTRS	T5	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	47	CDKLNTRS	T3	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	62	CDLN1XRS	T10	T9	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	62	CDLN1XRS	T11	T9	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	62	CDLN1XRS	T12	T9	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	47	CDKLNXR	T7	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	17	CDKLNT	T4	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	17	CDKLNT	T5	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	17	CDKLNT	T3	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	27	CDKLNTR	T4	T7	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	27	CDKLNTR	T5	T7	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	27	CDKLNTR	T3	T7	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	12	CDKLN	T5	T4	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	12	CDKLN	T3	T4	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	12	CDKLN	T3	T5	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	0	CD2	T1	T2	A role for T1 phosphorylation of T2 in cytokinesis
1	9	CDL2	T13	T14	These results suggest that T13 phosphorylation of T14 may influence cytokinesis
0	7	CDLN2	T11	T10	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	7	CDLN2	T12	T10	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	7	CDLN2	T12	T11	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
1	12	CDKLN	T9	T8	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	CDKLN1XS	T10	T8	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	CDKLN1XS	T11	T8	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	CDKLN1XS	T10	T9	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	CDKLN1XS	T11	T9	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	5	CDK	T7	T6	T5/T6 'T7'-binding protein CBP interacting with transcription factors is able to increase their activity on target gene promoters
0	20	CDKQ	T5	T6	T5/T6 'T7'-binding protein CBP interacting with transcription factors is able to increase their activity on target gene promoters
0	5	CDK	T5	T7	T5/T6 'T7'-binding protein CBP interacting with transcription factors is able to increase their activity on target gene promoters
1	5	CDK1	T2	T4	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
1	5	CDK	T3	T4	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
1	5	CDK1	T1	T4	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
0	5	CDK1	T3	T2	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
0	20	CDKQ2	T1	T2	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
0	5	CDK1	T1	T3	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
1	12	CDKLN2	T11	T10	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	40	BCDER	T5	T4	T4 is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing T5
1	0	CD1	T3	T2	A prominent isolate designated T1/T2 specifically interacts with the T3 not only in vivo but also in vitro
0	15	CDQ2	T1	T2	A prominent isolate designated T1/T2 specifically interacts with the T3 not only in vivo but also in vitro
1	0	CD1	T1	T3	A prominent isolate designated T1/T2 specifically interacts with the T3 not only in vivo but also in vitro
1	30	CDES	T7	T8	T7 also interacted with other members of the catenin gene family including T8 and gamma-catenin
0	69	CDKL1XRS	T10	T9	The interaction with T9 is likely to be direct as the interaction occurs in K562 cells lacking functional adherens junctions and T10 expression
0	44	CDLTRS	T4	T6	The T4 T5 also known as T6 is expressed predominantly in epithelial cells in a variety of tumor cell lines and in lymphocytes
0	44	CDLTRS	T5	T6	The T4 T5 also known as T6 is expressed predominantly in epithelial cells in a variety of tumor cell lines and in lymphocytes
0	9	CDL	T5	T4	The T4 T5 also known as T6 is expressed predominantly in epithelial cells in a variety of tumor cell lines and in lymphocytes
1	25	CD1X	T3	T2	The transmembrane T1 T2 interacts with T3
0	0	CD2	T1	T2	The transmembrane T1 T2 interacts with T3
1	5	CD1T	T1	T3	The transmembrane T1 T2 interacts with T3
0	12	CDKLN2	T12	T11	Catalytic domains of the tyrosine phosphatases T11 T12 and PTPbeta did not interact with proteins of the catenin family to detectable levels suggesting that the interaction of T13 with these proteins is specific
0	67	CDKLN2XRS	T13	T11	Catalytic domains of the tyrosine phosphatases T11 T12 and PTPbeta did not interact with proteins of the catenin family to detectable levels suggesting that the interaction of T13 with these proteins is specific
0	67	CDKLN2XRS	T13	T12	Catalytic domains of the tyrosine phosphatases T11 T12 and PTPbeta did not interact with proteins of the catenin family to detectable levels suggesting that the interaction of T13 with these proteins is specific
0	0	CD	T6	T8	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	0	CD	T7	T8	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	10	CDE	T5	T8	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	45	CD1XS	T10	T9	TBP and T9 however were not able to interact with T10
0	0	CD	T7	T6	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
1	10	CDE	T5	T6	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
1	10	CDE	T5	T7	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	0	CD	T3	T4	In contrast to T3 T4 did not interact with the AF2 domain of RXR
0	19	CDLO2T	T1	T2	Herein we show that a distinct IkappaB protein T1 also interacts with RXR as shown in the yeast two-hybrid tests and T2 pull-down assays
0	14	CDKL2	T13	T14	In addition coexpression of T13 but not T14 further stimulated the Bcl3-mediated enhancement of the 9-cis-RA-induced transactivations of RXR
0	40	CDK2XR	T12	T11	Accordingly T11 coactivated the 9-cis-RA-induced transactivations of RXR in contrast to the inhibitory actions of T12
1	60	[2, 3, 4, 11, 24, 29, 30]	T4	T6	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
1	60	[2, 3, 4, 11, 24, 29, 30]	T5	T6	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
0	45	[2, 3, 4, 11, 30]	T5	T4	However cytokines in particular T4 and T5 potentiated the DNA synthesis induced by cross-linking of T6
0	37	[3, 4, 11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag T2 increases in cellular volume RNA synthesis and T3 protein levels and enhanced binding of 7-aminoactinomycin D
1	27	[3, 4, 11, 12, 14, 18, 24, 29]	T1	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag T2 increases in cellular volume RNA synthesis and T3 protein levels and enhanced binding of 7-aminoactinomycin D
1	27	[3, 4, 11, 12, 14, 19, 24, 29]	T1	T3	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag T2 increases in cellular volume RNA synthesis and T3 protein levels and enhanced binding of 7-aminoactinomycin D
0	47	[3, 4, 11, 12, 14, 18, 24, 29, 30]	T11	T14	In the present investigation the differential binding of previously characterized endothelial cell EC  and smooth muscle cell T11 derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	47	[3, 4, 11, 12, 14, 18, 24, 29, 30]	T12	T14	In the present investigation the differential binding of previously characterized endothelial cell EC- and smooth muscle cell T11-derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	17	[3, 4, 11, 12, 14, 18, 24]	T13	T14	In the present investigation the differential binding of previously characterized endothelial cell EC- and smooth muscle cell T11-derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	58	[3, 4, 11, 14, 18, 26, 29, 30]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta 1-28 produced strong immunoreactivity with A beta antibodies at tissue sites enriched in T15 which was partially removed by pretreatment with heparitinase but not by chondroitin T16 lyase
0	78	[2, 3, 4, 11, 14, 18, 26, 29, 30]	T18	T17	[35S]-Sulfate labeled proteoglycans T17 derived from cultured ECs and SMCs bound to affinity columns containing A beta 1-28 or 1-40 with virtually no binding to A beta 40-1 reverse peptide beta-amyloid precursor protein 410-429 or bovine T18
0	72	[3, 4, 11, 12, 14, 19, 24, 25, 29, 30]	T9	T10	Overall the results indicate that specific vascular cell-derived T9 differentially interact with A beta and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of T10
0	37	[3, 4, 11, 12, 14, 18, 26]	T12	T11	In the present investigation the differential binding of previously characterized endothelial cell EC  and smooth muscle cell T11 derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	67	[3, 4, 11, 12, 14, 18, 26, 29, 30]	T13	T11	In the present investigation the differential binding of previously characterized endothelial cell EC  and smooth muscle cell T11 derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	67	[3, 4, 11, 12, 14, 18, 26, 29, 30]	T13	T12	In the present investigation the differential binding of previously characterized endothelial cell EC- and smooth muscle cell T11-derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	38	[3, 4, 11, 14, 18, 26, 29]	T21	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	[3, 4, 11, 14, 18]	T20	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	38	[3, 4, 11, 14, 19, 26, 29]	T23	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	38	[3, 4, 11, 14, 19, 26, 29]	T22	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 18, 29]	T25	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 19, 29]	T24	T19	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	7	[3, 4, 12, 14]	T6	T8	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
0	7	[3, 4, 12, 14]	T7	T8	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
1	7	[3, 4, 12, 14]	T5	T8	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
1	7	[3, 4, 12, 14]	T7	T6	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
0	7	[3, 4, 12, 14]	T5	T6	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
1	7	[3, 4, 12, 14]	T5	T7	Previous studies have demonstrated the immunolocalization of T5 a specific T6 to the T7 protein A beta-containing T8 deposits within the walls of blood vessels i.e. congophilic angiopathy in Alzheimer's disease AD brain
0	5	[3, 4, 11, 19]	T2	T4	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	[3, 4, 11]	T3	T4	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	[3, 4, 11, 19]	T1	T4	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	[3, 4, 11, 19]	T3	T2	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	[3, 4, 11, 18]	T1	T2	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
0	5	[3, 4, 11, 19]	T1	T3	Differential binding of vascular cell-derived proteoglycans T1 T2 T3 and T4 to the beta-amyloid protein of Alzheimer's disease
1	18	[3, 4, 11, 14, 18, 24, 29]	T20	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	[3, 4, 11, 14, 19]	T23	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	[3, 4, 11, 14, 19]	T22	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 18, 29]	T25	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 19, 29]	T24	T21	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	38	[3, 4, 11, 14, 19, 26, 29]	T23	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	38	[3, 4, 11, 14, 19, 26, 29]	T22	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 18, 29]	T25	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 19, 29]	T24	T20	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	3	[3, 4, 11, 14]	T22	T23	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 19, 29]	T25	T23	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 29]	T24	T23	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 19, 29]	T25	T22	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	13	[3, 4, 11, 14, 29]	T24	T22	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
0	18	[3, 4, 11, 14, 17, 19]	T24	T25	Characterization of EC and T19 T20 bound to A beta 1-28 revealed strong binding by T21 weak binding by T22 and T23 two dermatan sulfate proteoglycans and lack of binding by T24/T25 a large chondroitin sulfate proteoglycan
1	34	[2, 3, 4, 12, 24]	T3	T4	We show here that T3 phosphatase associates with T4 in somatic mammalian cells and in meiotic frog oocytes
1	35	[3, 4, 5, 6, 11, 18]	T1	T2	T1 interaction with T2 phosphatase ties mitogenic signal transduction to cell cycle activation
0	45	[3, 4, 19, 26, 30]	T3	T2	The tyrosine kinase T1 is physically associated with the Type I interferon T2 receptor complex and is rapidly activated during T3 stimulation
1	35	[3, 4, 18, 24, 29, 30]	T1	T2	The tyrosine kinase T1 is physically associated with the Type I interferon T2 receptor complex and is rapidly activated during T3 stimulation
1	35	[3, 4, 19, 24, 29, 30]	T1	T3	The tyrosine kinase T1 is physically associated with the Type I interferon T2 receptor complex and is rapidly activated during T3 stimulation
0	40	[3, 4, 11, 19, 24, 29, 30]	T2	T4	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
1	5	[3, 4, 11]	T3	T4	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	65	[3, 4, 5, 6, 11, 19, 29, 30]	T1	T4	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	60	[3, 4, 11, 19, 26, 29, 30]	T3	T2	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	45	[3, 4, 5, 6, 11, 18, 29]	T1	T2	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
1	65	[3, 4, 5, 6, 11, 19, 29, 30]	T1	T3	T1 dimers formed through self-association of the TATA-binding polypeptide T2 subunit and could be immunoprecipitated with antibodies to T3 the core subunit of T4
0	25	[3, 4, 24, 30]	T6	T8	The association of T6 with T7 was mediated by the NH2-terminal Src homology 2 SH2 domain of T8
1	25	[3, 4, 24, 30]	T7	T8	The association of T6 with T7 was mediated by the NH2-terminal Src homology 2 SH2 domain of T8
1	0	[3, 4, 19]	T10	T9	Complexes of either T9/T10/Syk/PLC-gamma1 could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate respectively
1	0	[3, 4]	T7	T6	The association of T6 with T7 was mediated by the NH2-terminal Src homology 2 SH2 domain of T8
1	34	[3, 4, 12, 26]	T5	T4	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for T4 regulates tyrosyl phosphorylation of T5
1	14	[3, 4, 12, 24]	T3	T4	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for T4 regulates tyrosyl phosphorylation of T5
0	14	[3, 4, 12, 24]	T3	T5	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for T4 regulates tyrosyl phosphorylation of T5
1	10	[3, 4, 5, 18]	T1	T2	T1 associates with T2 Syk and phospholipase C-gamma1 upon B cell activation
0	45	[3, 4, 18, 26, 30]	T15	T14	By contrast T14 was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type T15
0	14	[3, 4, 11, 12, 18]	T12	T11	Transient expression of T11 and a null mutant of T12 PTP-1CM in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
0	59	[3, 4, 11, 12, 18, 26, 30]	T13	T11	Transient expression of T11 and a null mutant of T12 PTP-1CM in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
1	59	[3, 4, 11, 12, 18, 26, 30]	T13	T12	Transient expression of T11 and a null mutant of T12 PTP-1CM in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
0	29	[2, 3, 4, 12]	T3	T4	We used cDNA probes for the T3 T4 and Etfa genes to determine localization of these mouse genes to chromosomes 3 7 and 13
0	0	[3, 4, 18]	T1	T2	Assignment of T1 T2 and Etfa to chromosomes 3 7 and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human
0	35	[3, 4, 26, 29]	T5	T4	The fact that the T3 mRNA editing protein also exists as a T4 has important implications for the mechanism of T5 mRNA editing in humans
0	25	[3, 4, 24, 30]	T3	T4	The fact that the T3 mRNA editing protein also exists as a T4 has important implications for the mechanism of T5 mRNA editing in humans
0	35	[3, 4, 24, 29, 30]	T3	T5	The fact that the T3 mRNA editing protein also exists as a T4 has important implications for the mechanism of T5 mRNA editing in humans
0	44	[3, 4, 12, 18, 24, 29, 30]	T1	T2	The human T1 mRNA editing protein is a T2 showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases
1	44	[2, 3, 4, 12, 15, 29]	T5	T4	This suggests that transmembrane T4 by providing docking sites for the Src homology 3 domain of T5 activates PI 3-kinase by mediating its recruitment to the membrane
1	30	[3, 4, 11, 19, 26]	T3	T2	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of T2 activates T3 in C2C12 cells
1	5	[3, 4, 11, 18]	T1	T2	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of T2 activates T3 in C2C12 cells
1	10	[3, 4, 11, 19, 24]	T1	T3	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of T2 activates T3 in C2C12 cells
1	94	[2, 3, 4, 5, 6, 11, 12, 29, 30]	T7	T8	T7 expressed in COS cells supported increased binding to immobilized T8
1	7	[3, 4, 12, 14, 19]	T10	T9	Finally T9 bound different glycoforms of T10 expressed in Chinese hamster ovary cells including unbranched core 1 and branched core 2 O:-linked glycans that are normally found on T11 in resting and activated T cells respectively
0	62	[3, 4, 12, 14, 19, 26, 29, 30]	T11	T9	Finally T9 bound different glycoforms of T10 expressed in Chinese hamster ovary cells including unbranched core 1 and branched core 2 O:-linked glycans that are normally found on T11 in resting and activated T cells respectively
0	5	[3, 4, 11]	T4	T6	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and T5 T6 respectively
0	5	[3, 4, 11]	T5	T6	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and T5 T6 respectively
0	5	[3, 4, 11]	T5	T4	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and T5 T6 respectively
0	0	[3, 4, 19]	T3	T2	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 T3
1	0	[3, 4, 18]	T1	T2	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 T3
1	0	[3, 4, 19]	T1	T3	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 T3
0	49	[3, 4, 11, 12, 18, 24, 29, 30]	T12	T14	These results identify T12 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
0	49	[3, 4, 11, 12, 18, 24, 29, 30]	T13	T14	These results identify T12 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
0	62	[3, 4, 12, 14, 18, 26, 29, 30]	T11	T10	Finally T9 bound different glycoforms of T10 expressed in Chinese hamster ovary cells including unbranched core 1 and branched core 2 O:-linked glycans that are normally found on T11 in resting and activated T cells respectively
1	14	[3, 4, 11, 12, 18]	T13	T12	These results identify T12 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
1	24	[3, 4, 12, 24, 29]	T7	T8	This work suggests that T7 is a regulated adapter between T8 and cytoplasmic dynein at sites involved in cargo-MT loading and/or in the control of MT dynamics
0	44	[3, 4, 11, 12, 29, 30]	T4	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	14	[3, 4, 11, 12]	T5	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	44	[3, 4, 11, 12, 29, 30]	T3	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	44	[3, 4, 11, 12, 29, 30]	T5	T4	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
1	14	[3, 4, 11, 12]	T3	T4	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	44	[3, 4, 11, 12, 29, 30]	T3	T5	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
1	14	[3, 4, 11, 12, 18]	T1	T2	Here we demonstrate colocalization and direct interaction between T1 and T2
0	-2	[3, 4, 14]	T9	T8	Specific glutamines or lysines of T7 were used to cross-link the different proteins such as glutamines 495 and 496 to T8 glutamine 288 to keratins and lysines 468 485 and 508 and glutamines 465 and 489 for interchain T9 cross-links
0	33	[3, 4, 14, 24, 29, 30]	T7	T8	Specific glutamines or lysines of T7 were used to cross-link the different proteins such as glutamines 495 and 496 to T8 glutamine 288 to keratins and lysines 468 485 and 508 and glutamines 465 and 489 for interchain T9 cross-links
0	33	[3, 4, 14, 24, 29, 30]	T7	T9	Specific glutamines or lysines of T7 were used to cross-link the different proteins such as glutamines 495 and 496 to T8 glutamine 288 to keratins and lysines 468 485 and 508 and glutamines 465 and 489 for interchain T9 cross-links
0	33	[2, 3, 4, 14, 24, 29]	T4	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	[2, 3, 4, 14, 24, 29]	T5	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	[2, 3, 4, 14, 19, 24, 29]	T2	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	[2, 3, 4, 14, 24, 29]	T3	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	53	[2, 3, 4, 14, 19, 24, 29, 30]	T1	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	53	[2, 3, 4, 14, 26, 29]	T5	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	18	[2, 3, 4, 14, 19]	T2	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	18	[2, 3, 4, 14]	T3	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	48	[2, 3, 4, 14, 19, 29, 30]	T1	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	[2, 3, 4, 14, 19, 24, 29]	T2	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	33	[2, 3, 4, 14, 24, 29]	T3	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	53	[2, 3, 4, 14, 19, 24, 29, 30]	T1	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
0	18	[2, 3, 4, 14, 19]	T3	T2	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	48	[2, 3, 4, 14, 18, 29, 30]	T1	T2	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	48	[2, 3, 4, 14, 19, 29, 30]	T1	T3	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components including T2 T3 T4 keratins members of the small proline-rich superfamily T5 and unknown proteins related to the T6 family
1	25	[3, 4, 26]	T9	T8	In addition T8 was immunoprecipitated from human neutrophil lysates by anti-human T9 mAb
0	49	[2, 3, 4, 12, 30]	T7	T6	T5 detected by anti-CD18 mAb was coprecipitated with T6 from human neutrophil lysates by a mAb to T7
1	69	[2, 3, 4, 5, 12, 29, 30]	T5	T6	T5 detected by anti-CD18 mAb was coprecipitated with T6 from human neutrophil lysates by a mAb to T7
0	69	[2, 3, 4, 5, 12, 29, 30]	T5	T7	T5 detected by anti-CD18 mAb was coprecipitated with T6 from human neutrophil lysates by a mAb to T7
1	50	[2, 3, 4, 11, 24, 30]	T3	T4	To clarify the mechanisms by which T3 functions on leukocytes we explored the possibility of its physical association with T4 which is important for leukocyte adherence locomotion and extravasation
1	0	[3, 4, 18]	T1	T2	Physical association of T1 with T2 a novel glycosylphosphatidylinositol-anchored protein with potential for regulating adhesion and migration
1	54	[3, 4, 12, 18, 26, 30]	T11	T10	These results clearly show that T10 is physically associated with T11 in human neutrophils
1	10	[3, 4, 5]	T3	T4	T3 and T4 are two structurally different endocytic receptors that interact to serve such functions
0	10	[3, 4, 5, 18]	T1	T2	T1 and T2: multifunctional endocytic receptors
0	30	[3, 4, 5, 18, 30]	T1	T2	T1 type II isozyme contains a T2 homology domain at the N terminus and a sterile alpha motif domain at the C terminus
1	9	[3, 4, 12, 18]	T12	T14	Yet whether T12 and/or T13 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
1	9	[3, 4, 12, 18]	T13	T14	Yet whether T12 and/or T13 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
0	9	[3, 4, 12, 18]	T16	T15	In this work we show that T15 and T16 specifically interact with the T17/CyclinB1 complex but not with other Cdk/Cyclin complexes in vitro and in vivo
1	9	[3, 4, 12, 18]	T17	T15	In this work we show that T15 and T16 specifically interact with the T17/CyclinB1 complex but not with other Cdk/Cyclin complexes in vitro and in vivo
1	9	[3, 4, 12, 18]	T17	T16	In this work we show that T15 and T16 specifically interact with the T17/CyclinB1 complex but not with other Cdk/Cyclin complexes in vitro and in vivo
1	9	[3, 4, 12, 18]	T11	T10	Recent evidence has implicated T10 in inhibition of T11/cyclinB1 kinase and in G2/M cell cycle arrest
0	9	[3, 4, 12, 18]	T13	T12	Yet whether T12 and/or T13 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
0	5	[3, 4, 11, 18]	T19	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	5	[3, 4, 11, 18]	T21	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	5	[3, 4, 11, 18]	T20	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	15	[3, 4, 11, 19, 29]	T22	T18	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	5	[3, 4, 11, 18]	T21	T19	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	5	[3, 4, 11, 18]	T20	T19	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	15	[3, 4, 11, 19, 29]	T22	T19	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	9	[3, 4, 12]	T9	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	[3, 4, 12]	T6	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	[3, 4, 12]	T7	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	[3, 4, 5, 12]	T4	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	[3, 4, 12]	T5	T8	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	[3, 4, 12]	T6	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	[3, 4, 12]	T7	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	[3, 4, 5, 12]	T4	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	[3, 4, 12]	T5	T9	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	[3, 4, 12]	T7	T6	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	[3, 4, 5, 12]	T4	T6	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	[3, 4, 12]	T5	T6	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	[3, 4, 5, 12]	T4	T7	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	9	[3, 4, 12]	T5	T7	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
0	19	[3, 4, 5, 12]	T5	T4	T4 T5 T6 T7 and T8 T9 constitute a family of evolutionarily conserved small acidic nuclear proteins which have been implicated in terminal differentiation growth suppression and apoptosis
1	15	[3, 4, 11, 19, 29]	T3	T2	T1 and T2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
0	35	[3, 4, 5, 6, 11, 18]	T1	T2	T1 and T2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
1	45	[3, 4, 5, 6, 11, 19, 29]	T1	T3	T1 and T2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
1	5	[3, 4, 11, 18]	T20	T21	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	15	[3, 4, 11, 19, 29]	T22	T21	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	15	[3, 4, 11, 19, 29]	T22	T20	Data also has been obtained that T18 and T19 as well as T20 interact with both T21 and cyclinB1 resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	14	[3, 4, 11, 12, 19]	T25	T23	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
1	14	[3, 4, 11, 12]	T24	T23	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	14	[3, 4, 11, 12]	T26	T23	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	14	[3, 4, 11, 12, 19]	T24	T25	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	39	[3, 4, 11, 12, 19, 26]	T26	T25	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	39	[3, 4, 11, 12, 26]	T26	T24	Inhibition of T23/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex whereas T26 did not disrupt the complex
0	59	[3, 4, 11, 12, 26, 30]	T5	T4	Subcellular fractionation and antibody-uptake experiments indicate that T4 is indeed a type-I membrane protein but unlike other T5 isoforms lacks an N-terminal extracellular domain
0	25	[3, 4, 19, 26]	T3	T2	Here we cloned and characterized a mouse orthologue of human T1 protein as an atypical T2 named T3
0	30	[3, 4, 18, 29, 30]	T1	T2	Here we cloned and characterized a mouse orthologue of human T1 protein as an atypical T2 named T3
0	35	[3, 4, 19, 24, 29, 30]	T1	T3	Here we cloned and characterized a mouse orthologue of human T1 protein as an atypical T2 named T3
0	8	[3, 4, 11, 14, 18, 24]	T1	T2	By constructing deletion mutants we identified that amino acid residues 229-309 of Akt were involved in the binding to T1 and amino acid residues 327-340 of T2 were involved in the binding to Akt
1	47	[3, 4, 11, 12, 14, 26, 29]	T5	T4	In this report we demonstrate the stable association of T3 with T4 in a clathrin-coated vesicle complex which not only binds to the carboxyl-terminal SH2 domain of T5 but also inhibits its enzymatic activity in a dose-dependent manner
1	12	[3, 4, 11, 12, 14]	T3	T4	In this report we demonstrate the stable association of T3 with T4 in a clathrin-coated vesicle complex which not only binds to the carboxyl-terminal SH2 domain of T5 but also inhibits its enzymatic activity in a dose-dependent manner
0	27	[3, 4, 11, 12, 14, 24, 29]	T3	T5	In this report we demonstrate the stable association of T3 with T4 in a clathrin-coated vesicle complex which not only binds to the carboxyl-terminal SH2 domain of T5 but also inhibits its enzymatic activity in a dose-dependent manner
1	35	[3, 4, 5, 6, 11, 18]	T1	T2	T1 binds to the C-terminal SH2 domain of T2 and inhibits its enzymatic activity
1	20	[2, 3, 4]	T9	T8	To identify the regions of T8 that contact its receptor T9 we substituted all surface-exposed residues with alanine
1	59	[2, 3, 4, 11, 12, 26]	T7	T6	It was previously shown that the N-terminus of T6 is critical for binding T7
0	5	[3, 4, 11]	T5	T4	The receptor binding site of T3 also is significantly different from the binding sites of T4 and T5 providing insight into the issue of receptor specificity
0	10	[3, 4, 11, 24]	T3	T4	The receptor binding site of T3 also is significantly different from the binding sites of T4 and T5 providing insight into the issue of receptor specificity
0	10	[3, 4, 11, 24]	T3	T5	The receptor binding site of T3 also is significantly different from the binding sites of T4 and T5 providing insight into the issue of receptor specificity
1	0	[3, 4, 18]	T1	T2	Identification of residues in the T1 that contact the MCP-1 receptor T2
0	5	[3, 4, 11, 19]	T3	T2	Cloning and characterization of two evolutionarily conserved subunits T1 and T2 of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	5	[3, 4, 11, 18]	T1	T2	Cloning and characterization of two evolutionarily conserved subunits T1 and T2 of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	5	[3, 4, 11, 19]	T1	T3	Cloning and characterization of two evolutionarily conserved subunits T1 and T2 of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	20	[2, 3, 4]	T7	T6	T5 promotes coprecipitation of p85 with T6 the signal-transducing component of the T7
1	30	[2, 3, 4, 5]	T5	T6	T5 promotes coprecipitation of p85 with T6 the signal-transducing component of the T7
0	30	[2, 3, 4, 5]	T5	T7	T5 promotes coprecipitation of p85 with T6 the signal-transducing component of the T7
0	0	[3, 4]	T3	T4	RESULTS: Tyrosine phosphorylation of p85 is upregulated by T3 in both LNCaP and T4
1	30	[2, 3, 4, 5, 18]	T1	T2	T1 activates T2 which inhibits apoptosis in human prostate cancer cell lines
0	9	[3, 4, 12]	T9	T8	Previously we showed that the T8 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains T10 and F beta alpha respectively
0	64	[3, 4, 12, 19, 26, 29, 30]	T10	T8	Previously we showed that the T8 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains T10 and F beta alpha respectively
0	64	[3, 4, 12, 19, 26, 29, 30]	T10	T9	Previously we showed that the T8 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains T10 and F beta alpha respectively
0	28	[2, 3, 4, 14, 29]	T7	T6	This is relevant for the case of LH and FSH because both are synthesized in the same cell i.e. pituitary gonadotrophs and several of the alpha subunit sequences required for association with either the T6 or T7 subunits are different
0	3	[3, 4, 11, 14]	T5	T4	The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/T4 subunit since CG single chain interacts with the monomeric T5 subunit and exhibits FSH activity
0	20	[2, 3, 4, 19]	T3	T2	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the T2 and T3 monomer
0	20	[2, 3, 4, 18]	T1	T2	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the T2 and T3 monomer
0	20	[2, 3, 4, 19]	T1	T3	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the T2 and T3 monomer
1	14	[3, 4, 11, 12]	T7	T8	Secondly T7 induces expression of an extracellular activation epitope of T8 and the exchange factor function is not essential for this activity
1	60	[3, 4, 11, 19, 26, 29, 30]	T10	T9	In contrast LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a T9 mutant which fails to catalyze T10 GDP-GTP exchange in vitro
1	5	[3, 4, 11]	T5	T6	Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of T5 depends on its interaction with T6 unless the integrin is activated by exogenous divalent cations
1	24	[3, 4, 11, 12, 29]	T3	T4	Here we provide evidence of how T3 an integrin-binding protein and guanine-nucleotide exchange factor GEF for T4 GTPases regulates cell adhesion
1	55	[2, 3, 4, 5, 6, 11, 18]	T1	T2	T1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with T2
1	50	[3, 4, 11, 18, 26, 30]	T12	T11	Thus T11 is involved in the activation of T12 most probably through direct interaction with the integrin and induces cell spreading by its ARF-GEF activity
0	0	[3, 4]	T4	T6	Immobilized T3 also bound T4 besides T5 and T6
0	0	[3, 4]	T5	T6	Immobilized T3 also bound T4 besides T5 and T6
1	50	[3, 4, 24, 25, 30]	T3	T6	Immobilized T3 also bound T4 besides T5 and T6
0	0	[3, 4]	T5	T4	Immobilized T3 also bound T4 besides T5 and T6
1	50	[3, 4, 24, 25, 30]	T3	T4	Immobilized T3 also bound T4 besides T5 and T6
1	50	[3, 4, 24, 25, 30]	T3	T5	Immobilized T3 also bound T4 besides T5 and T6
0	0	[3, 4, 18]	T1	T2	In solution FGFR4ed formed complexes with T1 and T2 both in the presence and absence of heparin
0	37	[3, 4, 12, 14, 29, 30]	T6	T8	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	7	[3, 4, 12, 14]	T7	T8	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	37	[3, 4, 12, 14, 29, 30]	T5	T8	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	50	[3, 4, 11, 19, 26, 30]	T10	T9	Finally a direct interaction between PPARgamma and T9 was confirmed by T10 pull-down assay
0	37	[3, 4, 12, 14, 29, 30]	T7	T6	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	22	[3, 4, 12, 14, 17]	T5	T6	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	37	[3, 4, 12, 14, 29, 30]	T5	T7	By electrophoretic mobility shift assay using the T5/T6 site and nuclear extracts from macrophages we observed a specific protein-DNA complex formation which was inhibited by a specific antibody against the transcription factor T7 T8
0	22	[3, 4, 12, 14, 17]	T3	T4	Deletion analysis showed that the element responsible for the PPARgamma effect is located in a region containing the nuclear factor E2 T3/T4 site -98/-88 which was indicated to be the major promoter of the TXS gene
1	5	[3, 4, 11, 18]	T1	T2	Suppression of rat thromboxane synthase gene transcription by T1 in macrophages via an interaction with T2
0	0	[3, 4]	T9	T8	Preincubation with genistein a tyrosine kinase inhibitor blocked the GH-stimulated adhesion and T8 T9 p125FAK and T10 phosphorylation
0	0	[3, 4, 19]	T10	T8	Preincubation with genistein a tyrosine kinase inhibitor blocked the GH-stimulated adhesion and T8 T9 p125FAK and T10 phosphorylation
0	0	[3, 4, 19]	T10	T9	Preincubation with genistein a tyrosine kinase inhibitor blocked the GH-stimulated adhesion and T8 T9 p125FAK and T10 phosphorylation
0	0	[3, 4]	T7	T6	Pituitary GH triggered the tyrosine phosphorylation of T5 T6 and T7 in neutrophils
0	0	[3, 4]	T5	T6	Pituitary GH triggered the tyrosine phosphorylation of T5 T6 and T7 in neutrophils
0	0	[3, 4]	T5	T7	Pituitary GH triggered the tyrosine phosphorylation of T5 T6 and T7 in neutrophils
0	9	[3, 4, 12]	T3	T4	These results suggest that pituitary GH modulates neutrophil adhesion through tyrosine phosphorylation of T3 p125FAK and T4 and actin polymerization
0	0	[3, 4, 18]	T1	T2	Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of T1 p125FAK and T2
1	0	[3, 4, 18]	T12	T11	Immunoprecipitation experiments revealed a physical association of T11 with p125FAK via T12 in vivo
0	42	[3, 4, 12, 14, 24, 29, 30]	T6	T8	In contrast phosphorylation of T6 by ATR is independent of T7 and replication protein A suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
0	27	[3, 4, 12, 14, 30]	T7	T8	In contrast phosphorylation of T6 by ATR is independent of T7 and replication protein A suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
0	18	[3, 4, 14, 19, 30]	T10	T9	In addition both T9 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG and phosphorylation of T11 is required for cellular survival
0	43	[3, 4, 14, 19, 26, 30]	T11	T9	In addition both T9 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG and phosphorylation of T11 is required for cellular survival
0	62	[3, 4, 12, 14, 26, 29, 30]	T7	T6	In contrast phosphorylation of T6 by ATR is independent of T7 and replication protein A suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
1	54	[2, 3, 4, 12, 26]	T5	T4	We found that phosphorylation of T4 by ATR also requires checkpoint proteins T5 and replication protein A
0	18	[2, 3, 4, 14, 19]	T3	T2	We report that T1 MutS homolog 2 protein interacts with the ATR ATM- and Rad3-related kinase to form a signaling module and regulate the phosphorylation of T2 and T3 structure maintenance of chromosome 1
1	48	[2, 3, 4, 14, 18, 24, 25]	T1	T2	We report that T1 MutS homolog 2 protein interacts with the ATR ATM- and Rad3-related kinase to form a signaling module and regulate the phosphorylation of T2 and T3 structure maintenance of chromosome 1
1	48	[2, 3, 4, 14, 19, 24, 25]	T1	T3	We report that T1 MutS homolog 2 protein interacts with the ATR ATM- and Rad3-related kinase to form a signaling module and regulate the phosphorylation of T2 and T3 structure maintenance of chromosome 1
0	23	[3, 4, 14, 18, 26]	T11	T10	In addition both T9 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG and phosphorylation of T11 is required for cellular survival
1	75	[2, 3, 4, 5, 6, 11, 30]	T9	T8	T8 is modified by T9 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
0	75	[2, 3, 4, 5, 6, 11, 19, 30]	T10	T8	T8 is modified by T9 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
0	25	[2, 3, 4, 11, 19]	T10	T9	T8 is modified by T9 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
1	67	[3, 4, 11, 12, 14, 26, 29, 30]	T7	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	12	[3, 4, 11, 12, 14]	T4	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	12	[3, 4, 11, 12, 14]	T5	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	22	[3, 4, 11, 12, 14, 29]	T3	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	47	[3, 4, 11, 12, 14, 24, 29, 30]	T4	T7	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	47	[3, 4, 11, 12, 14, 24, 29, 30]	T5	T7	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	47	[3, 4, 11, 12, 14, 24, 29, 30]	T3	T7	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
0	12	[3, 4, 11, 12, 14]	T5	T4	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	22	[3, 4, 11, 12, 14, 29]	T3	T4	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	22	[3, 4, 11, 12, 14, 29]	T3	T5	Here we show that T3 interacts with multiple components of the sumoylation machinery namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and T6 all of which are involved in conjugating the small ubiquitin-like modifier polypeptide T7 to its target proteins
1	5	[3, 4, 11, 18]	T1	T2	Modification of de novo DNA methyltransferase 3a T1 by T2 modulates its interaction with histone deacetylases HDACs and its capacity to repress transcription
1	5	[3, 4, 11, 18]	T12	T11	Functionally sumoylation of T11 disrupts its ability to interact with histone deacetylases T12/2 but not with another interaction partner T13
0	55	[3, 4, 11, 18, 26, 27]	T13	T11	Functionally sumoylation of T11 disrupts its ability to interact with histone deacetylases T12/2 but not with another interaction partner T13
0	5	[3, 4, 11, 18]	T13	T12	Functionally sumoylation of T11 disrupts its ability to interact with histone deacetylases T12/2 but not with another interaction partner T13
1	19	[3, 4, 11, 12, 24]	T3	T4	These results suggest that the relative abundance of the two splice variants of T3 in brain could be an important determinant for the expression of T4
1	39	[3, 4, 11, 12, 18, 24, 30]	T1	T2	Transient expression of the full-length T1 without RSRS in U1240MG glioblastoma cells resulted in repression of T2 promoter activity
1	78	[2, 3, 4, 14, 18, 24, 25, 29, 30]	T1	T2	We report here that PLZF and a structurally similar transcriptional repressor T1 can interact with a variety of corepressor proteins in addition to SMRT including the mSin3A protein and for PLZF T2
0	10	[3, 4, 11, 24]	T4	T6	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	5	[3, 4, 11]	T5	T6	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
0	10	[3, 4, 11, 24]	T3	T6	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	30	[3, 4, 11, 26]	T5	T4	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
0	5	[3, 4, 11]	T3	T4	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	10	[3, 4, 11, 24]	T3	T5	The sterol-independent regulatory element SIRE of the T3 T4 promoter mediates T5 OM-induced transcription of the T6 gene through a cholesterol-independent pathway
1	5	[3, 4, 11, 18]	T1	T2	Specific interaction of T1 and c/EBPbeta leads to the transcriptional activation of the human T2 gene
0	5	[3, 4, 11]	T9	T8	The interaction between AR and T7 was assessed by T8 T9 pull-down assay and mammalian two-hybrid system assay
0	30	[3, 4, 11, 24, 30]	T7	T8	The interaction between AR and T7 was assessed by T8 T9 pull-down assay and mammalian two-hybrid system assay
0	30	[3, 4, 11, 24, 30]	T7	T9	The interaction between AR and T7 was assessed by T8 T9 pull-down assay and mammalian two-hybrid system assay
0	9	[3, 4, 12]	T4	T6	BACKGROUND: Both T4 AR and orphan receptor T5 T6 belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	9	[3, 4, 12]	T5	T6	BACKGROUND: Both T4 AR and orphan receptor T5 T6 belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	9	[3, 4, 12]	T5	T4	BACKGROUND: Both T4 AR and orphan receptor T5 T6 belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	20	[2, 3, 4, 19]	T3	T2	T1 orphan receptor functions as negative modulator for T2 in prostate cancer cells T3
1	30	[2, 3, 4, 5, 18]	T1	T2	T1 orphan receptor functions as negative modulator for T2 in prostate cancer cells T3
0	30	[2, 3, 4, 5, 19]	T1	T3	T1 orphan receptor functions as negative modulator for T2 in prostate cancer cells T3
1	24	[3, 4, 12, 18, 24, 29]	T13	T14	Blockade of T13 expression by small interfering RNA siRNA causes prolonged degradation kinetics of T14
0	25	[3, 4, 11, 18, 30]	T16	T15	Several distinct mutations in exon 2 of T15 disrupt binding of T16 to T17
1	25	[3, 4, 11, 18, 30]	T17	T15	Several distinct mutations in exon 2 of T15 disrupt binding of T16 to T17
1	5	[3, 4, 11, 18]	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of T16 to T17
1	34	[3, 4, 12, 18, 26]	T11	T10	Overexpression of T10 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of T12
0	44	[3, 4, 12, 18, 26, 29]	T12	T10	Overexpression of T10 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of T12
1	44	[3, 4, 12, 18, 26, 29]	T12	T11	Overexpression of T10 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of T12
1	35	[3, 4, 18, 26, 29]	T19	T18	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	55	[3, 4, 18, 26, 29, 30]	T21	T18	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	35	[3, 4, 18, 26, 29]	T20	T18	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	55	[3, 4, 18, 26, 29, 30]	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	0	[3, 4, 18]	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
0	0	[3, 4]	T9	T8	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
1	10	[3, 4, 5]	T6	T8	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
0	0	[3, 4]	T7	T8	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
1	10	[3, 4, 5]	T6	T9	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
0	0	[3, 4]	T7	T9	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
1	10	[3, 4, 5]	T7	T6	T6 associates with the beta-domain of T7 and complexes with T8 and T9 in vivo
0	34	[2, 3, 4, 11, 12]	T5	T4	We establish that T3 binds to T4 T5 a component of the 19S regulatory complex of the proteasome
1	34	[2, 3, 4, 11, 12]	T3	T4	We establish that T3 binds to T4 T5 a component of the 19S regulatory complex of the proteasome
1	34	[2, 3, 4, 11, 12]	T3	T5	We establish that T3 binds to T4 T5 a component of the 19S regulatory complex of the proteasome
1	15	[3, 4, 18, 24, 29]	T1	T2	The protein T1 functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor T2 for proteasomal degradation during normoxia
0	35	[3, 4, 18, 24, 29, 30]	T20	T21	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19 but not T20 and does not promote degradation of T21
1	74	[3, 4, 11, 12, 24, 25, 29, 30]	T22	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	59	[3, 4, 11, 12, 19, 26, 30]	T25	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	14	[3, 4, 11, 12]	T24	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	59	[3, 4, 11, 12, 26, 30]	T26	T23	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	94	[3, 4, 11, 12, 19, 26, 27, 29, 30]	T25	T22	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
1	94	[3, 4, 11, 12, 26, 27, 29, 30]	T24	T22	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	94	[3, 4, 11, 12, 26, 27, 29, 30]	T26	T22	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	39	[3, 4, 11, 12, 19, 24, 30]	T24	T25	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
1	14	[3, 4, 11, 12, 19]	T26	T25	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	59	[3, 4, 11, 12, 26, 30]	T26	T24	Thus the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26 deficient tumors
0	0	[3, 4]	T5	T6	Three SR-rich proteins were identified that interact with the C-terminus of Pnn: T5 and T6 known components of spliceosome machinery and a novel 130-kDa nuclear protein SRrp130
1	0	[3, 4, 19]	T2	T4	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
0	0	[3, 4]	T3	T4	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
1	0	[3, 4, 19]	T1	T4	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
1	0	[3, 4, 19]	T3	T2	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
0	15	[3, 4, 17, 18]	T1	T2	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
1	0	[3, 4, 19]	T1	T3	T1/T2/memA interacts with T3 T4 and SRrp130 in corneal epithelial cells
0	12	[3, 4, 12, 14, 24]	T6	T8	The results of complementation experiments show that in contrast to mouse T6 mouse T7 can partially alleviate the growth defect of the corresponding yeast null strain indicating that the role of T8 in pre-rRNA processing is evolutionarily conserved
0	12	[3, 4, 12, 14, 24]	T7	T8	The results of complementation experiments show that in contrast to mouse T6 mouse T7 can partially alleviate the growth defect of the corresponding yeast null strain indicating that the role of T8 in pre-rRNA processing is evolutionarily conserved
0	9	[3, 4, 12, 19]	T10	T9	The results of density gradient centrifugation experiments show that in contrast to hU3-55K the human T9 and T10 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
1	9	[3, 4, 12, 19]	T11	T9	The results of density gradient centrifugation experiments show that in contrast to hU3-55K the human T9 and T10 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
0	7	[3, 4, 12, 14]	T7	T6	The results of complementation experiments show that in contrast to mouse T6 mouse T7 can partially alleviate the growth defect of the corresponding yeast null strain indicating that the role of T8 in pre-rRNA processing is evolutionarily conserved
0	20	[2, 3, 4]	T5	T4	We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins T4 and T5
1	35	[3, 4, 19, 26, 29]	T3	T2	The human T1 and T2 proteins form a ternary complex with hMpp10 which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	20	[3, 4, 18, 30]	T1	T2	The human T1 and T2 proteins form a ternary complex with hMpp10 which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	35	[3, 4, 19, 24, 29, 30]	T1	T3	The human T1 and T2 proteins form a ternary complex with hMpp10 which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	9	[3, 4, 12, 18]	T11	T10	The results of density gradient centrifugation experiments show that in contrast to hU3-55K the human T9 and T10 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
0	30	[3, 4, 29, 30]	T7	T8	In addition electron microscopy experiments revealed that T7 and T8 are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers
0	34	[3, 4, 12, 24, 30]	T4	T6	In contrast to T4 the potency of direct activation of T5 was not affected by co-expression with T6
0	34	[3, 4, 12, 24, 30]	T5	T6	In contrast to T4 the potency of direct activation of T5 was not affected by co-expression with T6
0	9	[3, 4, 12]	T5	T4	In contrast to T4 the potency of direct activation of T5 was not affected by co-expression with T6
0	9	[3, 4, 12, 19]	T3	T2	In the present study we observed evidence of cross-talk between the cannabinoid receptor T1 and the T2 T3 using a heterologous system
1	9	[3, 4, 12, 18]	T1	T2	In the present study we observed evidence of cross-talk between the cannabinoid receptor T1 and the T2 T3 using a heterologous system
1	9	[3, 4, 12, 19]	T1	T3	In the present study we observed evidence of cross-talk between the cannabinoid receptor T1 and the T2 T3 using a heterologous system
0	114	[2, 3, 4, 11, 12, 18, 26, 27, 29, 30]	T15	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	[2, 3, 4, 11, 12, 18, 24, 25, 29, 30]	T12	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	[2, 3, 4, 11, 12, 18, 24, 25, 29, 30]	T13	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	[2, 3, 4, 11, 12, 18, 24, 25, 29, 30]	T12	T15	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
1	94	[2, 3, 4, 11, 12, 18, 24, 25, 29, 30]	T13	T15	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
0	0	[3, 4, 18]	T17	T16	This work led to identification of a novel T16 T17 for Rho family GTPases
1	45	[3, 4, 18, 26, 30]	T11	T10	In addition T10 contains several classic proline-rich motifs and it interacts with the first SH3 domain of Crk and full-length T11 in vitro
0	34	[2, 3, 4, 11, 12, 18]	T13	T12	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli acting to regulate precisely Rac and T15 activities
0	39	[3, 4, 11, 12, 18, 26]	T19	T18	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA T19 and T20 in vitro
0	39	[3, 4, 11, 12, 18, 26]	T20	T18	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA T19 and T20 in vitro
0	14	[3, 4, 11, 12, 18]	T20	T19	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA T19 and T20 in vitro
0	0	[3, 4]	T9	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	15	[3, 4, 24, 29]	T6	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
0	0	[3, 4]	T7	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	20	[3, 4, 5, 29]	T5	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	15	[3, 4, 24, 29]	T6	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
0	0	[3, 4]	T7	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	20	[3, 4, 5, 29]	T5	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	35	[3, 4, 26, 29]	T7	T6	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
0	10	[3, 4, 5]	T5	T6	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	20	[3, 4, 5, 29]	T5	T7	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7 T8 T9 Shc and Crk
1	10	[3, 4, 19, 29]	T2	T4	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
0	0	[3, 4]	T3	T4	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	20	[3, 4, 5, 19, 29]	T1	T4	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	10	[3, 4, 19, 29]	T3	T2	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
0	10	[3, 4, 5, 18]	T1	T2	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	20	[3, 4, 5, 19, 29]	T1	T3	T1 a Rho family T2 that interacts with signaling adapters T3 and T4
1	85	[3, 4, 11, 19, 26, 27, 29, 30]	T23	T21	The protein was named T21 for its ability to interact with T22 proteins and its activity toward Rac and T23
1	85	[3, 4, 11, 19, 26, 27, 29, 30]	T22	T21	The protein was named T21 for its ability to interact with T22 proteins and its activity toward Rac and T23
0	5	[3, 4, 11]	T22	T23	The protein was named T21 for its ability to interact with T22 proteins and its activity toward Rac and T23
1	25	[3, 4, 19, 24, 30]	T24	T25	Expression of T24 in 293T cells led to a reduction in active T25 and T26 levels but not RhoA
0	0	[3, 4, 19]	T26	T25	Expression of T24 in 293T cells led to a reduction in active T25 and T26 levels but not RhoA
1	45	[3, 4, 26, 30]	T26	T24	Expression of T24 in 293T cells led to a reduction in active T25 and T26 levels but not RhoA
0	47	[3, 4, 11, 12, 14, 24, 29, 30]	T6	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	37	[3, 4, 11, 12, 14, 24, 30]	T7	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	47	[3, 4, 11, 12, 14, 24, 29, 30]	T4	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	47	[3, 4, 11, 12, 14, 24, 29, 30]	T5	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	47	[3, 4, 11, 12, 14, 24, 29, 30]	T3	T8	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	62	[3, 4, 12, 14, 19, 26, 29, 30]	T10	T9	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	62	[3, 4, 12, 14, 19, 26, 29, 30]	T11	T9	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	62	[3, 4, 12, 14, 19, 26, 29, 30]	T12	T9	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	47	[3, 4, 11, 12, 14, 26, 29]	T7	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	17	[3, 4, 11, 12, 14, 24]	T4	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	17	[3, 4, 11, 12, 14, 24]	T5	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	17	[3, 4, 11, 12, 14, 24]	T3	T6	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	27	[3, 4, 11, 12, 14, 24, 29]	T4	T7	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	27	[3, 4, 11, 12, 14, 24, 29]	T5	T7	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	27	[3, 4, 11, 12, 14, 24, 29]	T3	T7	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	12	[3, 4, 11, 12, 14]	T5	T4	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	12	[3, 4, 11, 12, 14]	T3	T4	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
0	12	[3, 4, 11, 12, 14]	T3	T5	Here we characterize the interaction between T3 and T4 show that T5 phosphorylates T6 at conserved S274 and S326 residues in vitro and present evidence that T7 is also a substrate for T8 in vivo
1	0	[3, 4, 18]	T1	T2	A role for T1 phosphorylation of T2 in cytokinesis
1	9	[3, 4, 12, 18]	T13	T14	These results suggest that T13 phosphorylation of T14 may influence cytokinesis
0	7	[3, 4, 12, 14, 18]	T11	T10	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	7	[3, 4, 12, 14, 18]	T12	T10	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
0	7	[3, 4, 12, 14, 18]	T12	T11	Downregulation of T9 by RNA interference results in multiple mitotic defects including multinucleation and cells arrested at the midbody stage which are rescued by ectopic expression of wild-type T10 but not by T11 with mutations in the T12 phosphorylation sites
1	12	[3, 4, 11, 12, 14]	T9	T8	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	[3, 4, 11, 12, 14, 19, 26, 30]	T10	T8	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	[3, 4, 11, 12, 14, 19, 26, 30]	T11	T8	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	[3, 4, 11, 12, 14, 19, 26, 30]	T10	T9	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	57	[3, 4, 11, 12, 14, 19, 26, 30]	T11	T9	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	5	[3, 4, 11]	T7	T6	T5/T6 'T7'-binding protein CBP interacting with transcription factors is able to increase their activity on target gene promoters
0	20	[3, 4, 11, 17]	T5	T6	T5/T6 'T7'-binding protein CBP interacting with transcription factors is able to increase their activity on target gene promoters
0	5	[3, 4, 11]	T5	T7	T5/T6 'T7'-binding protein CBP interacting with transcription factors is able to increase their activity on target gene promoters
1	5	[3, 4, 11, 19]	T2	T4	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
1	5	[3, 4, 11]	T3	T4	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
1	5	[3, 4, 11, 19]	T1	T4	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
0	5	[3, 4, 11, 19]	T3	T2	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
0	20	[3, 4, 11, 17, 18]	T1	T2	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
0	5	[3, 4, 11, 19]	T1	T3	T1/T2 'T3'-binding protein CBP modulates co-operation between myocyte enhancer factor 2A T4 and thyroid hormone receptor-retinoid X receptor
1	12	[3, 4, 11, 12, 14, 18]	T11	T10	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and T9 and our in vivo studies demonstrated that TR T10 and T11 form a ternary complex
0	40	[2, 3, 4, 5, 29]	T5	T4	T4 is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing T5
1	0	[3, 4, 19]	T3	T2	A prominent isolate designated T1/T2 specifically interacts with the T3 not only in vivo but also in vitro
0	15	[3, 4, 17, 18]	T1	T2	A prominent isolate designated T1/T2 specifically interacts with the T3 not only in vivo but also in vitro
1	0	[3, 4, 19]	T1	T3	A prominent isolate designated T1/T2 specifically interacts with the T3 not only in vivo but also in vitro
1	30	[3, 4, 5, 30]	T7	T8	T7 also interacted with other members of the catenin gene family including T8 and gamma-catenin
0	69	[3, 4, 11, 12, 19, 26, 29, 30]	T10	T9	The interaction with T9 is likely to be direct as the interaction occurs in K562 cells lacking functional adherens junctions and T10 expression
0	44	[3, 4, 12, 24, 29, 30]	T4	T6	The T4 T5 also known as T6 is expressed predominantly in epithelial cells in a variety of tumor cell lines and in lymphocytes
0	44	[3, 4, 12, 24, 29, 30]	T5	T6	The T4 T5 also known as T6 is expressed predominantly in epithelial cells in a variety of tumor cell lines and in lymphocytes
0	9	[3, 4, 12]	T5	T4	The T4 T5 also known as T6 is expressed predominantly in epithelial cells in a variety of tumor cell lines and in lymphocytes
1	25	[3, 4, 19, 26]	T3	T2	The transmembrane T1 T2 interacts with T3
0	0	[3, 4, 18]	T1	T2	The transmembrane T1 T2 interacts with T3
1	5	[3, 4, 19, 24]	T1	T3	The transmembrane T1 T2 interacts with T3
0	12	[3, 4, 11, 12, 14, 18]	T12	T11	Catalytic domains of the tyrosine phosphatases T11 T12 and PTPbeta did not interact with proteins of the catenin family to detectable levels suggesting that the interaction of T13 with these proteins is specific
0	67	[3, 4, 11, 12, 14, 18, 26, 29, 30]	T13	T11	Catalytic domains of the tyrosine phosphatases T11 T12 and PTPbeta did not interact with proteins of the catenin family to detectable levels suggesting that the interaction of T13 with these proteins is specific
0	67	[3, 4, 11, 12, 14, 18, 26, 29, 30]	T13	T12	Catalytic domains of the tyrosine phosphatases T11 T12 and PTPbeta did not interact with proteins of the catenin family to detectable levels suggesting that the interaction of T13 with these proteins is specific
0	0	[3, 4]	T6	T8	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	0	[3, 4]	T7	T8	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	10	[3, 4, 5]	T5	T8	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	45	[3, 4, 19, 26, 30]	T10	T9	TBP and T9 however were not able to interact with T10
0	0	[3, 4]	T7	T6	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
1	10	[3, 4, 5]	T5	T6	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
1	10	[3, 4, 5]	T5	T7	T5 specifically interacted with the general transcription factors T6 TBP and T7 but not with TFIIEalpha in the T8 pull-down assays
0	0	[3, 4]	T3	T4	In contrast to T3 T4 did not interact with the AF2 domain of RXR
0	19	[3, 4, 12, 15, 18, 24]	T1	T2	Herein we show that a distinct IkappaB protein T1 also interacts with RXR as shown in the yeast two-hybrid tests and T2 pull-down assays
0	14	[3, 4, 11, 12, 18]	T13	T14	In addition coexpression of T13 but not T14 further stimulated the Bcl3-mediated enhancement of the 9-cis-RA-induced transactivations of RXR
0	40	[3, 4, 11, 18, 26, 29]	T12	T11	Accordingly T11 coactivated the 9-cis-RA-induced transactivations of RXR in contrast to the inhibitory actions of T12
1	1	[11]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	1	[11]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	23	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
1	8	[12, 24]	T13	T14	Blockade of Protein1 expression by small interfering RNA causes prolonged degradation kinetics of Protein2
0	1	[11]	T16	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of Protein1 to T17
1	1	[11]	T17	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of T16 to Protein1
1	1	[11]	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of Protein2 to Protein1
1	8	[12, 24]	T13	T14	Blockade of Protein1 expression by small interfering RNA causes prolonged degradation kinetics of Protein2
0	1	[11]	T16	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of Protein1 to T17
1	1	[11]	T17	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of T16 to Protein1
1	1	[11]	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of Protein2 to Protein1
1	28	[12, 26]	T11	T10	Overexpression of Protein2 promotes degradation of Protein1 in a pVHL-dependent manner that requires the ATPase domain of T12
0	28	[12, 26]	T12	T10	Overexpression of Protein2 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	28	[12, 26]	T12	T11	Overexpression of T10 promotes degradation of Protein2 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	28	[12, 26]	T11	T10	Overexpression of Protein2 promotes degradation of Protein1 in a pVHL-dependent manner that requires the ATPase domain of T12
0	28	[12, 26]	T12	T10	Overexpression of Protein2 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	28	[12, 26]	T12	T11	Overexpression of T10 promotes degradation of Protein2 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	25	[26]	T19	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with Protein1, but not T20, and does not promote degradation of T21
0	25	[26]	T21	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not T20, and does not promote degradation of Protein1
0	25	[26]	T20	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of T21
0	25	[26]	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not T20, and does not promote degradation of Protein1
1	25	[26]	T19	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with Protein1, but not T20, and does not promote degradation of T21
0	0	[]	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not Protein1, and does not promote degradation of T21
0	0	[]	T9	T8	T6 associates with the beta-domain of T7 and complexes with Protein2 and Protein1 in vivo
1	0	[]	T6	T8	Protein1 associates with the beta-domain of T7 and complexes with Protein2 and T9 in vivo
0	25	[26]	T21	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not T20, and does not promote degradation of Protein1
0	0	[]	T7	T8	T6 associates with the beta-domain of Protein1 and complexes with Protein2 and T9 in vivo
0	25	[26]	T20	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of T21
1	0	[]	T6	T9	Protein1 associates with the beta-domain of T7 and complexes with T8 and Protein2 in vivo
0	25	[26]	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not T20, and does not promote degradation of Protein1
0	0	[]	T7	T9	T6 associates with the beta-domain of Protein1 and complexes with T8 and Protein2 in vivo
0	0	[]	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not Protein1, and does not promote degradation of T21
0	0	[]	T9	T8	T6 associates with the beta-domain of T7 and complexes with Protein2 and Protein1 in vivo
1	0	[]	T6	T8	Protein1 associates with the beta-domain of T7 and complexes with Protein2 and T9 in vivo
0	0	[]	T7	T8	T6 associates with the beta-domain of Protein1 and complexes with Protein2 and T9 in vivo
1	0	[]	T7	T6	Protein2 associates with the beta-domain of Protein1 and complexes with T8 and T9 in vivo
1	0	[]	T6	T9	Protein1 associates with the beta-domain of T7 and complexes with T8 and Protein2 in vivo
0	0	[]	T7	T9	T6 associates with the beta-domain of Protein1 and complexes with T8 and Protein2 in vivo
1	0	[]	T7	T6	Protein2 associates with the beta-domain of Protein1 and complexes with T8 and T9 in vivo
1	8	[12, 24]	T13	T14	Blockade of Protein1 expression by small interfering RNA causes prolonged degradation kinetics of Protein2
0	1	[11]	T16	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of Protein1 to T17
1	1	[11]	T17	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of T16 to Protein1
1	1	[11]	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of Protein2 to Protein1
1	28	[12, 26]	T11	T10	Overexpression of Protein2 promotes degradation of Protein1 in a pVHL-dependent manner that requires the ATPase domain of T12
0	28	[12, 26]	T12	T10	Overexpression of Protein2 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	28	[12, 26]	T12	T11	Overexpression of T10 promotes degradation of Protein2 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	8	[12, 24]	T13	T14	Blockade of Protein1 expression by small interfering RNA causes prolonged degradation kinetics of Protein2
0	1	[11]	T16	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of Protein1 to T17
1	1	[11]	T17	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of T16 to Protein1
1	1	[11]	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of Protein2 to Protein1
1	28	[12, 26]	T11	T10	Overexpression of Protein2 promotes degradation of Protein1 in a pVHL-dependent manner that requires the ATPase domain of T12
0	28	[12, 26]	T12	T10	Overexpression of Protein2 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	28	[12, 26]	T12	T11	Overexpression of T10 promotes degradation of Protein2 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	25	[26]	T19	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with Protein1, but not T20, and does not promote degradation of T21
0	25	[26]	T21	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not T20, and does not promote degradation of Protein1
0	25	[26]	T20	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of T21
0	25	[26]	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not T20, and does not promote degradation of Protein1
0	0	[]	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not Protein1, and does not promote degradation of T21
0	0	[]	T9	T8	T6 associates with the beta-domain of T7 and complexes with Protein2 and Protein1 in vivo
1	0	[]	T6	T8	Protein1 associates with the beta-domain of T7 and complexes with Protein2 and T9 in vivo
0	0	[]	T7	T8	T6 associates with the beta-domain of Protein1 and complexes with Protein2 and T9 in vivo
1	0	[]	T6	T9	Protein1 associates with the beta-domain of T7 and complexes with T8 and Protein2 in vivo
0	0	[]	T7	T9	T6 associates with the beta-domain of Protein1 and complexes with T8 and Protein2 in vivo
1	0	[]	T7	T6	Protein2 associates with the beta-domain of Protein1 and complexes with T8 and T9 in vivo
0	24	[2, 11, 12]	T5	T4	We establish that T3 binds to Protein1 , a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T4	We establish that Protein1 binds to Protein2 , a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T5	We establish that Protein1 binds to T4 , a component of the 19S regulatory complex of the proteasome
1	5	[24]	T1	T2	The protein Protein1 functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Protein2 for proteasomal degradation during normoxia
0	5	[24]	T20	T21	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of Protein2
1	34	[11, 12, 24, 25]	T22	T23	Thus, the ability of Protein1 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 26]	T25	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
0	4	[11, 12]	T24	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 26]	T26	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	54	[11, 12, 26, 27]	T25	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
1	54	[11, 12, 26, 27]	T24	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	54	[11, 12, 26, 27]	T26	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	9	[11, 12, 24]	T24	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for Protein2 stabilization in some T26-deficient tumors
1	4	[11, 12]	T26	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein2 stabilization in some Protein1-deficient tumors
0	29	[11, 12, 26]	T26	T24	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein2 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	26	[11, 26]	T10	T9	Finally, a direct interaction between PPARgamma and Protein2 was confirmed by Protein1 pull-down assay
1	1	[11]	T1	T2	Suppression of rat thromboxane synthase gene transcription by Protein1 in macrophages via an interaction with Protein2
1	8	[12, 24]	T13	T14	Blockade of Protein1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of Protein2
0	1	[11]	T16	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of Protein1 to T17
1	1	[11]	T17	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of T16 to Protein1
1	1	[11]	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of Protein2 to Protein1
1	28	[12, 26]	T11	T10	Overexpression of Protein2 promotes degradation of Protein1 in a pVHL-dependent manner that requires the ATPase domain of T12
0	28	[12, 26]	T12	T10	Overexpression of Protein2 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	28	[12, 26]	T12	T11	Overexpression of T10 promotes degradation of Protein2 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	25	[26]	T19	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with Protein1, but not T20, and does not promote degradation of T21
0	25	[26]	T21	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not T20, and does not promote degradation of Protein1
0	25	[26]	T20	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of T21
0	25	[26]	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not T20, and does not promote degradation of Protein1
0	0	[]	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not Protein1, and does not promote degradation of T21
0	0	[]	T9	T8	T6 associates with the beta-domain of T7 and complexes with Protein2 and Protein1 in vivo
1	0	[]	T6	T8	Protein1 associates with the beta-domain of T7 and complexes with Protein2 and T9 in vivo
0	0	[]	T7	T8	T6 associates with the beta-domain of Protein1 and complexes with Protein2 and T9 in vivo
1	0	[]	T6	T9	Protein1 associates with the beta-domain of T7 and complexes with T8 and Protein2 in vivo
0	0	[]	T7	T9	T6 associates with the beta-domain of Protein1 and complexes with T8 and Protein2 in vivo
1	0	[]	T7	T6	Protein2 associates with the beta-domain of Protein1 and complexes with T8 and T9 in vivo
0	24	[2, 11, 12]	T5	T4	We establish that T3 binds to Protein2 (Protein1), a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T4	We establish that Protein1 binds to Protein2 (T5), a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T5	We establish that Protein1 binds to T4 (Protein2), a component of the 19S regulatory complex of the proteasome
1	5	[24]	T1	T2	The protein Protein1 functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Protein2 for proteasomal degradation during normoxia
0	5	[24]	T20	T21	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of Protein2
1	34	[11, 12, 24, 25]	T22	T23	Thus, the ability of Protein1 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 26]	T25	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
0	4	[11, 12]	T24	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 26]	T26	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	54	[11, 12, 26, 27]	T25	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
1	54	[11, 12, 26, 27]	T24	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	54	[11, 12, 26, 27]	T26	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	9	[11, 12, 24]	T24	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for Protein2 stabilization in some T26-deficient tumors
1	4	[11, 12]	T26	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein2 stabilization in some Protein1-deficient tumors
0	29	[11, 12, 26]	T26	T24	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein2 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	26	[11, 26]	T10	T9	Finally, a direct interaction between PPARgamma and Protein2 was confirmed by Protein1 pull-down assay
0	3	[12, 14, 26]	T7	T6	By electrophoretic mobility shift assay using the T5/Protein2 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor Protein1 (T8)
1	1	[11]	T1	T2	Suppression of rat thromboxane synthase gene transcription by Protein1 in macrophages via an interaction with Protein2
1	8	[12, 18, 24]	T13	T14	Blockade of Protein1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of Protein2
0	1	[11, 18]	T16	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of Protein1 to T17
1	1	[11, 18]	T17	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of T16 to Protein1
1	1	[11, 18]	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of Protein2 to Protein1
1	28	[12, 18, 26]	T11	T10	Overexpression of Protein2 promotes degradation of Protein1 in a pVHL-dependent manner that requires the ATPase domain of T12
0	28	[12, 18, 26]	T12	T10	Overexpression of Protein2 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	28	[12, 18, 26]	T12	T11	Overexpression of T10 promotes degradation of Protein2 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	25	[18, 26]	T19	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with Protein1, but not T20, and does not promote degradation of T21
0	25	[18, 26]	T21	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not T20, and does not promote degradation of Protein1
0	25	[18, 26]	T20	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of T21
0	25	[18, 26]	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not T20, and does not promote degradation of Protein1
0	0	[18]	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not Protein1, and does not promote degradation of T21
0	0	[]	T9	T8	T6 associates with the beta-domain of T7 and complexes with Protein2 and Protein1 in vivo
1	0	[]	T6	T8	Protein1 associates with the beta-domain of T7 and complexes with Protein2 and T9 in vivo
0	0	[]	T7	T8	T6 associates with the beta-domain of Protein1 and complexes with Protein2 and T9 in vivo
1	0	[]	T6	T9	Protein1 associates with the beta-domain of T7 and complexes with T8 and Protein2 in vivo
0	0	[]	T7	T9	T6 associates with the beta-domain of Protein1 and complexes with T8 and Protein2 in vivo
1	0	[]	T7	T6	Protein2 associates with the beta-domain of Protein1 and complexes with T8 and T9 in vivo
0	24	[2, 11, 12]	T5	T4	We establish that T3 binds to Protein2 (Protein1), a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T4	We establish that Protein1 binds to Protein2 (T5), a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T5	We establish that Protein1 binds to T4 (Protein2), a component of the 19S regulatory complex of the proteasome
1	5	[18, 24]	T1	T2	The protein Protein1 functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Protein2 for proteasomal degradation during normoxia
0	5	[18, 24]	T20	T21	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of Protein2
1	34	[11, 12, 24, 25]	T22	T23	Thus, the ability of Protein1 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 19, 26]	T25	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
0	4	[11, 12]	T24	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 26]	T26	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	54	[11, 12, 19, 26, 27]	T25	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
1	54	[11, 12, 26, 27]	T24	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	54	[11, 12, 26, 27]	T26	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	9	[11, 12, 19, 24]	T24	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for Protein2 stabilization in some T26-deficient tumors
1	4	[11, 12, 19]	T26	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein2 stabilization in some Protein1-deficient tumors
0	29	[11, 12, 26]	T26	T24	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein2 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	26	[11, 19, 26]	T10	T9	Finally, a direct interaction between PPARgamma and Protein2 was confirmed by Protein1 pull-down assay
0	3	[12, 14, 26]	T7	T6	By electrophoretic mobility shift assay using the T5/Protein2 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor Protein1 (T8)
1	1	[11, 18]	T1	T2	Suppression of rat thromboxane synthase gene transcription by Protein1 in macrophages via an interaction with Protein2
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	-4	[2, 11, 14, 18]	T18	T17	[35S]-Sulfate labeled proteoglycans (Protein2) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine Protein1
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
0	4	[11, 12, 14, 18, 26]	T13	T12	In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (T11)-derived Protein2 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	1	[11, 14, 18, 26]	T21	T19	Characterization of EC and Protein2 T20 bound to A beta (1-28) revealed strong binding by Protein1, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T23	T19	Characterization of EC and Protein2 T20 bound to A beta (1-28) revealed strong binding by T21, weak binding by T22 and Protein1, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
1	8	[12, 18, 24]	T13	T14	Blockade of Protein1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of Protein2
0	1	[11, 18]	T16	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of Protein1 to T17
1	1	[11, 18]	T17	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of T16 to Protein1
1	1	[11, 18]	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of Protein2 to Protein1
1	28	[12, 18, 26]	T11	T10	Overexpression of Protein2 promotes degradation of Protein1 in a pVHL-dependent manner that requires the ATPase domain of T12
0	28	[12, 18, 26]	T12	T10	Overexpression of Protein2 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	28	[12, 18, 26]	T12	T11	Overexpression of T10 promotes degradation of Protein2 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	25	[18, 26]	T19	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with Protein1, but not T20, and does not promote degradation of T21
0	25	[18, 26]	T21	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not T20, and does not promote degradation of Protein1
0	25	[18, 26]	T20	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of T21
0	25	[18, 26]	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not T20, and does not promote degradation of Protein1
0	0	[18]	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not Protein1, and does not promote degradation of T21
0	0	[]	T9	T8	T6 associates with the beta-domain of T7 and complexes with Protein2 and Protein1 in vivo
1	0	[]	T6	T8	Protein1 associates with the beta-domain of T7 and complexes with Protein2 and T9 in vivo
0	0	[]	T7	T8	T6 associates with the beta-domain of Protein1 and complexes with Protein2 and T9 in vivo
1	0	[]	T6	T9	Protein1 associates with the beta-domain of T7 and complexes with T8 and Protein2 in vivo
0	0	[]	T7	T9	T6 associates with the beta-domain of Protein1 and complexes with T8 and Protein2 in vivo
1	0	[]	T7	T6	Protein2 associates with the beta-domain of Protein1 and complexes with T8 and T9 in vivo
0	24	[2, 11, 12]	T5	T4	We establish that T3 binds to Protein2 (Protein1), a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T4	We establish that Protein1 binds to Protein2 (T5), a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T5	We establish that Protein1 binds to T4 (Protein2), a component of the 19S regulatory complex of the proteasome
1	5	[18, 24]	T1	T2	The protein Protein1 functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Protein2 for proteasomal degradation during normoxia
0	5	[18, 24]	T20	T21	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of Protein2
1	34	[11, 12, 24, 25]	T22	T23	Thus, the ability of Protein1 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 19, 26]	T25	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
0	4	[11, 12]	T24	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 26]	T26	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	54	[11, 12, 19, 26, 27]	T25	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
1	54	[11, 12, 26, 27]	T24	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	54	[11, 12, 26, 27]	T26	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	9	[11, 12, 19, 24]	T24	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for Protein2 stabilization in some T26-deficient tumors
1	4	[11, 12, 19]	T26	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein2 stabilization in some Protein1-deficient tumors
0	29	[11, 12, 26]	T26	T24	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein2 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	26	[11, 19, 26]	T10	T9	Finally, a direct interaction between PPARgamma and Protein2 was confirmed by Protein1 pull-down assay
0	3	[12, 14, 26]	T7	T6	By electrophoretic mobility shift assay using the T5/Protein2 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor Protein1 (T8)
1	1	[11, 18]	T1	T2	Suppression of rat thromboxane synthase gene transcription by Protein1 in macrophages via an interaction with Protein2
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	-4	[2, 11, 14, 18]	T18	T17	[35S]-Sulfate labeled proteoglycans (Protein2) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine Protein1
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
0	4	[11, 12, 14, 18, 26]	T13	T12	In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (T11)-derived Protein2 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	1	[11, 14, 18, 26]	T21	T19	Characterization of EC and Protein2 T20 bound to A beta (1-28) revealed strong binding by Protein1, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T23	T19	Characterization of EC and Protein2 T20 bound to A beta (1-28) revealed strong binding by T21, weak binding by T22 and Protein1, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T22	T19	Characterization of EC and Protein2 T20 bound to A beta (1-28) revealed strong binding by T21, weak binding by Protein1 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 18, 26]	T25	T19	Characterization of EC and Protein2 T20 bound to A beta (1-28) revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T24	T19	Characterization of EC and Protein2 T20 bound to A beta (1-28) revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 19]	T2	T4	Differential binding of vascular cell-derived proteoglycans (T1, Protein1, T3, and Protein2) to the beta-amyloid protein of Alzheimer's disease
0	1	[11]	T3	T4	Differential binding of vascular cell-derived proteoglycans (T1, T2, Protein1, and Protein2) to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 19]	T1	T4	Differential binding of vascular cell-derived proteoglycans (Protein1, T2, T3, and Protein2) to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 19]	T3	T2	Differential binding of vascular cell-derived proteoglycans (T1, Protein2, Protein1, and T4) to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 18]	T1	T2	Differential binding of vascular cell-derived proteoglycans (Protein1, Protein2, T3, and T4) to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 19]	T1	T3	Differential binding of vascular cell-derived proteoglycans (Protein1, T2, Protein2, and T4) to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 14, 18, 26]	T25	T21	Characterization of EC and T19 T20 bound to A beta (1-28) revealed strong binding by Protein2, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T24	T21	Characterization of EC and T19 T20 bound to A beta (1-28) revealed strong binding by Protein2, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
1	1	[11, 14, 19, 26]	T23	T20	Characterization of EC and T19 Protein2 bound to A beta (1-28) revealed strong binding by T21, weak binding by T22 and Protein1, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
1	1	[11, 14, 19, 26]	T22	T20	Characterization of EC and T19 Protein2 bound to A beta (1-28) revealed strong binding by T21, weak binding by Protein1 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 18, 26]	T25	T20	Characterization of EC and T19 Protein2 bound to A beta (1-28) revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T24	T20	Characterization of EC and T19 Protein2 bound to A beta (1-28) revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T25	T23	Characterization of EC and T19 T20 bound to A beta (1-28) revealed strong binding by T21, weak binding by T22 and Protein2, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 26]	T24	T23	Characterization of EC and T19 T20 bound to A beta (1-28) revealed strong binding by T21, weak binding by T22 and Protein2, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T25	T22	Characterization of EC and T19 T20 bound to A beta (1-28) revealed strong binding by T21, weak binding by Protein2 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 26]	T24	T22	Characterization of EC and T19 T20 bound to A beta (1-28) revealed strong binding by T21, weak binding by Protein2 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
1	28	[2, 12, 24]	T3	T4	We show here that Protein1 phosphatase associates with Protein2 in somatic mammalian cells and in meiotic frog oocytes
1	1	[11, 18]	T1	T2	Protein1 interaction with Protein2 phosphatase ties mitogenic signal transduction to cell cycle activation
0	0	[19]	T3	T2	The tyrosine kinase T1 is physically associated with the Type I interferon (Protein2) receptor complex and is rapidly activated during Protein1 stimulation
1	0	[18]	T1	T2	The tyrosine kinase Protein1 is physically associated with the Type I interferon (Protein2) receptor complex and is rapidly activated during T3 stimulation
1	5	[19, 24]	T1	T3	The tyrosine kinase Protein1 is physically associated with the Type I interferon (T2) receptor complex and is rapidly activated during Protein2 stimulation
0	1	[11, 19]	T2	T4	T1 dimers formed through self-association of the TATA-binding polypeptide (Protein1) subunit and could be immunoprecipitated with antibodies to T3, the core subunit of Protein2
1	1	[11]	T3	T4	T1 dimers formed through self-association of the TATA-binding polypeptide (T2) subunit and could be immunoprecipitated with antibodies to Protein1, the core subunit of Protein2
0	1	[11, 19]	T1	T4	Protein1 dimers formed through self-association of the TATA-binding polypeptide (T2) subunit and could be immunoprecipitated with antibodies to T3, the core subunit of Protein2
0	1	[11, 19]	T3	T2	T1 dimers formed through self-association of the TATA-binding polypeptide (Protein2) subunit and could be immunoprecipitated with antibodies to Protein1, the core subunit of T4
0	1	[11, 18]	T1	T2	Protein1 dimers formed through self-association of the TATA-binding polypeptide (Protein2) subunit and could be immunoprecipitated with antibodies to T3, the core subunit of T4
1	1	[11, 19]	T1	T3	Protein1 dimers formed through self-association of the TATA-binding polypeptide (T2) subunit and could be immunoprecipitated with antibodies to Protein2, the core subunit of T4
0	5	[24]	T6	T8	The association of Protein1 with T7 was mediated by the NH2-terminal Src homology 2 (SH2) domain of Protein2
1	5	[24]	T7	T8	The association of T6 with Protein1 was mediated by the NH2-terminal Src homology 2 (SH2) domain of Protein2
1	0	[19]	T10	T9	Complexes of either Protein2/Protein1/Syk/PLC-gamma(1) could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate, respectively
1	0	[]	T7	T6	The association of Protein2 with Protein1 was mediated by the NH2-terminal Src homology 2 (SH2) domain of T8
1	28	[12, 26]	T5	T4	These results suggest that tyrosyl-phosphorylated T3 may be a substrate for Protein2 regulates tyrosyl phosphorylation of Protein1
1	8	[12, 24]	T3	T4	These results suggest that tyrosyl-phosphorylated Protein1 may be a substrate for Protein2 regulates tyrosyl phosphorylation of T5
0	8	[12, 24]	T3	T5	These results suggest that tyrosyl-phosphorylated Protein1 may be a substrate for T4 regulates tyrosyl phosphorylation of Protein2
1	0	[18]	T1	T2	Protein1 associates with Protein2, Syk, and phospholipase C-gamma(1) upon B cell activation
0	25	[18, 26]	T15	T14	By contrast, Protein2 was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type Protein1
0	4	[11, 12, 18]	T12	T11	Transient expression of Protein2 and a null mutant of Protein1 (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of T13 and its interaction with PTP-1CM
0	29	[11, 12, 18, 26]	T13	T11	Transient expression of Protein2 and a null mutant of T12 (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of Protein1 and its interaction with PTP-1CM
1	29	[11, 12, 18, 26]	T13	T12	Transient expression of T11 and a null mutant of Protein2 (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of Protein1 and its interaction with PTP-1CM
0	23	[2, 12]	T3	T4	We used cDNA probes for the Protein1, Protein2, and Etfa genes to determine localization of these mouse genes to chromosomes 3, 7, and 13
0	0	[18]	T1	T2	Assignment of Protein1, Protein2, and Etfa to chromosomes 3, 7, and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human
0	25	[26]	T5	T4	The fact that the T3 mRNA editing protein also exists as a Protein2 has important implications for the mechanism of Protein1 mRNA editing in humans
0	5	[24]	T3	T4	The fact that the Protein1 mRNA editing protein also exists as a Protein2 has important implications for the mechanism of T5 mRNA editing in humans
0	5	[24]	T3	T5	The fact that the Protein1 mRNA editing protein also exists as a T4 has important implications for the mechanism of Protein2 mRNA editing in humans
0	8	[12, 18, 24]	T1	T2	The human Protein1 mRNA editing protein is a Protein2 showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases
1	28	[2, 12, 15]	T5	T4	This suggests that transmembrane Protein2, by providing docking sites for the Src homology 3 domain of Protein1, activates PI 3-kinase by mediating its recruitment to the membrane
1	26	[11, 19, 26]	T3	T2	Direct interaction between the cytoplasmic tail of T1 and the Src homology 3 domain of Protein2 activates Protein1 in C2C12 cells
1	1	[11, 18]	T1	T2	Direct interaction between the cytoplasmic tail of Protein1 and the Src homology 3 domain of Protein2 activates T3 in C2C12 cells
1	6	[11, 19, 24]	T1	T3	Direct interaction between the cytoplasmic tail of Protein1 and the Src homology 3 domain of T2 activates Protein2 in C2C12 cells
1	24	[2, 11, 12]	T7	T8	Protein1 expressed in COS cells supported increased binding to immobilized Protein2
0	3	[12, 14, 19, 26]	T11	T9	Finally, Protein2 bound different glycoforms of T10 expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on Protein1 in resting and activated T cells, respectively
0	1	[11]	T4	T6	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins Protein1 and T5 (Protein2), respectively
0	1	[11]	T5	T6	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins T4 and Protein1 (Protein2), respectively
0	1	[11]	T5	T4	The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins Protein2 and Protein1 (T6), respectively
0	0	[19]	T3	T2	Cutting edge: T1 functions as a T cell counterreceptor for the macrophage adhesion receptor Protein2 (Protein1)
1	0	[18]	T1	T2	Cutting edge: Protein1 functions as a T cell counterreceptor for the macrophage adhesion receptor Protein2 (T3)
1	0	[19]	T1	T3	Cutting edge: Protein1 functions as a T cell counterreceptor for the macrophage adhesion receptor T2 (Protein2)
0	9	[11, 12, 18, 24]	T12	T14	These results identify Protein1 as a T cell counterreceptor for T13 and suggest that in addition to its anti-adhesive role Protein2 may promote cell-cell interactions
0	9	[11, 12, 18, 24]	T13	T14	These results identify T12 as a T cell counterreceptor for Protein1 and suggest that in addition to its anti-adhesive role Protein2 may promote cell-cell interactions
0	3	[12, 14, 18, 26]	T11	T10	Finally, T9 bound different glycoforms of Protein2 expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on Protein1 in resting and activated T cells, respectively
1	4	[11, 12, 18]	T13	T12	These results identify Protein2 as a T cell counterreceptor for Protein1 and suggest that in addition to its anti-adhesive role T14 may promote cell-cell interactions
1	8	[12, 24]	T7	T8	This work suggests that Protein1 is a regulated adapter between Protein2 and cytoplasmic dynein at sites involved in cargo-MT loading, and/or in the control of MT dynamics
0	4	[11, 12]	T4	T6	Overexpression of T3 results in a zinc finger-dependent localization of a Protein1 isoform and dynactin to MT bundles, raising the possibility that T5 and Protein2 regulate dynein/dynactin binding to MTs
0	4	[11, 12]	T5	T6	Overexpression of T3 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles, raising the possibility that Protein1 and Protein2 regulate dynein/dynactin binding to MTs
0	4	[11, 12]	T3	T6	Overexpression of Protein1 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles, raising the possibility that T5 and Protein2 regulate dynein/dynactin binding to MTs
0	4	[11, 12]	T5	T4	Overexpression of T3 results in a zinc finger-dependent localization of a Protein2 isoform and dynactin to MT bundles, raising the possibility that Protein1 and T6 regulate dynein/dynactin binding to MTs
1	4	[11, 12]	T3	T4	Overexpression of Protein1 results in a zinc finger-dependent localization of a Protein2 isoform and dynactin to MT bundles, raising the possibility that T5 and T6 regulate dynein/dynactin binding to MTs
0	4	[11, 12]	T3	T5	Overexpression of Protein1 results in a zinc finger-dependent localization of a T4 isoform and dynactin to MT bundles, raising the possibility that Protein2 and T6 regulate dynein/dynactin binding to MTs
1	4	[11, 12, 18]	T1	T2	Here we demonstrate colocalization and direct interaction between Protein1 and Protein2
0	0	[2, 14, 24]	T4	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including T2, T3, Protein1, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the Protein2 family
0	0	[2, 14, 24]	T5	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including T2, T3, T4, keratins, members of the small proline-rich superfamily, Protein1, and unknown proteins related to the Protein2 family
0	0	[2, 14, 19, 24]	T2	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including Protein1, T3, T4, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the Protein2 family
0	0	[2, 14, 24]	T3	T6	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including T2, Protein1, T4, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the Protein2 family
1	0	[2, 14, 19, 24]	T1	T6	Subsequent amino acid sequencing revealed many peptides involving Protein1 cross-linked either to itself or to a variety of other known CE protein components, including T2, T3, T4, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the Protein2 family
0	20	[2, 14, 26]	T5	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including T2, T3, Protein2, keratins, members of the small proline-rich superfamily, Protein1, and unknown proteins related to the T6 family
0	-5	[2, 14, 19]	T2	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including Protein1, T3, Protein2, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the T6 family
0	-5	[2, 14]	T3	T4	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including T2, Protein1, Protein2, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the T6 family
1	0	[2, 14, 19, 24]	T1	T4	Subsequent amino acid sequencing revealed many peptides involving Protein1 cross-linked either to itself or to a variety of other known CE protein components, including T2, T3, Protein2, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the T6 family
0	0	[2, 14, 19, 24]	T2	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including Protein1, T3, T4, keratins, members of the small proline-rich superfamily, Protein2, and unknown proteins related to the T6 family
0	0	[2, 14, 24]	T3	T5	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including T2, Protein1, T4, keratins, members of the small proline-rich superfamily, Protein2, and unknown proteins related to the T6 family
1	0	[2, 14, 19, 24]	T1	T5	Subsequent amino acid sequencing revealed many peptides involving Protein1 cross-linked either to itself or to a variety of other known CE protein components, including T2, T3, T4, keratins, members of the small proline-rich superfamily, Protein2, and unknown proteins related to the T6 family
0	-5	[2, 14, 19]	T3	T2	Subsequent amino acid sequencing revealed many peptides involving T1 cross-linked either to itself or to a variety of other known CE protein components, including Protein2, Protein1, T4, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the T6 family
1	0	[2, 14, 18, 24]	T1	T2	Subsequent amino acid sequencing revealed many peptides involving Protein1 cross-linked either to itself or to a variety of other known CE protein components, including Protein2, T3, T4, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the T6 family
1	0	[2, 14, 19, 24]	T1	T3	Subsequent amino acid sequencing revealed many peptides involving Protein1 cross-linked either to itself or to a variety of other known CE protein components, including T2, Protein2, T4, keratins, members of the small proline-rich superfamily, T5, and unknown proteins related to the T6 family
1	25	[26]	T9	T8	In addition, Protein2 was immunoprecipitated from human neutrophil lysates by anti-human Protein1 mAb
0	23	[2, 12]	T7	T6	T5, detected by anti-CD18 mAb, was coprecipitated with Protein2 from human neutrophil lysates by a mAb to Protein1
1	23	[2, 12]	T5	T6	Protein1, detected by anti-CD18 mAb, was coprecipitated with Protein2 from human neutrophil lysates by a mAb to T7
0	23	[2, 12]	T5	T7	Protein1, detected by anti-CD18 mAb, was coprecipitated with T6 from human neutrophil lysates by a mAb to Protein2
1	26	[2, 11, 24]	T3	T4	To clarify the mechanisms by which Protein1 functions on leukocytes, we explored the possibility of its physical association with Protein2 which is important for leukocyte adherence, locomotion, and extravasation
1	0	[18]	T1	T2	Physical association of Protein1 with Protein2, a novel glycosylphosphatidylinositol-anchored protein with potential for regulating adhesion and migration
1	28	[12, 18, 26]	T11	T10	These results clearly show that Protein2 is physically associated with Protein1 in human neutrophils
1	0	[]	T3	T4	Protein1 and Protein2 are two structurally different endocytic receptors that interact to serve such functions
0	0	[18]	T1	T2	Protein1 and Protein2: multifunctional endocytic receptors
0	0	[18]	T1	T2	Protein1 (type II isozyme) contains a Protein2 homology domain at the N terminus and a sterile alpha motif domain at the C terminus
1	3	[12, 18]	T12	T14	Yet, whether Protein1 and/or T13 function as inhibitors of Protein2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
1	3	[12, 18]	T13	T14	Yet, whether T12 and/or Protein1 function as inhibitors of Protein2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
0	3	[12, 18]	T16	T15	In this work, we show that Protein2 and Protein1 specifically interact with the T17/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo
1	53	[12, 18, 26, 27]	T17	T15	In this work, we show that Protein2 and T16 specifically interact with the Protein1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo
1	53	[12, 18, 26, 27]	T17	T16	In this work, we show that T15 and Protein2 specifically interact with the Protein1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo
1	3	[12, 18]	T11	T10	Recent evidence has implicated Protein2 in inhibition of Protein1/cyclinB1 kinase and in G2/M cell cycle arrest
0	3	[12, 18]	T13	T12	Yet, whether Protein2 and/or Protein1 function as inhibitors of T14/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established
0	1	[11, 18]	T19	T18	Data also has been obtained that Protein2 and Protein1, as well as T20, interact with both T21 and cyclinB1, resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	1	[11, 18]	T21	T18	Data also has been obtained that Protein2 and T19, as well as T20, interact with both Protein1 and cyclinB1, resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	1	[11, 18]	T20	T18	Data also has been obtained that Protein2 and T19, as well as Protein1, interact with both T21 and cyclinB1, resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	1	[11, 19]	T22	T18	Data also has been obtained that Protein2 and T19, as well as T20, interact with both T21 and cyclinB1, resulting in inhibition of the kinase activity of the Protein1/cyclinB1 complex
1	1	[11, 18]	T21	T19	Data also has been obtained that T18 and Protein2, as well as T20, interact with both Protein1 and cyclinB1, resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	1	[11, 18]	T20	T19	Data also has been obtained that T18 and Protein2, as well as Protein1, interact with both T21 and cyclinB1, resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
1	1	[11, 19]	T22	T19	Data also has been obtained that T18 and Protein2, as well as T20, interact with both T21 and cyclinB1, resulting in inhibition of the kinase activity of the Protein1/cyclinB1 complex
0	3	[12]	T9	T8	T4 (T5), T6 (T7), and Protein2 (Protein1) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T6	T8	T4 (T5), Protein1 (T7), and Protein2 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T7	T8	T4 (T5), T6 (Protein1), and Protein2 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T4	T8	Protein1 (T5), T6 (T7), and Protein2 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T5	T8	T4 (Protein1), T6 (T7), and Protein2 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T6	T9	T4 (T5), Protein1 (T7), and T8 (Protein2) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T7	T9	T4 (T5), T6 (Protein1), and T8 (Protein2) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T4	T9	Protein1 (T5), T6 (T7), and T8 (Protein2) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T5	T9	T4 (Protein1), T6 (T7), and T8 (Protein2) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T7	T6	T4 (T5), Protein2 (Protein1), and T8 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T4	T6	Protein1 (T5), Protein2 (T7), and T8 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T5	T6	T4 (Protein1), Protein2 (T7), and T8 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T4	T7	Protein1 (T5), T6 (Protein2), and T8 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T5	T7	T4 (Protein1), T6 (Protein2), and T8 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
0	3	[12]	T5	T4	Protein2 (Protein1), T6 (T7), and T8 (T9) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis
1	26	[11, 19, 26]	T3	T2	T1 and Protein2 are Protein1/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
0	1	[11, 18]	T1	T2	Protein1 and Protein2 are T3/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
1	1	[11, 19]	T1	T3	Protein1 and T2 are Protein2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress
1	1	[11, 18]	T20	T21	Data also has been obtained that T18 and T19, as well as Protein1, interact with both Protein2 and cyclinB1, resulting in inhibition of the kinase activity of the T22/cyclinB1 complex
0	1	[11, 19]	T22	T21	Data also has been obtained that T18 and T19, as well as T20, interact with both Protein2 and cyclinB1, resulting in inhibition of the kinase activity of the Protein1/cyclinB1 complex
1	1	[11, 19]	T22	T20	Data also has been obtained that T18 and T19, as well as Protein2, interact with both T21 and cyclinB1, resulting in inhibition of the kinase activity of the Protein1/cyclinB1 complex
1	4	[11, 12, 19]	T25	T23	Inhibition of Protein2/cyclinB1 kinase activity by T24 and Protein1 was found to involve disruption of the complex, whereas T26 did not disrupt the complex
1	4	[11, 12]	T24	T23	Inhibition of Protein2/cyclinB1 kinase activity by Protein1 and T25 was found to involve disruption of the complex, whereas T26 did not disrupt the complex
0	29	[11, 12, 26]	T26	T23	Inhibition of Protein2/cyclinB1 kinase activity by T24 and T25 was found to involve disruption of the complex, whereas Protein1 did not disrupt the complex
0	4	[11, 12, 19]	T24	T25	Inhibition of T23/cyclinB1 kinase activity by Protein1 and Protein2 was found to involve disruption of the complex, whereas T26 did not disrupt the complex
0	29	[11, 12, 19, 26]	T26	T25	Inhibition of T23/cyclinB1 kinase activity by T24 and Protein2 was found to involve disruption of the complex, whereas Protein1 did not disrupt the complex
0	29	[11, 12, 26]	T26	T24	Inhibition of T23/cyclinB1 kinase activity by Protein2 and T25 was found to involve disruption of the complex, whereas Protein1 did not disrupt the complex
0	29	[11, 12, 26]	T5	T4	Subcellular fractionation and antibody-uptake experiments indicate that Protein2 is indeed a type-I membrane protein, but, unlike other Protein1 isoforms, lacks an N-terminal extracellular domain
0	0	[19]	T3	T2	Here, we cloned and characterized a mouse orthologue of human T1 protein as an atypical Protein2 (named Protein1)
0	0	[18]	T1	T2	Here, we cloned and characterized a mouse orthologue of human Protein1 protein as an atypical Protein2 (named T3)
0	0	[19]	T1	T3	Here, we cloned and characterized a mouse orthologue of human Protein1 protein as an atypical T2 (named Protein2)
1	4	[11, 12, 14, 26]	T5	T4	In this report, we demonstrate the stable association of T3 with Protein2 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of Protein1, but also inhibits its enzymatic activity in a dose-dependent manner
1	1	[11, 18]	T1	T2	Protein1 binds to the C-terminal SH2 domain of Protein2 and inhibits its enzymatic activity
1	20	[2]	T9	T8	To identify the regions of Protein2 that contact its receptor, Protein1, we substituted all surface-exposed residues with alanine
1	49	[2, 11, 12, 26]	T7	T6	It was previously shown that the N-terminus of Protein2 is critical for binding Protein1
0	1	[11]	T5	T4	The receptor binding site of T3 also is significantly different from the binding sites of Protein2 and Protein1, providing insight into the issue of receptor specificity
0	6	[11, 24]	T3	T4	The receptor binding site of Protein1 also is significantly different from the binding sites of Protein2 and T5, providing insight into the issue of receptor specificity
0	6	[11, 24]	T3	T5	The receptor binding site of Protein1 also is significantly different from the binding sites of T4 and Protein2, providing insight into the issue of receptor specificity
1	0	[18]	T1	T2	Identification of residues in the Protein1 that contact the MCP-1 receptor, Protein2
0	1	[11, 19]	T3	T2	Cloning and characterization of two evolutionarily conserved subunits (T1 and Protein2) of human Protein1 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	1	[11, 18]	T1	T2	Cloning and characterization of two evolutionarily conserved subunits (Protein1 and Protein2) of human T3 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	1	[11, 19]	T1	T3	Cloning and characterization of two evolutionarily conserved subunits (Protein1 and T2) of human Protein2 and their involvement in functional interactions with TFIIIB and RNA polymerase III
0	20	[2]	T7	T6	T5 promotes coprecipitation of p85 with Protein2, the signal-transducing component of the Protein1
1	20	[2]	T5	T6	Protein1 promotes coprecipitation of p85 with Protein2, the signal-transducing component of the T7
0	20	[2]	T5	T7	Protein1 promotes coprecipitation of p85 with T6, the signal-transducing component of the Protein2
0	0	[]	T3	T4	RESULTS: Tyrosine phosphorylation of p85 is upregulated by Protein1 in both LNCaP and Protein2
1	20	[2, 18]	T1	T2	Protein1 activates Protein2, which inhibits apoptosis in human prostate cancer cell lines
0	3	[12]	T9	T8	Previously, we showed that the Protein2 or Protein1 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, T10 and F beta alpha, respectively
0	28	[12, 19, 26]	T10	T8	Previously, we showed that the Protein2 or T9 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, Protein1 and F beta alpha, respectively
0	28	[12, 19, 26]	T10	T9	Previously, we showed that the T8 or Protein2 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, Protein1 and F beta alpha, respectively
0	-5	[2, 14]	T7	T6	This is relevant for the case of LH and FSH, because both are synthesized in the same cell (i.e., pituitary gonadotrophs) and several of the alpha subunit sequences required for association with either the Protein2 or Protein1 subunits are different
0	20	[2, 19]	T3	T2	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the T1 subunit or the Protein2 and Protein1 monomer
0	20	[2, 18]	T1	T2	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the Protein1 subunit or the Protein2 and T3 monomer
0	20	[2, 19]	T1	T3	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the Protein1 subunit or the T2 and Protein2 monomer
1	4	[11, 12]	T7	T8	Secondly, Protein1 induces expression of an extracellular activation epitope of Protein2, and the exchange factor function is not essential for this activity
1	26	[11, 19, 26]	T10	T9	In contrast, LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a Protein2 mutant, which fails to catalyze Protein1 GDP-GTP exchange in vitro
1	1	[11]	T5	T6	Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of Protein1 depends on its interaction with Protein2, unless the integrin is activated by exogenous divalent cations
1	4	[11, 12]	T3	T4	Here we provide evidence of how Protein1, an integrin-binding protein and guanine-nucleotide exchange factor (GEF) for Protein2 GTPases, regulates cell adhesion
1	21	[2, 11, 18]	T1	T2	Protein1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with Protein2
1	26	[11, 18, 26]	T12	T11	Thus, Protein2 is involved in the activation of Protein1, most probably through direct interaction with the integrin, and induces cell spreading by its ARF-GEF activity
0	0	[]	T4	T6	Immobilized T3 also bound Protein1 besides T5 and Protein2
0	0	[]	T5	T6	Immobilized T3 also bound T4 besides Protein1 and Protein2
1	30	[24, 25]	T3	T6	Immobilized Protein1 also bound T4 besides T5 and Protein2
0	0	[]	T5	T4	Immobilized T3 also bound Protein2 besides Protein1 and T6
1	30	[24, 25]	T3	T4	Immobilized Protein1 also bound Protein2 besides T5 and T6
1	30	[24, 25]	T3	T5	Immobilized Protein1 also bound T4 besides Protein2 and T6
0	0	[18]	T1	T2	In solution, FGFR4ed formed complexes with Protein1 and Protein2, both in the presence and absence of heparin
0	26	[11, 19, 26]	T10	T9	Finally, a direct interaction between PPARgamma and Protein2 was confirmed by Protein1 pull-down assay
0	3	[12, 14, 26]	T7	T6	By electrophoretic mobility shift assay using the T5/Protein2 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor Protein1 (T8)
1	1	[11, 18]	T1	T2	Suppression of rat thromboxane synthase gene transcription by Protein1 in macrophages via an interaction with Protein2
0	0	[]	T9	T8	Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Protein2, Protein1, p125FAK, and T10 phosphorylation
0	0	[19]	T10	T8	Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and Protein2, T9, p125FAK, and Protein1 phosphorylation
0	0	[19]	T10	T9	Preincubation with genistein, a tyrosine kinase inhibitor, blocked the GH-stimulated adhesion and T8, Protein2, p125FAK, and Protein1 phosphorylation
0	0	[]	T7	T6	Pituitary GH triggered the tyrosine phosphorylation of T5 (Protein2) and Protein1 in neutrophils
0	0	[]	T5	T6	Pituitary GH triggered the tyrosine phosphorylation of Protein1 (Protein2) and T7 in neutrophils
0	0	[]	T5	T7	Pituitary GH triggered the tyrosine phosphorylation of Protein1 (T6) and Protein2 in neutrophils
0	3	[12]	T3	T4	These results suggest that pituitary GH modulates neutrophil adhesion through tyrosine phosphorylation of Protein1, p125FAK, and Protein2 and actin polymerization
0	0	[18]	T1	T2	Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of Protein1, p125FAK, and Protein2
1	0	[18]	T12	T11	Immunoprecipitation experiments revealed a physical association of Protein2 with p125FAK via Protein1 in vivo
0	0	[14, 19, 26]	T11	T9	In addition, both Protein2 and T10 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of Protein1 is required for cellular survival
0	3	[12, 14, 26]	T7	T6	In contrast, phosphorylation of Protein2 by ATR is independent of Protein1 and replication protein A, suggesting that the signaling pathway leading to T8 phosphorylation is distinct from that mediated by the checkpoint proteins
1	48	[2, 12, 26]	T5	T4	We found that phosphorylation of Protein2 by ATR also requires checkpoint proteins Protein1 and replication protein A
0	-5	[2, 14, 19]	T3	T2	We report that T1 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of Protein2 and Protein1 (structure maintenance of chromosome 1)
1	0	[2, 14, 18, 24]	T1	T2	We report that Protein1 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of Protein2 and T3 (structure maintenance of chromosome 1)
1	0	[2, 14, 19, 24]	T1	T3	We report that Protein1 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of T2 and Protein2 (structure maintenance of chromosome 1)
0	0	[14, 18, 26]	T11	T10	In addition, both T9 and Protein2 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of Protein1 is required for cellular survival
1	21	[2, 11]	T9	T8	Protein2 is modified by Protein1 in vivo and in vitro and the region of T10 responsible for interaction maps to the N-terminal regulatory domain
0	21	[2, 11, 19]	T10	T8	Protein2 is modified by T9 in vivo and in vitro and the region of Protein1 responsible for interaction maps to the N-terminal regulatory domain
0	21	[2, 11, 19]	T10	T9	T8 is modified by Protein2 in vivo and in vitro and the region of Protein1 responsible for interaction maps to the N-terminal regulatory domain
1	4	[11, 12, 14, 26]	T7	T6	Here we show that T3 interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme T4 and the E3 sumo ligases T5 and Protein2, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, Protein1, to its target proteins
1	1	[11, 18]	T1	T2	Modification of de novo DNA methyltransferase 3a (Protein1) by Protein2 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription
1	1	[11, 18]	T12	T11	Functionally, sumoylation of Protein2 disrupts its ability to interact with histone deacetylases (Protein1/2), but not with another interaction partner, T13
0	51	[11, 18, 26, 27]	T13	T11	Functionally, sumoylation of Protein2 disrupts its ability to interact with histone deacetylases (T12/2), but not with another interaction partner, Protein1
0	1	[11, 18]	T13	T12	Functionally, sumoylation of T11 disrupts its ability to interact with histone deacetylases (Protein2/2), but not with another interaction partner, Protein1
1	9	[11, 12, 24]	T3	T4	These results suggest that the relative abundance of the two splice variants of Protein1 in brain could be an important determinant for the expression of Protein2
1	9	[11, 12, 18, 24]	T1	T2	Transient expression of the full-length Protein1 without RSRS in U1240MG glioblastoma cells resulted in repression of Protein2 promoter activity
1	25	[2, 14, 18, 24, 25]	T1	T2	We report here that PLZF, and a structurally similar transcriptional repressor, Protein1, can interact with a variety of corepressor proteins in addition to SMRT, including the mSin3A protein and (for PLZF) Protein2
0	1	[11]	T4	T6	The sterol-independent regulatory element (SIRE) of the T3 (Protein1) promoter mediates T5 (OM)-induced transcription of the Protein2 gene through a cholesterol-independent pathway
1	6	[11, 24]	T5	T6	The sterol-independent regulatory element (SIRE) of the T3 (T4) promoter mediates Protein1 (OM)-induced transcription of the Protein2 gene through a cholesterol-independent pathway
0	6	[11, 24]	T3	T6	The sterol-independent regulatory element (SIRE) of the Protein1 (T4) promoter mediates T5 (OM)-induced transcription of the Protein2 gene through a cholesterol-independent pathway
1	1	[11]	T5	T4	The sterol-independent regulatory element (SIRE) of the T3 (Protein2) promoter mediates Protein1 (OM)-induced transcription of the T6 gene through a cholesterol-independent pathway
0	1	[11]	T3	T4	The sterol-independent regulatory element (SIRE) of the Protein1 (Protein2) promoter mediates T5 (OM)-induced transcription of the T6 gene through a cholesterol-independent pathway
1	6	[11, 24]	T3	T5	The sterol-independent regulatory element (SIRE) of the Protein1 (T4) promoter mediates Protein2 (OM)-induced transcription of the T6 gene through a cholesterol-independent pathway
1	1	[11, 18]	T1	T2	Specific interaction of Protein1 and c/EBPbeta leads to the transcriptional activation of the human Protein2 gene
0	1	[11]	T9	T8	The interaction between AR and T7 was assessed by Protein2 (Protein1) pull-down assay and mammalian two-hybrid system assay
0	6	[11, 24]	T7	T8	The interaction between AR and Protein1 was assessed by Protein2 (T9) pull-down assay and mammalian two-hybrid system assay
0	1	[11]	T7	T9	The interaction between AR and Protein1 was assessed by T8 (Protein2) pull-down assay and mammalian two-hybrid system assay
0	3	[12]	T4	T6	BACKGROUND: Both Protein1 (AR) and orphan receptor T5 (Protein2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	3	[12]	T5	T6	BACKGROUND: Both T4 (AR) and orphan receptor Protein1 (Protein2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	3	[12]	T5	T4	BACKGROUND: Both Protein2 (AR) and orphan receptor Protein1 (T6) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines
0	20	[2, 19]	T3	T2	T1 orphan receptor functions as negative modulator for Protein2 in prostate cancer cells Protein1
1	20	[2, 18]	T1	T2	Protein1 orphan receptor functions as negative modulator for Protein2 in prostate cancer cells T3
0	20	[2, 19]	T1	T3	Protein1 orphan receptor functions as negative modulator for T2 in prostate cancer cells Protein2
1	8	[12, 18, 24]	T13	T14	Blockade of Protein1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of Protein2
0	1	[11, 18]	T16	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of Protein1 to T17
1	1	[11, 18]	T17	T15	Several distinct mutations in exon 2 of Protein2 disrupt binding of T16 to Protein1
1	1	[11, 18]	T17	T16	Several distinct mutations in exon 2 of T15 disrupt binding of Protein2 to Protein1
1	28	[12, 18, 26]	T11	T10	Overexpression of Protein2 promotes degradation of Protein1 in a pVHL-dependent manner that requires the ATPase domain of T12
0	28	[12, 18, 26]	T12	T10	Overexpression of Protein2 promotes degradation of T11 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	28	[12, 18, 26]	T12	T11	Overexpression of T10 promotes degradation of Protein2 in a pVHL-dependent manner that requires the ATPase domain of Protein1
1	25	[18, 26]	T19	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with Protein1, but not T20, and does not promote degradation of T21
0	25	[18, 26]	T21	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not T20, and does not promote degradation of Protein1
0	25	[18, 26]	T20	T18	A Protein2 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of T21
0	25	[18, 26]	T21	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not T20, and does not promote degradation of Protein1
0	0	[18]	T20	T19	A T18 mutant containing a P154L substitution coimmunoprecipitates with Protein2, but not Protein1, and does not promote degradation of T21
0	0	[]	T9	T8	T6 associates with the beta-domain of T7 and complexes with Protein2 and Protein1 in vivo
1	0	[]	T6	T8	Protein1 associates with the beta-domain of T7 and complexes with Protein2 and T9 in vivo
0	0	[]	T7	T8	T6 associates with the beta-domain of Protein1 and complexes with Protein2 and T9 in vivo
1	0	[]	T6	T9	Protein1 associates with the beta-domain of T7 and complexes with T8 and Protein2 in vivo
0	0	[]	T7	T9	T6 associates with the beta-domain of Protein1 and complexes with T8 and Protein2 in vivo
1	0	[]	T7	T6	Protein2 associates with the beta-domain of Protein1 and complexes with T8 and T9 in vivo
0	24	[2, 11, 12]	T5	T4	We establish that T3 binds to Protein2 (Protein1), a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T4	We establish that Protein1 binds to Protein2 (T5), a component of the 19S regulatory complex of the proteasome
1	24	[2, 11, 12]	T3	T5	We establish that Protein1 binds to T4 (Protein2), a component of the 19S regulatory complex of the proteasome
1	5	[18, 24]	T1	T2	The protein Protein1 functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Protein2 for proteasomal degradation during normoxia
0	5	[18, 24]	T20	T21	A T18 mutant containing a P154L substitution coimmunoprecipitates with T19, but not Protein1, and does not promote degradation of Protein2
1	34	[11, 12, 24, 25]	T22	T23	Thus, the ability of Protein1 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 19, 26]	T25	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
0	4	[11, 12]	T24	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	29	[11, 12, 26]	T26	T23	Thus, the ability of T22 to degrade Protein2 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	54	[11, 12, 19, 26, 27]	T25	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein1 stabilization in some T26-deficient tumors
1	54	[11, 12, 26, 27]	T24	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for T25 stabilization in some T26-deficient tumors
0	54	[11, 12, 26, 27]	T26	T22	Thus, the ability of Protein2 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	9	[11, 12, 19, 24]	T24	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein1 and suggests a new mechanism for Protein2 stabilization in some T26-deficient tumors
1	4	[11, 12, 19]	T26	T25	Thus, the ability of T22 to degrade T23 depends in part on its interaction with T24 and suggests a new mechanism for Protein2 stabilization in some Protein1-deficient tumors
0	29	[11, 12, 26]	T26	T24	Thus, the ability of T22 to degrade T23 depends in part on its interaction with Protein2 and suggests a new mechanism for T25 stabilization in some Protein1-deficient tumors
0	0	[]	T5	T6	Three SR-rich proteins were identified that interact with the C-terminus of Pnn: Protein1 and Protein2, known components of spliceosome machinery, and a novel 130-kDa nuclear protein, SRrp130
1	5	[19, 24]	T2	T4	T1/Protein1/memA interacts with T3, Protein2 and SRrp130 in corneal epithelial cells
0	0	[]	T3	T4	T1/T2/memA interacts with Protein1, Protein2 and SRrp130 in corneal epithelial cells
1	0	[19]	T1	T4	Protein1/T2/memA interacts with T3, Protein2 and SRrp130 in corneal epithelial cells
1	25	[19, 26]	T3	T2	T1/Protein2/memA interacts with Protein1, T4 and SRrp130 in corneal epithelial cells
0	0	[18]	T1	T2	Protein1/Protein2/memA interacts with T3, T4 and SRrp130 in corneal epithelial cells
1	0	[19]	T1	T3	Protein1/T2/memA interacts with Protein2, T4 and SRrp130 in corneal epithelial cells
0	3	[12, 19]	T10	T9	The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Protein2 and Protein1 proteins predominantly interact with the U3 T11 in 60-80S ribonucleoprotein complexes
1	3	[12, 19]	T11	T9	The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Protein2 and T10 proteins predominantly interact with the U3 Protein1 in 60-80S ribonucleoprotein complexes
0	20	[2]	T5	T4	We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins Protein2 and Protein1
1	25	[19, 26]	T3	T2	The human T1 and Protein2 proteins form a ternary complex with hMpp10, which only interacts with the U3 Protein1 in 60-80S ribonucleoprotein complexes
1	0	[18]	T1	T2	The human Protein1 and Protein2 proteins form a ternary complex with hMpp10, which only interacts with the U3 T3 in 60-80S ribonucleoprotein complexes
1	5	[19, 24]	T1	T3	The human Protein1 and T2 proteins form a ternary complex with hMpp10, which only interacts with the U3 Protein2 in 60-80S ribonucleoprotein complexes
1	3	[12, 18]	T11	T10	The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human T9 and Protein2 proteins predominantly interact with the U3 Protein1 in 60-80S ribonucleoprotein complexes
0	0	[]	T7	T8	In addition, electron microscopy experiments revealed that Protein1 and Protein2 are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers
0	8	[12, 24]	T4	T6	In contrast to Protein1, the potency of direct activation of T5 was not affected by co-expression with Protein2
0	8	[12, 24]	T5	T6	In contrast to T4, the potency of direct activation of Protein1 was not affected by co-expression with Protein2
0	3	[12]	T5	T4	In contrast to Protein2, the potency of direct activation of Protein1 was not affected by co-expression with T6
0	3	[12, 19]	T3	T2	In the present study, we observed evidence of cross-talk between the cannabinoid receptor T1 and the Protein2 (Protein1) using a heterologous system
1	3	[12, 18]	T1	T2	In the present study, we observed evidence of cross-talk between the cannabinoid receptor Protein1 and the Protein2 (T3) using a heterologous system
1	3	[12, 19]	T1	T3	In the present study, we observed evidence of cross-talk between the cannabinoid receptor Protein1 and the T2 (Protein2) using a heterologous system
0	74	[2, 11, 12, 18, 26, 27]	T15	T14	We propose that T12 and T13 in cooperation with other adapter molecules might regulate the cellular localization of Protein2 under specific stimuli, acting to regulate precisely Rac and Protein1 activities
1	54	[2, 11, 12, 18, 24, 25]	T12	T14	We propose that Protein1 and T13 in cooperation with other adapter molecules might regulate the cellular localization of Protein2 under specific stimuli, acting to regulate precisely Rac and T15 activities
1	54	[2, 11, 12, 18, 24, 25]	T13	T14	We propose that T12 and Protein1 in cooperation with other adapter molecules might regulate the cellular localization of Protein2 under specific stimuli, acting to regulate precisely Rac and T15 activities
1	54	[2, 11, 12, 18, 24, 25]	T12	T15	We propose that Protein1 and T13 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli, acting to regulate precisely Rac and Protein2 activities
1	54	[2, 11, 12, 18, 24, 25]	T13	T15	We propose that T12 and Protein1 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli, acting to regulate precisely Rac and Protein2 activities
0	0	[18]	T17	T16	This work led to identification of a novel Protein2 (Protein1) for Rho family GTPases
1	25	[18, 26]	T11	T10	In addition, Protein2 contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length Protein1 in vitro
0	24	[2, 11, 12, 18]	T13	T12	We propose that Protein2 and Protein1 in cooperation with other adapter molecules might regulate the cellular localization of T14 under specific stimuli, acting to regulate precisely Rac and T15 activities
0	29	[11, 12, 18, 26]	T19	T18	The GAP domain shows high similarity to the recently cloned Protein2 and displays activity toward RhoA, Protein1, and T20 in vitro
0	29	[11, 12, 18, 26]	T20	T18	The GAP domain shows high similarity to the recently cloned Protein2 and displays activity toward RhoA, T19, and Protein1 in vitro
0	4	[11, 12, 18]	T20	T19	The GAP domain shows high similarity to the recently cloned T18 and displays activity toward RhoA, Protein2, and Protein1 in vitro
0	0	[]	T9	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7, Protein2, Protein1, Shc, and Crk
1	5	[24]	T6	T8	T5 and Protein1 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7, Protein2, T9, Shc, and Crk
0	0	[]	T7	T8	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Protein1, Protein2, T9, Shc, and Crk
1	0	[]	T5	T8	Protein1 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7, Protein2, T9, Shc, and Crk
1	5	[24]	T6	T9	T5 and Protein1 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7, T8, Protein2, Shc, and Crk
0	0	[]	T7	T9	T5 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Protein1, T8, Protein2, Shc, and Crk
1	0	[]	T5	T9	Protein1 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7, T8, Protein2, Shc, and Crk
1	25	[26]	T7	T6	T5 and Protein2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Protein1, T8, T9, Shc, and Crk
0	0	[]	T5	T6	Protein1 and Protein2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as T7, T8, T9, Shc, and Crk
1	0	[]	T5	T7	Protein1 and T6 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Protein2, T8, T9, Shc, and Crk
1	0	[19]	T2	T4	T1, a Rho family Protein1 that interacts with signaling adapters T3 and Protein2
0	0	[]	T3	T4	T1, a Rho family T2 that interacts with signaling adapters Protein1 and Protein2
1	0	[19]	T1	T4	Protein1, a Rho family T2 that interacts with signaling adapters T3 and Protein2
1	0	[19]	T3	T2	T1, a Rho family Protein2 that interacts with signaling adapters Protein1 and T4
0	0	[18]	T1	T2	Protein1, a Rho family Protein2 that interacts with signaling adapters T3 and T4
1	0	[19]	T1	T3	Protein1, a Rho family T2 that interacts with signaling adapters Protein2 and T4
1	51	[11, 19, 26, 27]	T23	T21	The protein was named Protein2 for its ability to interact with T22 proteins and its activity toward Rac and Protein1
1	51	[11, 19, 26, 27]	T22	T21	The protein was named Protein2 for its ability to interact with Protein1 proteins and its activity toward Rac and T23
0	1	[11]	T22	T23	The protein was named T21 for its ability to interact with Protein1 proteins and its activity toward Rac and Protein2
1	5	[19, 24]	T24	T25	Expression of Protein1 in 293T cells led to a reduction in active Protein2 and T26 levels but not RhoA
0	0	[19]	T26	T25	Expression of T24 in 293T cells led to a reduction in active Protein2 and Protein1 levels but not RhoA
1	25	[26]	T26	T24	Expression of Protein2 in 293T cells led to a reduction in active T25 and Protein1 levels but not RhoA
0	3	[12, 14, 19, 26]	T10	T9	Downregulation of Protein2 by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type Protein1, but not by T11 with mutations in the T12 phosphorylation sites
0	3	[12, 14, 19, 26]	T11	T9	Downregulation of Protein2 by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type T10, but not by Protein1 with mutations in the T12 phosphorylation sites
0	3	[12, 14, 19, 26]	T12	T9	Downregulation of Protein2 by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type T10, but not by T11 with mutations in the Protein1 phosphorylation sites
0	4	[11, 12, 14, 26]	T7	T6	Here, we characterize the interaction between T3 and T4, show that T5 phosphorylates Protein2 at conserved S274 and S326 residues in vitro, and present evidence that Protein1 is also a substrate for T8 in vivo
1	0	[18]	T1	T2	A role for Protein1 phosphorylation of Protein2 in cytokinesis
1	3	[12, 18]	T13	T14	These results suggest that Protein1 phosphorylation of Protein2 may influence cytokinesis
0	4	[11, 12, 14, 19, 26]	T10	T8	Our findings showed that the same C-terminal portion of Protein2 binds the N-terminal domains of both TR and T9, and our in vivo studies demonstrated that TR, Protein1 and T11 form a ternary complex
0	4	[11, 12, 14, 19, 26]	T11	T8	Our findings showed that the same C-terminal portion of Protein2 binds the N-terminal domains of both TR and T9, and our in vivo studies demonstrated that TR, T10 and Protein1 form a ternary complex
0	4	[11, 12, 14, 19, 26]	T10	T9	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and Protein2, and our in vivo studies demonstrated that TR, Protein1 and T11 form a ternary complex
0	4	[11, 12, 14, 19, 26]	T11	T9	Our findings showed that the same C-terminal portion of T8 binds the N-terminal domains of both TR and Protein2, and our in vivo studies demonstrated that TR, T10 and Protein1 form a ternary complex
0	1	[11]	T7	T6	T5/Protein2 ('Protein1')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters
0	1	[11]	T5	T6	Protein1/Protein2 ('T7')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters
0	1	[11]	T5	T7	Protein1/T6 ('Protein2')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters
1	1	[11, 19]	T2	T4	T1/Protein1 ('T3')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (Protein2) and thyroid hormone receptor-retinoid X receptor
1	1	[11]	T3	T4	T1/T2 ('Protein1')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (Protein2) and thyroid hormone receptor-retinoid X receptor
1	1	[11, 19]	T1	T4	Protein1/T2 ('T3')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (Protein2) and thyroid hormone receptor-retinoid X receptor
0	1	[11, 19]	T3	T2	T1/Protein2 ('Protein1')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (T4) and thyroid hormone receptor-retinoid X receptor
0	1	[11, 18]	T1	T2	Protein1/Protein2 ('T3')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (T4) and thyroid hormone receptor-retinoid X receptor
0	1	[11, 19]	T1	T3	Protein1/T2 ('Protein2')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (T4) and thyroid hormone receptor-retinoid X receptor
0	20	[2]	T5	T4	Protein2 is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing Protein1
1	25	[19, 26]	T3	T2	A prominent isolate, designated T1/Protein2, specifically interacts with the Protein1 not only in vivo but also in vitro
0	0	[18]	T1	T2	A prominent isolate, designated Protein1/Protein2, specifically interacts with the T3 not only in vivo but also in vitro
1	5	[19, 24]	T1	T3	A prominent isolate, designated Protein1/T2, specifically interacts with the Protein2 not only in vivo but also in vitro
1	0	[]	T7	T8	Protein1 also interacted with other members of the catenin gene family including Protein2 and gamma-catenin
0	29	[11, 12, 19, 26]	T10	T9	The interaction with Protein2 is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and Protein1 expression
0	8	[12, 24]	T4	T6	The Protein1 T5, also known as Protein2, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes
0	8	[12, 24]	T5	T6	The T4 Protein1, also known as Protein2, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes
0	3	[12]	T5	T4	The Protein2 Protein1, also known as T6, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes
1	25	[19, 26]	T3	T2	The transmembrane T1 Protein2 interacts with Protein1
0	0	[18]	T1	T2	The transmembrane Protein1 Protein2 interacts with T3
1	5	[19, 24]	T1	T3	The transmembrane Protein1 T2 interacts with Protein2
0	4	[11, 12, 14, 18, 26]	T13	T11	Catalytic domains of the tyrosine phosphatases Protein2, T12, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of Protein1 with these proteins is specific
0	4	[11, 12, 14, 18, 26]	T13	T12	Catalytic domains of the tyrosine phosphatases T11, Protein2, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of Protein1 with these proteins is specific
0	0	[]	T6	T8	T5 specifically interacted with the general transcription factors Protein1, TBP, and T7 but not with TFIIEalpha in the Protein2 pull-down assays
0	0	[]	T7	T8	T5 specifically interacted with the general transcription factors T6, TBP, and Protein1 but not with TFIIEalpha in the Protein2 pull-down assays
0	0	[]	T5	T8	Protein1 specifically interacted with the general transcription factors T6, TBP, and T7 but not with TFIIEalpha in the Protein2 pull-down assays
0	25	[19, 26]	T10	T9	TBP and Protein2, however, were not able to interact with Protein1
0	0	[]	T7	T6	T5 specifically interacted with the general transcription factors Protein2, TBP, and Protein1 but not with TFIIEalpha in the T8 pull-down assays
1	0	[]	T5	T6	Protein1 specifically interacted with the general transcription factors Protein2, TBP, and T7 but not with TFIIEalpha in the T8 pull-down assays
1	0	[]	T5	T7	Protein1 specifically interacted with the general transcription factors T6, TBP, and Protein2 but not with TFIIEalpha in the T8 pull-down assays
0	0	[]	T3	T4	In contrast to Protein1, Protein2 did not interact with the AF2 domain of RXR
0	13	[12, 15, 18, 24]	T1	T2	Herein, we show that a distinct IkappaB protein Protein1 also interacts with RXR, as shown in the yeast two-hybrid tests and Protein2 pull-down assays
0	4	[11, 12, 18]	T13	T14	In addition, coexpression of Protein1 but not Protein2 further stimulated the Bcl3-mediated enhancement of the 9-cis-RA-induced transactivations of RXR
0	26	[11, 18, 26]	T12	T11	Accordingly, Protein2 coactivated the 9-cis-RA-induced transactivations of RXR, in contrast to the inhibitory actions of Protein1
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	-4	[2, 11, 14, 18]	T18	T17	[35S]-Sulfate labeled proteoglycans (Protein2) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine Protein1
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
0	4	[11, 12, 14, 18, 26]	T13	T12	In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (T11)-derived Protein2 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	21	[2, 11, 14, 18, 26]	T18	T17	[35S]-Sulfate labeled proteoglycans  Protein2  derived from cultured ECs and SMCs bound to affinity columns containing A beta  1-28  or  1-40 , with virtually no binding to A beta  40-1   reverse peptide , beta-amyloid precursor protein  410-429 , or bovine Protein1
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
0	4	[11, 12, 14, 18, 26]	T12	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived Protein1 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 18, 26]	T13	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 18, 26]	T13	T12	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  T11 -derived Protein2 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	1	[11, 14, 18, 26]	T21	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by Protein1, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T23	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and Protein1, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T22	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by Protein1 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 18, 26]	T25	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T24	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 19]	T2	T4	Differential binding of vascular cell-derived proteoglycans  T1, Protein1, T3, and Protein2  to the beta-amyloid protein of Alzheimer's disease
0	1	[11]	T3	T4	Differential binding of vascular cell-derived proteoglycans  T1, T2, Protein1, and Protein2  to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 19]	T1	T4	Differential binding of vascular cell-derived proteoglycans  Protein1, T2, T3, and Protein2  to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 19]	T3	T2	Differential binding of vascular cell-derived proteoglycans  T1, Protein2, Protein1, and T4  to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 18]	T1	T2	Differential binding of vascular cell-derived proteoglycans  Protein1, Protein2, T3, and T4  to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 19]	T1	T3	Differential binding of vascular cell-derived proteoglycans  Protein1, T2, Protein2, and T4  to the beta-amyloid protein of Alzheimer's disease
0	1	[11, 14, 18, 26]	T25	T21	Characterization of EC and T19 T20 bound to A beta  1-28  revealed strong binding by Protein2, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T24	T21	Characterization of EC and T19 T20 bound to A beta  1-28  revealed strong binding by Protein2, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
1	1	[11, 14, 19, 26]	T23	T20	Characterization of EC and T19 Protein2 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and Protein1, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
1	1	[11, 14, 19, 26]	T22	T20	Characterization of EC and T19 Protein2 bound to A beta  1-28  revealed strong binding by T21, weak binding by Protein1 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 18, 26]	T25	T20	Characterization of EC and T19 Protein2 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T24	T20	Characterization of EC and T19 Protein2 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T25	T23	Characterization of EC and T19 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and Protein2, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 26]	T24	T23	Characterization of EC and T19 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and Protein2, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T25	T22	Characterization of EC and T19 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by Protein2 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 26]	T24	T22	Characterization of EC and T19 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by Protein2 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
1	28	[2, 12, 24]	T3	T4	We show here that Protein1 phosphatase associates with Protein2 in somatic mammalian cells and in meiotic frog oocytes
1	1	[11, 18]	T1	T2	Protein1 interaction with Protein2 phosphatase ties mitogenic signal transduction to cell cycle activation
0	25	[19, 26]	T3	T2	The tyrosine kinase T1 is physically associated with the Type I interferon  Protein2  receptor complex and is rapidly activated during Protein1 stimulation
1	5	[18, 24]	T1	T2	The tyrosine kinase Protein1 is physically associated with the Type I interferon  Protein2  receptor complex and is rapidly activated during T3 stimulation
1	5	[19, 24]	T1	T3	The tyrosine kinase Protein1 is physically associated with the Type I interferon  T2  receptor complex and is rapidly activated during Protein2 stimulation
0	6	[11, 19, 24]	T2	T4	T1 dimers formed through self-association of the TATA-binding polypeptide  Protein1  subunit and could be immunoprecipitated with antibodies to T3, the core subunit of Protein2
1	1	[11]	T3	T4	T1 dimers formed through self-association of the TATA-binding polypeptide  T2  subunit and could be immunoprecipitated with antibodies to Protein1, the core subunit of Protein2
0	1	[11, 19]	T1	T4	Protein1 dimers formed through self-association of the TATA-binding polypeptide  T2  subunit and could be immunoprecipitated with antibodies to T3, the core subunit of Protein2
0	26	[11, 19, 26]	T3	T2	T1 dimers formed through self-association of the TATA-binding polypeptide  Protein2  subunit and could be immunoprecipitated with antibodies to Protein1, the core subunit of T4
0	1	[11, 18]	T1	T2	Protein1 dimers formed through self-association of the TATA-binding polypeptide  Protein2  subunit and could be immunoprecipitated with antibodies to T3, the core subunit of T4
1	1	[11, 19]	T1	T3	Protein1 dimers formed through self-association of the TATA-binding polypeptide  T2  subunit and could be immunoprecipitated with antibodies to Protein2, the core subunit of T4
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
0	5	[24]	T6	T8	The association of Protein1 with T7 was mediated by the NH2-terminal Src homology 2  SH2  domain of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
1	5	[24]	T7	T8	The association of T6 with Protein1 was mediated by the NH2-terminal Src homology 2  SH2  domain of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
1	0	[19]	T10	T9	Complexes of either Protein2/Protein1/Syk/PLC-gamma 1  could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate, respectively
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	21	[2, 11, 14, 18, 26]	T18	T17	[35S]-Sulfate labeled proteoglycans  Protein2  derived from cultured ECs and SMCs bound to affinity columns containing A beta  1-28  or  1-40 , with virtually no binding to A beta  40-1   reverse peptide , beta-amyloid precursor protein  410-429 , or bovine Protein1
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
0	21	[2, 11, 14, 18, 26]	T18	T17	[35S]-Sulfate labeled proteoglycans  Protein2  derived from cultured ECs and SMCs bound to affinity columns containing A beta  1-28  or  1-40 , with virtually no binding to A beta  40-1   reverse peptide , beta-amyloid precursor protein  410-429 , or bovine Protein1
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	4	[11, 12, 14, 18, 26]	T12	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived Protein1 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	4	[11, 12, 14, 18, 26]	T13	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 18, 26]	T12	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived Protein1 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 18, 26]	T13	T12	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  T11 -derived Protein2 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	21	[2, 11, 14, 18, 26]	T18	T17	[35S]-Sulfate labeled proteoglycans  Protein2  derived from cultured ECs and SMCs bound to affinity columns containing A beta  1-28  or  1-40 , with virtually no binding to A beta  40-1   reverse peptide , beta-amyloid precursor protein  410-429 , or bovine Protein1
0	21	[2, 11, 14, 18, 26]	T18	T17	[35S]-Sulfate labeled proteoglycans  Protein2  derived from cultured ECs and SMCs bound to affinity columns containing A beta  1-28  or  1-40 , with virtually no binding to A beta  40-1   reverse peptide , beta-amyloid precursor protein  410-429 , or bovine Protein1
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 18, 26]	T12	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived Protein1 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 18, 26]	T13	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	4	[11, 12, 14, 18, 26]	T13	T12	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  T11 -derived Protein2 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11, 14, 18, 26]	T21	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by Protein1, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	1	[11, 14, 19, 26]	T23	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and Protein1, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T22	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by Protein1 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 18, 26]	T25	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11, 14, 19, 26]	T24	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11, 19]	T2	T4	Differential binding of vascular cell-derived proteoglycans  T1, Protein1, T3, and Protein2  to the beta-amyloid protein of Alzheimer's disease
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	21	[2, 11, 14, 18, 26]	T18	T17	[35S]-Sulfate labeled proteoglycans  Protein2  derived from cultured ECs and SMCs bound to affinity columns containing A beta  1-28  or  1-40 , with virtually no binding to A beta  40-1   reverse peptide , beta-amyloid precursor protein  410-429 , or bovine Protein1
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	21	[2, 11, 14, 18, 26]	T18	T17	[35S]-Sulfate labeled proteoglycans  Protein2  derived from cultured ECs and SMCs bound to affinity columns containing A beta  1-28  or  1-40 , with virtually no binding to A beta  40-1   reverse peptide , beta-amyloid precursor protein  410-429 , or bovine Protein1
0	4	[11, 12, 14, 18, 26]	T12	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived Protein1 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
1	6	[11, 24]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	6	[11, 24]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 18, 26]	T13	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
0	1	[11, 14, 18, 26]	T16	T15	Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta  1-28  produced strong immunoreactivity with A beta antibodies at tissue sites enriched in Protein2 which was partially removed by pretreatment with heparitinase, but not by chondroitin Protein1 lyase
0	21	[2, 11, 14, 18, 26]	T18	T17	[35S]-Sulfate labeled proteoglycans  Protein2  derived from cultured ECs and SMCs bound to affinity columns containing A beta  1-28  or  1-40 , with virtually no binding to A beta  40-1   reverse peptide , beta-amyloid precursor protein  410-429 , or bovine Protein1
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
0	21	[2, 11, 14, 18, 26]	T18	T17	[35S]-Sulfate labeled proteoglycans  Protein2  derived from cultured ECs and SMCs bound to affinity columns containing A beta  1-28  or  1-40 , with virtually no binding to A beta  40-1   reverse peptide , beta-amyloid precursor protein  410-429 , or bovine Protein1
0	29	[11, 12, 14, 19, 26, 27]	T9	T10	Overall, the results indicate that specific vascular cell-derived Protein2 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of Protein1
0	4	[11, 12, 14, 18, 26]	T12	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived Protein1 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 18, 26]	T13	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 18, 26]	T12	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived Protein1 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular T13 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 18, 26]	T13	T12	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  T11 -derived Protein2 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 18, 26]	T13	T11	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  Protein2 -derived T12 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	4	[11, 12, 14, 18, 26]	T13	T12	In the present investigation, the differential binding of previously characterized endothelial cell  EC - and smooth muscle cell  T11 -derived Protein2 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular Protein1 deposits may be due to its interactions with T14
0	1	[11, 14, 18, 26]	T21	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by Protein1, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T23	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and Protein1, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 18, 26]	T21	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by Protein1, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T22	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by Protein1 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T23	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and Protein1, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 18, 26]	T25	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T22	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by Protein1 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T24	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 18, 26]	T25	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by T24/Protein1, a large chondroitin sulfate proteoglycan
0	1	[11, 14, 19, 26]	T24	T19	Characterization of EC and Protein2 T20 bound to A beta  1-28  revealed strong binding by T21, weak binding by T22 and T23, two dermatan sulfate proteoglycans, and lack of binding by Protein1/T25, a large chondroitin sulfate proteoglycan
0	1	[11, 19]	T2	T4	Differential binding of vascular cell-derived proteoglycans  T1, Protein1, T3, and Protein2  to the beta-amyloid protein of Alzheimer's disease
0	1	[11]	T3	T4	Differential binding of vascular cell-derived proteoglycans  T1, T2, Protein1, and Protein2  to the beta-amyloid protein of Alzheimer's disease
1	36	[11, 24, 29, 30]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	36	[11, 24, 29, 30]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6
0	4	[11, 12, 14, 19, 26]	T3	T2	Cross-linking of T1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag Protein2, increases in cellular volume, RNA synthesis, and Protein1 protein levels, and enhanced binding of 7-aminoactinomycin D
1	36	[11, 24, 29, 30]	T4	T6	However, cytokines, in particular Protein1 and T5, potentiated the DNA synthesis induced by cross-linking of Protein2
1	36	[11, 24, 29, 30]	T5	T6	However, cytokines, in particular T4 and Protein1, potentiated the DNA synthesis induced by cross-linking of Protein2
0	1	[11]	T5	T4	However, cytokines, in particular Protein2 and Protein1, potentiated the DNA synthesis induced by cross-linking of T6